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For over half a century, pressurised metered dose inhalers (pMDIs) have been the
most sold inhaler devices for the treatment of lung diseases. However, they suf-
fer from significant drug deposition in the mouth and throat, mainly due to the
aerosolisation of large and fast-moving droplets. This causes a high occurrence of
side effects and is wasteful of drug. They are also affected by a low consistency of
dosing and as a result users might not benefit from maximal device efficiencies.
The hypothesis of this work was that the performance of pMDIs is dependent on
numerous factors which might alter the characteristics of their particles and their
deposition location within the respiratory tract. For example, it was thought that
the variations in actuation forces of pMDIs and temperatures at which they are
used might contribute to their low consistency.
A one-dimensional Matlab computational model was developed in order to calcu-
late spray properties at the exit of the device where experimental measurements
are difficult to conduct. The model simulated the discharge of pure HFA134a
formulations and HFA134a-based suspension formulations containing fluticasone
propionate; the latter representing a commercially available formulation.
The results showed that the actuation force of a“healthy” adult led to a higher
valve opening rate and to the aerosolisation of smaller droplets than the actuation
force provided by a “weak” adult. The model also showed that an increase of
temperature led to the aerosolisation of smaller droplets. The model was validated
using impaction measurements and laser techniques.
The next generation impactor (NGI) experiments revealed the importance of actu-
ation forces on the throat deposition. Automated actuation forces with high valve
opening rates led to a lower throat deposition than a manual actuation force with
low valve opening rate.
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The laser diffraction experiments showed that the automated actuations led to the
aerosolisation of smaller droplets than manual actuations, validating the results
obtained with the computational model.
The combination of these computational and experimental methods allowed the
investigation of the spray along its entire trajectory, providing a deeper insight on
the spray properties from the device to the respiratory system.
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A Area . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . [ m2 ]
A′ Specific part of the valve orifice area . . . . . . . . . . [ m2 ]
B Velocity per unit force . . . . . . . . . . . . . . . . . . . [ m·s−1N−1 ]
B′ Specific part of the valve orifice area . . . . . . . . . . [ m2 ]
C Percentage by weight . . . . . . . . . . . . . . . . . . . . [− ]
C ′ Valve orifice opening area . . . . . . . . . . . . . . . . . [ m2 ]
Cd Discharge coefficient . . . . . . . . . . . . . . . . . . . . . [− ]
Cp Specific heat capacity at constant pressure . . . . . . . [ kJ·kg−1K−1 ]
Cpg Specific heat capacity of gas at constant pressure . . [ kJ·kg−1K−1 ]
Cv Specific heat capacity at constant volume . . . . . . . [ kJ·kg−1K−1 ]
D Displacement . . . . . . . . . . . . . . . . . . . . . . . . . [ m ]
Diff Diffusion coefficient . . . . . . . . . . . . . . . . . . . . . [ m2·s−1 ]
D10 10th percentile of the cumulative particle under-size frequency distribu-
tion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . [µm ]
D50 50th percentile of the cumulative particle under-size frequency distribu-
tion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . [µm ]
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D90 90th percentile of the cumulative particle under-size frequency distribu-
tion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . [µm ]
Dis Displacement of the particle between two laser pulses [ m ]
E Elastance of the oesophagus . . . . . . . . . . . . . . . . [ cmH2O·min·L−1 ]
ERV Expiratory reserve volume . . . . . . . . . . . . . . . . . [ L ]
F Force applied to the canister during its actuation . . [ N ]
FEV1 Forced expiratory volume in the first second . . . . . [ L ]
FPF Fine particle fraction . . . . . . . . . . . . . . . . . . . . [ % ]
FRC Functional residual capacity . . . . . . . . . . . . . . . . [ L ]
FV C Forced vital capacity . . . . . . . . . . . . . . . . . . . . [ L ]
GSD Geometric standard deviation . . . . . . . . . . . . . . [µm ]
H Total enthalpy . . . . . . . . . . . . . . . . . . . . . . . . [ kJ ]
Ha Total enthalpy of air . . . . . . . . . . . . . . . . . . . . [ kJ ]
Hlp Total enthalpy of liquid propellant . . . . . . . . . . . . [ kJ ]
Hp Total enthalpy of propellant . . . . . . . . . . . . . . . . [ kJ ]
Hvp Total enthalpy of vapour propellant . . . . . . . . . . . [ kJ ]
IP Impaction parameter . . . . . . . . . . . . . . . . . . . . [µm2·L·min−1 ]
IRV Inspiratory reserve volume . . . . . . . . . . . . . . . . . [ L ]
K Boltzmann constant . . . . . . . . . . . . . . . . . . . . . [ J·K−1 ]
L Length . . . . . . . . . . . . . . . . . . . . . . . . . . . . . [ m ]
LOD Limit of detection . . . . . . . . . . . . . . . . . . . . . . [µg·mL−1 ]
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MMD Mass median diameter . . . . . . . . . . . . . . . . . . [µm ]
N Total number of velocity measurements . . . . . . . . [− ]
P Pressure . . . . . . . . . . . . . . . . . . . . . . . . . . . . [ cmH2O,Pa ]
PM Picture magnification . . . . . . . . . . . . . . . . . . . . [− ]
Q Inhalation flow rate . . . . . . . . . . . . . . . . . . . . . [ L·min−1,m3·s−1 ]
Ra Ratio . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . [− ]
Re Reynolds number . . . . . . . . . . . . . . . . . . . . . . [− ]
Res Resistance of the lungs . . . . . . . . . . . . . . . . . . . [ cmH2O·L−1 ]
Rs Specific gas constant . . . . . . . . . . . . . . . . . . . . [ kJ·K−1·kg−1 ]
Ru Universal gas constant . . . . . . . . . . . . . . . . . . . [ kJ·K−1·kmol−1 ]
RV Residual volume . . . . . . . . . . . . . . . . . . . . . . . [ L ]
S Stopping distance of the particle . . . . . . . . . . . . . [ m ]
Sc Distance travelled by the canister during its actuation [ m ]
Sf Distance between the fringes . . . . . . . . . . . . . . . [ m ]
St Surface tension . . . . . . . . . . . . . . . . . . . . . . . . [ kJ·m−2 ]
Stk Stokes number . . . . . . . . . . . . . . . . . . . . . . . . [− ]
T Thermodynamic temperature . . . . . . . . . . . . . . . [ K ]
TLC Total lung capacity . . . . . . . . . . . . . . . . . . . . . [ L ]
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TV Tidal volume . . . . . . . . . . . . . . . . . . . . . . . . . [ L ]
U Velocity . . . . . . . . . . . . . . . . . . . . . . . . . . . . [ m·s−1 ]
U ′ Turbulence of the spray . . . . . . . . . . . . . . . . . . [ m·s−1 ]
U¯ Mean velocity . . . . . . . . . . . . . . . . . . . . . . . . . [ m·s−1 ]
Ul Velocity of the liquid phase . . . . . . . . . . . . . . . . [ m·s−1 ]
Uv Velocity of the vapour phase . . . . . . . . . . . . . . . [ m·s−1 ]
V Volume . . . . . . . . . . . . . . . . . . . . . . . . . . . . . [µL,mL,L,m3 ]
V C Vital capacity . . . . . . . . . . . . . . . . . . . . . . . . . [ L ]
VMD Volume median diameter . . . . . . . . . . . . . . . . . [µm ]
V v Vapour volume . . . . . . . . . . . . . . . . . . . . . . . . [ m3 ]
V˙ Volumetric flow rate . . . . . . . . . . . . . . . . . . . . . [ L·min−1,L·s−1 ]
Z Elevation of a point in the flow . . . . . . . . . . . . . . [ m ]
Lower case
a Acceleration . . . . . . . . . . . . . . . . . . . . . . . . . . [ m·s−2 ]
b Specific length within the valve orifice . . . . . . . . . [ m ]
c Constant . . . . . . . . . . . . . . . . . . . . . . . . . . . . [− ]
d Diameter . . . . . . . . . . . . . . . . . . . . . . . . . . . . [µm,mm,m ]
dt Time step . . . . . . . . . . . . . . . . . . . . . . . . . . . [ s ]
e Coefficient . . . . . . . . . . . . . . . . . . . . . . . . . . . [− ]
f Frequency of oscillations . . . . . . . . . . . . . . . . . . [ Hz ]
g Gravitational acceleration . . . . . . . . . . . . . . . . . [ m·s−2 ]
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h Specific enthalpy . . . . . . . . . . . . . . . . . . . . . . . [ kJ·kg−1 ]
hlp Specific enthalpy of liquid propellant . . . . . . . . . . [ kJ·kg−1 ]
hlvp Specific enthalpy of propellant vaporisation . . . . . . [ kJ·kg−1 ]
hvp Specific enthalpy of propellant vapour . . . . . . . . . [ kJ·kg−1 ]
m Mass . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . [ kg ]
ma Air mass . . . . . . . . . . . . . . . . . . . . . . . . . . . . [ kg ]
mlp Liquid propellant mass . . . . . . . . . . . . . . . . . . . [ kg ]
mp Propellant mass . . . . . . . . . . . . . . . . . . . . . . . [ kg ]
mvp Vapour propellant mass . . . . . . . . . . . . . . . . . . [ kg ]
m˙ Mass flow rate . . . . . . . . . . . . . . . . . . . . . . . . [ kg·s−1 ]
m˙a Mass flow rate of air . . . . . . . . . . . . . . . . . . . . [ kg·s−1 ]
m˙l Mass flow rate of the liquid phase . . . . . . . . . . . . [ kg·s−1 ]
m˙p Propellant mass flow rate . . . . . . . . . . . . . . . . . [ kg·s−1 ]
m˙v Mass flow rate of the vapour phase . . . . . . . . . . . [ kg·s−1 ]
q Quality . . . . . . . . . . . . . . . . . . . . . . . . . . . . . [− ]
r Radius . . . . . . . . . . . . . . . . . . . . . . . . . . . . . [ m ]
t Time . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . [ s ]
u Unknown used to solve the density and enthalpy equations [− ]
v Unknown used to solve the pressure equation . . . . . [− ]
w Displacement of the canister during actuation . . . . [ m ]
x Number of calculated velocity components . . . . . . . [− ]
y Number of domain dimensions . . . . . . . . . . . . . . [− ]
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Nomenclature
z Determinant of velocity measurements type . . . . . . [− ]
Greek characters
α Angle of the intersecting beams . . . . . . . . . . . . . [ rad ]
η Viscosity . . . . . . . . . . . . . . . . . . . . . . . . . . . . [ kg·m−1·s−1 ]
γ Propellant vapour heat capacity ratio . . . . . . . . . . [− ]
λ Laser wavelength . . . . . . . . . . . . . . . . . . . . . . . [ m ]
µ Flow dynamic viscosity . . . . . . . . . . . . . . . . . . . [ kg·m−1·s−1 ]
ρ Density . . . . . . . . . . . . . . . . . . . . . . . . . . . . . [ g·cm−3, kg·m−3 ]
ρ Average density of propellant . . . . . . . . . . . . . . . [ kg·m−3 ]
ρlp Propellant liquid density . . . . . . . . . . . . . . . . . . [ kg·m−3 ]
ρvp Propellant vapour density . . . . . . . . . . . . . . . . . [ kg·m−3 ]
ρv Density of the mixture of propellant vapour and air . [ kg·m−3 ]
ρ0 Unit density . . . . . . . . . . . . . . . . . . . . . . . . . [ g·cm−3 ]
σ Random error . . . . . . . . . . . . . . . . . . . . . . . . [− ]
















f Airflow in the airways
flash Flashing
FP Fluticasone propionate


























ACI Andersen cascade impactor
API Active pharmaceutical ingredient
APS Aerodynamic particle sizer
CC Cross-correlation
CCD Charged couple device
CFC Chlorofluorocarbon
CFD Computational fluid dynamics
COPD Chronic obstructive pulmonary disease
DIVAS Droplet imaging velocimeter and sizer
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Nomenclature
DPI Dry powder inhaler
DPIV Digital particle image velocimetry
DUSA Dosage unit sampling apparatus
FPD Fine particle dose
FP Fluticasone propionate
HCP High capacity pump
HEF HFA134a, ethanol and fluticasone propionate formulation
HEM Homogeneous equilibrium model
HF HFA134a and fluticasone propionate formulation
HFA Hydrofluoroalkane
HPEF HFA134a, ethanol, PEG400 and fluticasone propionate formulation
HPLC High-pressure liquid chromatography
ICH International Conference on Harmonisation
IPACT International Pharmaceutical Aerosol Consortium for Toxicity Testing
LDA Laser Doppler anemometry
LSD Laser speckle velocimetry
LVDT Linear variable differential transformer
NGI Next generation impactor
NIST National Institute of Standards and Technology
NEM Non-homogeneous equilibrium model
ODR Orifice diameter ratio
PDA Phase Doppler anemometry
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PDPA Phase Doppler particle analyser
PEG Polyethylene glycol
PET Polyethylene terephthalate
PIPM Particle image pattern matching technique
PIV Particle image velocimetry
pMDI Pressurised metered dose inhaler
PTV Particle tracking velocimetry
RANS Reynolds averaged Navier-Stokes
RMS Root mean square
SD Standard deviation
SFM Separated flow model





1.1 Inhaled drug delivery
1.1.1 History and definition
Delivery of medications by inhalation was invented more than four thousand years
ago and was first applied to treat asthma in India two thousand years ago with
users smoking herbal preparations (Anderson, 2005). In Egyptian times (around
1500 BC), physicians achieved vaporisation of black henbane using hot bricks so
that patients could inhale the vaporised content of the herb (Sanders, 2007). In
ancient Greece, Hippocrates used inhalation to deliver vapours distilled in a pot in
order to cure airways inflammation (Clarke and Newman, 1984). The pot used by
Hippocrates represents the oldest design of inhaler devices and was not modified
until the late 18th century when similar devices were still in use (Anderson, 2005).
The word inhaler was first used in 1778 by John Mudge to describe his own design
(Anderson, 2005). Several designs followed during the 19th century. In 1899,
Helbing developed an inhaler that used the heat of the hand to increase the vapour
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pressure of ethyl or methyl chloride inside the canister to develop an aerosol. In
the 20th century, the inhalation route became more common as the reproducible
creation of aerosols became industrially feasible. However, it was only following the
discovery of Freon propellants in the 1930s that aerosols became popular. The first
major industrial application of aerosols was as an insecticide designed to combat
malaria during Second World War with thirty million units used. In the post-war
years aerosols became households products, leading ultimately to the combination
of aerosol technology and inhalation therapy to achieve a tremendous commercial
success in the 1950s with the first therapeutic aerosol commercialised in 1956 by
Riker laboratories (Purewal, 1997). This therapeutic aerosol, the Medihaler, was
a pressurised metered dose inhaler (Fradley, 2006).
1.1.2 Medical indications of inhaled drug delivery
In inhaled drug delivery, the active pharmaceutical ingredient (API) is delivered
via the respiratory tract. Inhalers can be used to treat a wide range of conditions
including infections and diabetes. However, they remain mainly used for the topical
treatment of lung disease (the drug is deposited on the target site). There are two
major types of lung diseases, the obstructive and restrictive diseases.
Most lung diseases are obstructive diseases. Chronic obstructive pulmonary disease
(COPD) is an obstructive disease which generally combines chronic bronchitis and
emphysema (Luo et al., 2007). COPD is characterised by an inflammation of the
lining of the bronchial tubes, impairing the capacity of the patient to efficiently
inhale and exhale. This inflammation may then cause a scarring and thickening of
the bronchial airways, increasing the severity of the disease. Symptoms of COPD
include excessive production of mucus, cough and shortness of breath. Bronchitis
is referred as chronic when the patient suffers cough and shortness of breath for
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at least three months a year for two or more consecutive years (Braman, 2006).
Emphysema is defined by the destruction of the most distal airways of the lungs.
As a result, lungs transfer of oxygen to the systemic circulation is less efficient and
may cause a breath shortage.
COPD is the 4th leading cause of mortality worldwide and represents approxi-
mately 5% of all deaths globally (Global initiative for chronic obstructive lung
diseases, 2011). Approximately 64 million people were affected by COPD in 2004,
and more than 3 million people died of the disease in 2005 (Global initiative for
chronic obstructive lung diseases, 2011). COPD is closely linked to an ageing pop-
ulation and the majority of the estimated 210 million people worldwide suffering
from the disease are long-term smokers and elderly people (Global initiative for
chronic obstructive lung diseases, 2011). With an ageing population, the number
of deaths due to COPD is forecasted to increase by 30% within 10 years (World
Health Organization, 2012).
Asthma is a chronic disease causing obstruction of small and medium-size airways
upon contact with irritants. It affects approximately 300 million people worldwide
and is more prevalent in pediatric population with 10% of children suffering from
the disease (AstraZeneca, 2011).
Inhaled drug delivery is mainly used for the treatment of lung conditions such as
COPD, asthma, cystic fibrosis, bacterial infections as well as lung tumours through
topical action on the lungs (Kleinstreuer and Zhang, 2011). The fact that inhaled
drugs can reach the blood system can be a drawback for lung therapy as it in-
creases the risk of side effects. This is an issue for the delivery of some inhaled
APIs such as corticosteroids which increase the risk of osteoporosis in particular
for menopausal women (Lipworth, 1999). On the other hand, it can also present an
advantage for inhalation therapy on the whole as it allows the delivery of different
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proteins targeting the systemic circulation, via the inhalation route. Chemother-
apeutic drugs, nicotine, insulin and anti-migraine agents could be produced as
inhalable compounds (Laube, 2005). For example, Afrezza is an inhaler for insulin
delivery currently developed by MannKind which completed Phase 3 clinical trials
(Mannkind Corporation, 2013).
1.1.3 Advantages of inhalation delivery compared to other
delivery routes
The main advantage of the inhalation route compared to other delivery methods is
its fast onset of action. It can be used to deliver APIs to the target sites much faster
than the oral route which is the most common non-invasive delivery route. For
example, short-acting bronchodilators such as albuterol start acting within minutes
after inhalation (Merck, 2012). This advantage is of particular importance for the
relief of asthma crisis where the fast effect of a drug can be vital (Sheffer, 2005).
Conversely, orally administered bronchodilators must pass through the digestive
system to reach the intestines where they are absorbed into the bloodstream. As
a result, the drug has its peak effect between 45 minutes and 90 minutes after
absorption (Milner, 1981).
Treatment of lung diseases by inhalation also requires a lower amount of API than
other delivery routes. Contrary to orally absorbed drugs, inhaled drugs avoid the
first pass metabolism in the liver which destroys small molecules. Big molecules
such as proteins are also destroyed by acid and enzymes in the gastrointestinal
tract. Systemically delivered drugs are distributed through the entire circulatory
system whereas inhaled drugs are administered directly to the site of action in the
lungs. As a result, much greater doses of API must be delivered orally in order to
obtain the same therapeutic effect as inhaled drugs (Tiddens, 2004). For example,
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inhaled salbutamol is therapeutically effective at deliveries of 100µg to 200µg per
actuation. Conversely, oral salbutamol is administered at a dose of 4 mg to 8 mg
with a maximum dose of 32 mg per day in adults (drugs.com, 2009). Delivering
low amounts of drugs can lower the costs of a therapy and help reduce side effects.
In the treatment of pulmonary diseases, all drug particles target a specific location
in the airways and only a small drug amount is absorbed by the rest of the body.
It was shown that anti-inflammatory inhaled steroids cause much fewer side effects
than orally administered steroid tablets (van der Molen et al., 2010). The highest
risk of side effects for inhaled drugs is caused by the fraction of drug reaching the
most distal airways, which are greatly vascularised. The impact of the systemi-
cally absorbed fraction of inhaled corticosteroids has been reported. For example,
inhaled budesonide has been shown to reduce the growth rate in children at doses
of 0.4 mg a day or more (Toogood, 1998). Another survey found that high doses of
inhaled budesonide (greater than 1.5 mg a day) increases the risk of exacerbation
of glaucomas (Toogood, 1998). The second source of side effects in inhalation ther-
apy is due to drug deposition at oropharynx level which causes conditions such as
oral candidiasis, cough or bronchospasm in approximately 5% of patients (Versteeg
et al., 2006). To avoid such systemic and local side effects, new types of APIs
have been researched. For example, ciclesonide is a new corticosteroid that has low
systemic bioavailability, requires bioconversion to the active entity in the lungs and
is rapidly eliminated from the body (van der Molen et al., 2010).
There are two methods of inhalation which are nasal and oral inhalations. Oral
inhalation is more efficient as a greater proportion of the aerosol can avoid filtration
and reach the lungs (Agnew, 1984). For this reason, the industry and academic
community focus particularly on the oral inhalation route. The three main types
of inhalation devices using the oral inhalation route are the nebulisers, the dry
powder inhalers (DPIs) and the pressurised metered dose inhalers (pMDIs).
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1.2 Pulmonary anatomy and function
1.2.1 Structure of the respiratory system
The respiratory system comprises the mouth, the pharynx, the trachea and the
lungs and extends from the nose or the mouth to the alveoli. The respiratory
system is shown in Figure 1.1.
Figure 1.1: Schematic of the human respiratory system (Kleinstreuer et al., 2008).
The lungs are the organs responsible for respiration by letting gas circulate in
and outside of the body. Their volume adapts to the volume of air inhaled at a
given moment. After being absorbed through the nose, the air goes through the
nasopharynx, the oropharynx, the larynx, the trachea, the two main bronchi, the
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five lobar bronchi (three on the right lung, two on the left lung) and the bronchioles
down to the alveoli. The upper airways are composed of the nose, the mouth and
the larynx. The lower respiratory tract has the structure of an inverted tree with
two branches departing from the trachea and many branches departing from the
bronchi as shown in Figure 1.1.
The respiratory system is divided into the conducting and the respiratory zones.
The conducting zone starts at generation 0 with the trachea which has a length of
120 mm to 150 mm and a diameter of 15 mm to 20 mm in an average adult. The
first generation consists of the two main bronchi. Each bronchus is then divided
into bronchi at generation 2. The bronchi are then divided into bronchioles which
have a diameter inferior or equal to 1 mm and are located between generation 3
and 15. At generation 16, the terminal bronchioles are divided into respiratory
bronchioles. The conducting zone is shown in Figure 1.2.
Figure 1.2: Schematic representing the conducting zone (Cumming, 2001).
The respiratory zone consists of the respiratory bronchioles located at generations
17 to 19, the alveolar ducts at generation 20 to 22 and the alveoli at generation
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23 (Kleinstreuer and Zhang, 2011). Groups of alveoli form the alveolar sacs. The
respiratory zone is shown in Figure 1.3.
Figure 1.3: Schematic representing the respiratory zone (Cumming, 2001).
When looking at the physiology of the lungs, the potential of inhalation therapy
for the delivery of systemic drugs becomes clear. Each alveolus, having an average
diameter of 200µm to 300µm, is surrounded by a capillary blood vessel located at
a distance of between 0.1µm and 0.2µm. In comparison, this distance is approxi-
mately 30µm to 40µm in the bronchial tract (Siekmeier and Scheuch, 2008). The
total cross-sectional area at alveoli level is approximately 140 m2 and represents a
significantly bigger surface area than at any other point in the respiratory tract
(Siekmeier and Scheuch, 2008). The large surface area of the alveoli as well as
the small distance between the alveoli and the capillary blood vessels make the
alveolar region an ideal zone of exchange with the systemic circulation. For this
reason, inhaled compounds reaching the most distal airways are increasingly used
to treat systemic conditions.
In order to maximise the efficiency of inhaled therapeutic agents and minimise their
side effects, their deposition location should be as close as possible to their target
site in the respiratory system.
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1.2.2 Anatomical and physiological modelling of the lungs
Several airway characteristics such as airways segment lengths, diameters and
branching angles, angles between airway branches, affect the way APIs deposit
in the respiratory system. From the 1930s onwards, scientists started developing
lung models helping to predict the deposition site of APIs. As lung function and
drug deposition within the respiratory system are complex to simulate, the first
anatomical lung models assumed simple lungs structures.
The first anatomical lung model developed by Findeisen in 1935 was a “9 gener-
ation” bronchial tree. Landahl (1950), Davies (1961), Weibel and Gomez (1962),
Olson et al (1970) and Horsfield et al (1971) also assumed simple lung structures.
In Weibel’s model which is the most famous of those early models, the bronchial tree
consists of 24 generations. The 0 generation corresponds to the trachea, the 19th
generation corresponds to terminal bronchioles and the 23rd generation corresponds
to alveolar sacs. The bronchial tree is composed of successive parallel and semi-rigid
tubes connected in series at each bifurcation. The nose and the mouth are treated
as flow filters; and the lower respiratory system as an expandable surface where
exchanges with the systemic system take place. Table 1.1 shows the geometry and




















































































































































































































































































































































































































































































































































































































































where ρa is the density of air in the airways in kg·m−3, Uf is the velocity of the
airflow in the airways in m·s−1, dairways is the airways diameter in m and µ is the
dynamic viscosity of the airflow in kg·m−1·s−1.
Table 1.1 shows that the Reynolds number is high at the oropharynx compared
with the lower airways. This means that the level of turbulence, characterised
by significant variations in the flow velocity inside the airways, decreases deeper
into the lungs. The decrease of the Reynolds number as a function of the airway
generation can be seen in Figure 1.4 which also shows that the level of turbulence
in the airways decreases with the flow rate of the patient (Finlay, 2001).
Figure 1.4: Reynolds number Re plotted against generation number of an idealised
lung geometry developed by Finlay for two flow rates (18 L·min−1 and 60 L·min−1)
(Finlay, 2001).
Table 1.1 and Figure 1.4 show properties of the airways at varying generations.
Those data were gathered using the early lung models such as the ones developed
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by Weibel and Horsfield.
Weibel assumes that the respiratory system contains 300 million alveoli, 14 million
alveolar ducts and 280 billion capillary segments (Weibel and Gomez, 1962). In
more recent studies, the average alveoli number in 6 adult human lungs was found
to be 480 million (Ochs et al., 2004). Weibel’s model has other limitations such
as the assumption of lungs symmetry although in reality, the left lung is slightly
bigger than the right one.
These early models remain simple and can only roughly approximate the geometry
of the lungs. Anatomical lung models developed from replica casts of the bronchial
tree are believed to approximate better the lower part of the respiratory tract
(Ferron, 1994).
The Reynolds number of value higher than 2000 calculated by Finlay in the larynx
agrees with the values in Table 1.1. All anatomical models describe high levels of
turbulence in the upper respiratory tract, which, coupled with airways bifurcations,
increase the collision of particles with the airways walls and prevent most particles
from reaching the deep lungs.
1.3 Pulmonary ventilation characteristics
1.3.1 Definitions of pulmonary volumes
In order to identify respiratory problems, characteristic lung volumes have been
defined. The total lung capacity (TLC) represents the maximum volume to which
lungs can expand at maximum inspiratory effort. The TLC has a value of 6 L for
an average male adult, 4.2 L for an average female adult and 3 L for a child (Lyons
and Tanner, 1962). The tidal volume (TV), which corresponds to the volume of air
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of individual breath in quiet breathing is 500 mL for an average adult (Irwin and
Rippe, 2008). The inspiratory reserve volume (IRV) corresponds to the volume
of air than can be inhaled forcefully after a normal inhalation. It has a value
of 3.1 L for an average male adult and 1.9 L for an average female adult. The
expiratory reserve volume (ERV) corresponds to the volume of gas than can be
exhaled forcefully after a normal exhalation. It has a value of 1.2 L for an average
male adult and 0.7 L for an average female adult. The residual volume (RV) is the
volume of gas remaining in the lungs after a forced exhalation. It has a value of
1.2 L for an average male adult and 1.1 L for an average female adult (Cumming,
2001). The vital capacity (VC) corresponds to the maximum volume of gas that
can be exhaled after a maximum inspiratory effort. It has a value of 4.8 L for an
average male adult, 3.1 L for an average female adult and should represent roughly
80% of the TLC. The inspiratory capacity represents the maximum volume of air
that can be inhaled after a normal expiration. It has a value of 3.6 L for an average
male adult and 2.4 L for an average female adult. The functional residual capacity
(FRC) is the volume of gas remaining in the lungs after a normal expiration. It
has a value of 2.4 L for an average male adult and 1.8 L for an average female adult
(Cumming, 2001).
1.3.2 Ventilation and inspiratory physiology
During inhalation, the diaphragm contracts down and the lungs expand, causing
a sub-atmospheric pressure in the airways. Intercostal muscles which allow an in-
crease of the lung volume by raising the ribs and the sternum, are also involved
in the expansion of the thorax. The sub-atmospheric pressure resulting from in-
creased lung volume causes air to penetrate into the lungs. During expiration, the
intercostal muscles and the diaphragm relax, leading to a reduction of the volume
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occupied by the lungs. The pressure inside the lungs becomes higher than atmo-
spheric pressure, causing gas to exit the respiratory system. Between an exhalation
and an inhalation, the alveolar pressure equals atmospheric pressure. This is the
reason why there is no gas flowing at this stage.
Inhalation is considered to be an active mechanism as it is caused by the con-
traction of the diaphragm and intercostal muscles. On the contrary, exhalation is
a passive mechanism as it is caused by the relaxation of the diaphragm and the
intercostal muscles. The pressure difference between the atmosphere and the air-
ways is −250 Pa before inhalation and 350 to 800 Pa before expiration. A sufficient
pressure gradient between the respiratory airways and the exterior environment is
necessary in order to achieve the right volume of gas breathed in and out at each
inhalation and expiration. In order to achieve an efficient ventilation process, lungs
should be elastic, strong and in overall good shape. Equation (1.2) is used to link
the pressure in the lungs to different variables such as the elastance which is the
rate of change of pressure related to the change in volume. The elastance can be
defined as the ability of an object to resist deformation and to return to its original
form (Waechter, 2005), (Ingenito et al., 1998).
Plungs = ResVRS + E ˙VRS (1.2)
where Plungs is the pressure produced by the lungs in cmH2O, Res is the resistance
of the lungs in cmH2O·L−1, VRS is the volume of the respiratory system in L, E is the
elastance in cmH2O·min·L−1 and ˙VRS is the volumetric flow rate in the respiratory
system in L·min−1. The lung volume increases more steeply at the beginning of a
respiratory cycle than at the end when the pressure inside the system is already
high (Muramatsu et al., 2001). It can thus be assumed that the elastance of the
lungs reduces at the end of the cycle.
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Average respiratory rates are 12 to 20 breaths per minute in adults and 15 to
30 breaths per minute in children aged 3 to 10 (Yuan et al., 2013). The average
inspiratory flow rate through the trachea in healthy adults is 15 L·min−1 (Tobin
et al., 1983). The flow rates in other airways are assessed as percentages of the
flow rate through the trachea as shown in Table 1.1.
Airway resistance and volumetric flow rate are similar in persons suffering from
restrictive diseases as in non-affected persons (Waechter, 2005). However the TLC
and elastance vary depending on patient’s conditions and can be used as a diagnosis
tool for respiratory diseases.
Restrictive diseases such as idiopathic fibrosis, hypersensitivity pneumonitis and
sarcoidosis prevent an efficient lung expansion, leading to a reduced TLC and a
higher lung elastance. For persons affected by obstructive diseases, the elastance is
decreased so that the lungs need to expand to a greater volume to achieve a normal
pressure gradient, leading to a higher TLC value (Cumming, 2001).
Obstructive diseases such as COPD and asthma are characterised by narrow air-
ways and prevent efficient airflow in the respiratory system particularly during
expiration. In obstructive diseases, the reduced elastance of the respiratory system
prevents the lungs to spring back to their original shape. As a result, air remains
trapped inside the lungs after expirations, causing hyperinflation of the airways.
The FRC is higher in persons suffering from obstructive diseases than in healthy
persons due to the reduced elastance of the lungs (O’Donnell and Laveneziana,
2006). On the contrary, as restrictive diseases tend to lead to smaller lung vol-
umes, the FRC tends to be lower in persons affected by those types of diseases.
For example, persons affected by emphysema have lower flow rates, particularly
in the lower respiratory system as small airways can be destroyed by the disease
(Ingenito et al., 1998).
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The forced vital capacity (FVC) and the forced expiratory volume in the first
second (FEV1) are powerful tools to diagnose obstructive diseases. The FVC is the
maximum volume obtained as one exhales the fastest after a maximum inspiration.
The FEV1 corresponds to the volume obtained during the first second of a forced
expiration. The ratio of those two measures is approximately 80% for healthy
persons, which means that in one second a healthy person can exhale around 80%
of his FVC. When the volume of the respiratory system is smaller, the volume
exhaled at the first second and the total volume exhaled are lower but the FEV1
and the FVC remain proportional. The FEV1 to FVC ratio is thus normal for
patients suffering from restrictive diseases (Waechter, 2005). Obstructive diseases
cause the partial blockage or narrowing of airways, leading to a reduction in airway
diameters. The expiration therefore takes a longer time, causing the FEV1 to be
small compared to the FVC. As a result, the FEV1 to FVC ratio is lower in patients
suffering from obstructive diseases (Waechter, 2005).
Asthma can be diagnosed by using the tidal expiratory flow rate as most persons
suffering from this condition appear to have tidal expiratory limitations. This
means that during tidal breathing, flow-limiting segments appear in the airways,
preventing the high pressure inside the lungs to result in a high expiratory flow rate
(Smaldone et al., 1993). The FEV1 can therefore be used to diagnose asthmatic
persons. Persons with a severe asthma have a FEV1 ≤ 40% of their personal best
and patients with a moderate asthma have a FEV1 between 40% and 69% of their
personal best (Sveum et al., 2012). Table 1.2 summarises the characteristics of
obstructive and restrictive diseases (O’Brien, 2012).
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Measure Obstructive diseases Restrictive diseases
FEV1/FVC Decreased Normal or increased
FEV1 Decreased Decreased, normal or increased
FVC Decreased or normal Decreased
TLC Normal or increased Decreased
FRC Increased Decreased
Table 1.2: Characteristics of obstructive and restrictive diseases.
1.4 Lung deposition mechanisms
1.4.1 Target sites within the lungs
Inhalation therapy is ideal for the treatment of respiratory diseases as it is non-
invasive and causes fewer systemic side effects than systemically administered
drugs. It seems to be promising for the delivery of APIs aiming at the systemic cir-
culation as the inhalation route preserves APIs and provides an excellent exchange
platform with the blood system at alveolar level. When particles such as APIs are
inhaled, they either deposit at different locations inside the respiratory system or
are breathed out during the subsequent exhalation. The main issue associated with
inhalation therapy is the poor control over the deposition location of API particles
and the amount of API particles reaching the target site.
Each API delivered by inhalation therapy has a specific target site within the
lungs. For the treatment of pulmonary diseases, the most commonly prescribed
therapeutics include β2adrenergic agonists, anticholinergics and corticosteroids.
β2adrenergic agonists and anticholinergics achieve bronchodilation by relaxing the
smooth muscles. The targets of the β2adrenergic are the β2receptors, which are
mainly located in the alveoli although their role at this location remains unknown,
as this region does not contain smooth muscles. β2adrenergic are most active in
the conducting airways which are lined with smooth muscles although the density
of β2receptors is lower in this region (Labiris and Dolovich, 2003). The targets of
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the anticholinergic are the muscarinic receptors which are also located in smooth
muscles throughout the airways. However, muscarinic receptors reside mostly in
submucosal glands and airway ganglia in the conducting airways which as a con-
sequence represent the ideal target location of anticholinergic drugs (Labiris and
Dolovich, 2003). Bronchodilators should therefore be deposited in the conducting
airways (Usmani et al., 2003).
Corticosteroids achieve their pharmacological effect on inflammatory cells located
in both the airways and the alveoli so should ideally be distributed throughout
the lungs (Telko and Hickey, 2005). When deposited in the mouth and throat
instead of reaching the lungs, drug particles might cause side effects such as oral
candidiasis and dysphonia (Fadl et al., 2010). When deposited in peripheral air-
ways (in the alveoli), the systemic bioavailability of the drug increases, leading to
an augmentation of side effects. Certain drugs can cause serious side effects, for
example corticosteroids can increase the incidence of osteoporosis when absorbed
at high therapeutic dose (Toogood, 1998). This might have been an issue for Qvar,
an extrafine corticosteroids formulation. Qvar has the same therapeutic effect as
some corticosteroid formulations at half their dose; this may be due to the increased
deposition of Qvar in the peripheral airways. As it deposits mainly in the most
distal part of the respiratory system, the risk of systemic side effects with Qvar
was thought to be higher than with traditional aerosols. However, a long-term
study on children revealed that Qvar did not cause adverse effects on growth, bone
formation, resorption or adrenal suppression (Schayck and Donnell, 2004).
For the drug delivery of molecules targeting the systemic circulation, the API
should be deposited at alveoli level where exchanges with the systemic system
are maximised. The performance of aerosols depends on the quantity of drug
reaching the target site. There are several particles deposition mechanisms in the




1.4.2 Mechanisms of particles deposition in the lungs
In inhaled drug delivery, an aerosol describes the cloud of mist or dry particles
formed by different aerosol devices. Once the formulation is propelled out of the
device, it is atomised into small particles forming a cloud, which upon inhalation
may deposit in the patient’s throat. Particles which pass the throat deposit in the
respiratory airways according to varying processes which are inertial impaction,
sedimentation and diffusion.
Inertial impaction occurs for the biggest particles at oropharynx level and at
branching points. Inertial impaction can be explained by Equation (1.3), describing
the stopping distance of particles.
S = Bmp Up (1.3)
where S is the stopping distance of particles in m, B is the velocity per unit force
in m·s−1·N−1, mp is the mass of the particle in kg and Up is the velocity of the
particle in m·s−1. Equation (1.3) shows that heavy particles (i.e. particles of high
diameter for a given density) achieve longer straight trajectories and therefore have
a higher probability of impacting at bifurcations as they cannot easily adapt their
trajectory to the airflow inside the respiratory system.
As the main change in direction in the respiratory tract is located at the orophar-
ynx, most of the particles of diameter greater than 10µm deposit by inertial im-
paction in this region. Inertial impaction also occurs in the first 10 generations of
the lungs for particles of diameter greater than 5µm (Labiris and Dolovich, 2003).
Equation (1.3) also shows that inertial impaction increases with particle velocity.
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This is due to the fact that a high velocity would also prevent a particle from
adapting its trajectory to the airflow inside the respiratory system. The particles
deposition pattern is therefore dependent on the inspiratory flow rate as it repre-
sents one of the main factors controlling the particles velocity inside the respiratory
system.
Sedimentation occurs in the terminal bronchi for smaller particles reaching the
lower part of the respiratory tract. The sedimentation process can be described
using Equation (1.4).
Uts =
(ρp − ρa) dp 2 g
18 η
(1.4)
where Uts is the particle’s terminal settling velocity in m·s−1, ρp is the particle
density in kg·m−3, ρa is the density of air in kg·m−3, dp is the particle diameter in
m, g is the gravitational acceleration in m·s−2 and η is the formulation viscosity in
kg·m−1·s−1.
Sedimentation concerns particles with a diameter of 0.5µm to 5µm (Labiris and
Dolovich, 2003). Those particles are sufficiently small to reach the lower respiratory
tract but sufficiently heavy to be governed by gravity and sediment in the airways.
Sedimentation occurs mainly in the last five to six generations of the airways which
correspond to the smaller bronchi and bronchioles (Labiris and Dolovich, 2003).
Diffusion is a process in which particles randomly collide with the airway walls. It
is also referred to as Brownian motion. It concerns the smallest particles (primarily
particles of diameter less than 0.5µm) and occurs mainly in the alveoli (Storey and
Yme´n, 2011). The diffusion coefficient can be described using Equation (1.5).
Dif =
K T
3 pi η dp
(1.5)
where Dif is the diffusion coefficient in m2·s−1, K is the Boltzmann constant
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in m2·kg·s−2·K−1 and T is the thermodynamic temperature in K. The diffusion
coefficient is inversely related to the size of particles for particles of diameter smaller
than 1µm (it becomes negligible for particles of higher diameters) (Heyder, 2004).
Particles of diameter between 0.1µm and 1µm can therefore deposit by sedimen-
tation and diffusion. Submicron particles can also be breathed out without having
deposited which can be a problem for the delivery of small particles (Storey and
Yme´n, 2011).
The last two mechanisms of deposition are of less significance. Interception occurs
in peripheral regions where the airways diameter becomes comparable in size to the
particles diameter. Electrostatic precipitation concerns charged particles (typically
charged during the atomisation process) which deposit on walls with a charge of
opposite sign. This process is said to mostly occur for particles of diameter smaller
than 1µm (Smyth, 2003).
1.4.3 Mucociliary clearance of inhaled particles
The lungs provide a direct access to target sites for the treatment of pulmonary
diseases and a direct route to the blood system for the systemic delivery of thera-
peutic agents, representing an ideal target for drug delivery. As they are exposed to
the exterior environment, the lungs need a defence system against foreign bodies.
This defence system, composed of mucociliary clearance and alveolar macrophages,
represents a barrier reducing the efficiency of inhaled drugs delivery (Labiris and
Dolovich, 2003).
Mucus is a substance produced by goblet cells and submucosal glands (Labiris and
Dolovich, 2003). It forms a protective layer that prevents airborne foreign bod-
ies from entering the respiratory airways (Rubin, 2002). Mucus contains sodium,
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chloride, potassium, calcium ions and glycoproteins which give its slimy consistency
(Clarke and Pavia, 1980). Mucociliary clearance is the process in which mucus is
transported from the lower respiratory airways to the upper respiratory airways in
an escalator like manner. The mucus blanket lies on top of the ciliated epithelium
extending from the larynx to the terminal bronchioles (Clarke and Pavia, 1980).
Each cilia has a length of approximately 6µm and a diameter of 0.5µm (Clarke
and Pavia, 1980). The cilia structure moves the mucus layer from the lower air-
ways towards the upper airways. This is done by a whip-like motion in which each
cilia has a rate of 700 to 1000 beats per minute. The foreign bodies trapped in
the mucus blanket are cleared from the upper airways in less than 6 hours. They
are either pushed to the nostrils where they are removed by expiration or to the
pharynx where they are digested. In healthy subjects, mucociliary clearance occurs
faster in central than in peripheral airways (Smaldone et al., 1993). Clearance from
the terminal bronchi is completed in several hours to one day (Clarke and Pavia,
1980).
For the bodies deposited in the alveoli, the clearance takes from one day up to
several months (Clarke and Pavia, 1980). The alveoli are not lined with a ciliated
structure. At alveolar level, the clearance is realised by macrophage cells known as
alveolar macrophages, which engulf the foreign bodies (Clarke and Pavia, 1980).
Other mechanisms such as cough and expiratory flow help to remove foreign bodies
from the respiratory airways. Coughing is caused by nerve endings which are stim-
ulated when irritants are present in excess in the airways. As mucociliary clearance
is generally impaired in patients affected by lung diseases, coughing replaces it as
the main system of airway clearance (Labiris and Dolovich, 2003).
When a drug is deposited in the conducting airways, most of the particles are
trapped in the mucus gel and are removed from the airways by mucociliary clear-
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ance. Only a fraction is absorbed through the airway epithelium to reach its target
site. In the alveolar region, drugs are mostly cleared by alveolar macrophages and
only a fraction is absorbed into the systemic circulation (Labiris and Dolovich,
2003). One of the difficulties associated with aerosol therapy is to deliver APIs to
the lungs, organs that reject foreign bodies.
1.5 Factors affecting lung deposition
1.5.1 Particle velocity
Particles velocity can influence deposition location by increasing particles momen-
tum as shown in Equation (1.3) earlier in the chapter. Particles velocity might
affect the percentage of the spray impacting on the back of the throat by influenc-
ing the amount of particles depositing by inertial impaction. This is illustrated in
Equation (1.6) developed by Kleinstreuer et al (2007).
IP = d2pQ (1.6)
where IP is the impaction parameter in m2·L·min−1 and Q is the inhalation flow
rate in L·min−1. A higher impaction factor has been shown to increase the deposi-
tion of particles in the throat (Kleinstreuer et al., 2007). As the impaction factor
is proportional to the flow rate, an increased flow rate is expected to also lead to
an increased throat deposition.
Patients flow rates might increase the velocity of particles once they reach the
airways. As a result, particles may not be able to adapt their trajectory to the
airflow path and might tend to deposit on the airway walls at the biggest bifurcation
located in the oropharynx. Numerical modelling work and in vitro experiments
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using idealised representations of the mouth-throat region are used to simulate
the trajectory of particles through this part of the respiratory system. In the
respiratory system, air velocity decreases as the air goes deeper into the lungs. This
is explained by the fact that the cross sectional area increases from the trachea to
the terminal bronchi, leading to a decrease in linear velocity (Clarke and Pavia,
1980). In the first 10 generations of the respiratory system, the airflow is high and
turbulent. It is considerably reduced in the terminal bronchi and can be negligible
in the alveolar region (Labiris and Dolovich, 2003). At lower airway generations,
the airflow decreases linearly with the number of airways and thus impaction does
not occur at this level of the respiratory system. The decrease of airflow rate causes
the gravitational force to overcome the air resistance and leads to the sedimentation
of particles in the terminal bronchi. This implies that lower respiratory flow rates
might increase the chance of deposition by sedimentation (Agnew, 1984), (Heyder,
2004).
1.5.2 Size, density, porosity and shape of the particles
The particles size is assessed using several measures such as the aerodynamic diam-
eter daero and the volumetric diameter dv. The relationship between those measures





where ρp is the density of the particle in g·cm−3 and ρ0 is the unit-density (1.0 g·cm−3).
Equation (1.7) assumes that particles are spherical which could be a wrong as-
sumption and lead to errors in the measurements. When quoting particles size, the
aerodynamic diameter is more commonly used as it can assess the size of particles
of all shapes. The deposition mechanisms of several types of particles within the
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respiratory tract are shown in Figure 1.5.
Figure 1.5: Relationship between particles size and lung deposition as printed by
Labiris and Dolovich (2003).
Figure 1.5 illustrates the fact that particles with different aerodynamic diameters
have different deposition mechanisms.
As particles size is the main factor affecting the deposition mechanisms of particles
within the respiratory tract, it also affects their deposition location. For the treat-
ment of lung diseases, particles size should be sufficiently small to avoid deposition
in the mouth or in the throat. However they should not be too small in order to
avoid being directly breathed out or reaching the bloodstream which may cause
side effects.
For the treatment of respiratory diseases, the optimum particle diameter is between
1µm and 5µm (Storey and Yme´n, 2011). For the treatment of systemic conditions,
particles with diameters lower than 3µm must be delivered (Labiris and Dolovich,
2003). Heyder et al (2004) showed the deposition locations of particles in the
respiratory system according to their diameter (Figure 1.6). As they developed a




Figure 1.6: Total and regional depositions of unit-density spheres in the human
respiratory tract predicted by a deposition model for oral inhalation at rest (Heyder,
2004).
Figure 1.6 shows that the oropharynx is the main deposition location for particles
of 10µm diameter and that alveolar deposition is the main deposition location for
particles of diameter smaller than 0.5µm. As shown in Equation (1.6), an increase
in particles diameter leads to an increase in the impaction factor and therefore to
an increased throat deposition (Zhang et al., 2003). The shape of the particles also
plays a role as it affects their aerodynamics.
1.5.3 Obstruction of the airways
Both COPD and asthma cause inflammation of the lungs, leading to the narrow-
ing and obstruction of the respiratory airways. When studying obstructed and
non-obstructed airways, airway geometry is shown to have an effect on particles
deposition in particular for particles of diameter larger than 6µm and for high flow
rates (Inthavong et al., 2010). This was observed when comparing a healthy lung
model with an asthma lung model. The asthma model had a greater percentage
of particle recovery than the healthy model (Inthavong et al., 2010). This means
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that drug particles would have more chance to deposit in the airways when inhaled
by an asthmatic patient compared with a healthy person. It was also shown that
obstructions influence particles deposition process particularly after the obstruc-
tion (Luo et al., 2007). The flow rate in the respiratory system is highly dependent
on airways diameter. As a result obstruction could significantly influence the air-
flow rate and subsequently, the deposition pattern of particles. Luo et al (2007)
developed a model in which particles are at a branch leading to obstructed and
unobstructed airways. Their results show that the obstruction prevent many parti-
cles from entering the airway and as a result more particles would penetrate in the
unobstructed airway. The particles that managed to enter the obstructed airway
will tend to deposit on the inflammation due to inertial impaction.
1.5.4 The influence of hygroscopicity on deposition
Hygroscopicity of particles is the process by which particles increase in size due
to the effect of humidity. As drug particles are generally hygroscopic, they are
expected to grow when entering the lungs which have a relative humidity of ap-
proximately 99.5% (Labiris and Dolovich, 2003). The rate of growth depends on
the initial size of the particles. Particles of diameter smaller than 1µm can in-
crease up to five–fold whereas particles of diameter higher than 2µm can increase
two to three-fold (Labiris and Dolovich, 2003). This shift in the particle size dis-
tribution might result in a more proximal deposition and can be an issue if the
drug needs to reach the more distal airways (Barnes and Godfrey, 1998). Xu and
Yu for example showed that hygroscopicity could cause particles of 1µm diame-
ter to be deposited primarily by impaction instead of sedimentation (Labiris and
Dolovich, 2003). However, hygroscopicity is not believed to affect particles issued
from pMDIs as much as they affect particles issued from DPIs (Terzano, 1999).
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1.6 Performance of inhalation technology
1.6.1 The efficiency of conventional inhaler devices
The performance of inhalers has increased in past years. It is characterised by the
percentage of drug reaching the target site which was reported to be approximately
20% of the emitted dose in 2000 compared to 40% to 60% of the emitted dose
for some devices in 2005 (Kleinstreuer et al., 2008). However, all inhalers still
suffer from the lack of control over the particles deposition location. This prevents
aerosols from being used to maximum efficiency in the treatment of many conditions
such as local lung tumours or diseases treated systemically via the lungs. The lack
of consistency in the deposition location of APIs mainly arise from poor patient
technique as well as poor control over the size and velocity of the particles in
the aerosol (Kleinstreuer and Zhang, 2011). The factors influencing those aerosol
characteristics will be reviewed later in this chapter.
1.6.2 Characterisation of inhaler performance
As seen above, the particle size range of a formulation greatly influences its depo-
sition location in the respiratory system. Different measures help to assess the size
of particles in aerosols. The main measure is the mass median aerodynamic di-
ameter (MMAD), a statistical measure of the aerodynamic size of the spray which
represents “the aerodynamic diameter that divides the particle size distribution
into two halves with respect to mass” (Smyth, 2003). The MMAD is crucial to
characterise pMDIs as it influences greatly the sites of particles deposition. The
MMAD is more relevant to determine the deposition location of a particle than
its geometrical diameter. This is due to the fact that two particles with different
shapes, sizes and densities can still behave identically in an airflow and deposit at
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the same location. The D50 and the MMAD are used depending on the method
chosen to measure particles size.
The geometric standard deviation (GSD) is a measure of the spread of particle
diameters in the aerosol. An aerosol is considered monodisperse at a GSD value
lower than 1.22 and heterodisperse at a GSD value higher than 1.22 (Schuepp
et al., 2004). As the GSD controls the spread in the particle size distribution,
it directly affects the deposition location of particles and determines the preci-
sion with which drug particles deposit at a particular location (Stein and Myrdal,
2004). Monodisperse aerosols should therefore be used to control more accurately
the deposition location of the particles. If the size of the particles is appropriately
engineered, monodisperse formulations have a greater percentage of drug reaching
the target site than heterodisperse formulations and might therefore cause fewer
side effects (Usmani et al., 2003). It was shown that using a monodisperse formu-
lation, the amount of drug delivered can be reduced without reducing the efficacy
of the treatment (Usmani et al., 2003). However, most commercial aerosols remain
heterodisperse (Rubin and Fink, 2003).
The last common measure employed to characterise the particle size range of an
aerosol is the fine particle fraction (FPF). It corresponds to the percentage of the
total emitted dose that is of a particle size suitable for deposition in the lungs; it
is also referred to as the respirable fraction. The FPF represents the percentage
of particles with an MMAD<5µm. For the treatment of lung diseases, the target
site is the lower respiratory tract. In order to achieve deposition at this location, it
was shown that particles should have a diameter between 2µm and 4.7µm (Berry
et al., 2003). Other methods defining the performance of an aerosol spray include
spray geometry and spray velocity (Smyth, 2003).
60
Chapter 1
1.7 Inhalation therapies and devices
1.7.1 Nebulisers
Nebulisers were the first inhalation devices to be developed for the treatment of
asthma after the early atomisers of the 19th century and were the most common
devices in early inhalation technology. The first nebuliser was invented by Dr
Auphon Euget-Les Bain in 1849 and the first portable nebuliser was developed by
Dr Sales-Girons in 1858 (Anderson, 2005). Glass-bulb nebulisers were commonly
developed in the 1930s (e.g. the Parke-Davis Glaseptic) and plastic-bulb nebulisers
in the 1940s (e.g. the AsthmaNefrin) (Anderson, 2005). The first compressor
nebuliser, the Pneumostat R© was designed in Germany in the early 1930s (Anderson,
2005).
As nebulisers can be used during tidal breathing, they are often recommended for
patients having problems using pMDIs and DPIs and are suitable for patients of
any age and with different diseases severities.
Data from 1995 suggests that nebulisers efficiencies range from 10% to 50% (Clark,
1995). In nebuliser devices, the API is dissolved in water by itself or with the
help of a cosolvent such as ethanol or propylene glycol. It can also be suspended
in water to form an aqueous suspension formulation (Clarke and Newman, 1984),
(O’Riordan, 2002).
Traditional nebulisers use an air compressor which is generally electrically operated
(Dhand, 2003). Those devices are composed of three parts which are the face-mask
or mouthpiece, the nebuliser chamber and the compressor. The energy of the
compressed gas is used to aerosolise the medication into a mist. This principle is
somehow similar to the principle behind pMDIs. However, in the case of nebulisers,
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the compressed gas is only used to aerosolise the formulation and is not a component
of the aerosol as in pMDIs. The mist is then inhaled by the patient through the
face-mask or the mouthpiece.
Traditional nebulisers are difficult to transport as they require an electrical or
compressed gas source to operate (Dhand, 2003). They are also difficult to maintain
as the compressor should ideally be checked every six months and the nebulising
chamber should be checked every two months and cleaned daily (Dhand, 2003).
Nebulisers generally deliver coarse droplets which tend to deposit on the throat
rather than on the lower respiratory tract (Clark, 1995). More sophisticated nebu-
lisers were invented to resolve this problem. Those nebulisers recirculate the coarse
particles and thus deliver smaller particles. However, they are much slower to
deliver the medication.
Ultrasonic nebulisers use another operating technology such as the Omron R© tech-
nology. In those devices, the formulation is aerosolised using high frequency waves
generated by piezo-electric crystals. Ultrasonic nebulisers are less bulky than pneu-
matic ones as they do not require a compressor and can produce fine particles.
Other devices such as the Aerogen R© aerosol generator are known to have a similar
size and drug delivery time to other inhalers (Dhand, 2003). The Aerodose R© is a
portable nebuliser using the Aerogen R© technology. It has approximately the same
size as a pMDI but is significantly more expensive. For these reasons, nebulisers
are not as popular as DPIs and pMDIs (Clark, 1995).
1.7.2 Dry Powder Inhalers
DPIs are devices that deliver drugs to the lungs in the form of a dry powder. The
first DPI was patented in 1864 by Newton in London. The patent outlined that
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the powder should be kept dry before being finely propelled out of the device. The
first commercial DPI was the Aerohaler R© patented by Fields in 1948 and marketed
in 1949 by Abbott Laboratories (Clark, 1995). It was used to deliver penicillin.
DPIs are generally composed of one-phase solid particles blends containing the
API in micronised form mixed with coarse and large “carrier” particles (Telko and
Hickey, 2005). Those particles were originally aimed to dilute the drugs, thus
improving the dose-to-dose reproducibility (Bisgaard et al., 1998). After a time it
was noticed that they also improved the flow properties as well as the dispersion
and de-agglomeration of the particles (Telko and Hickey, 2005).
The first DPIs provided single-dose medication but evolved to provide multi-doses.
Multi-dose DPIs can either be pre-metered in blisters or measured in the device in
a powder reservoir (Chan et al., 2007).
When a patient inhales through a DPI, an airflow penetrates the static powder bed
(on which the API is lying), creating turbulence and shear stress, which fluidizes
and entrains the drug-carrier mixture. As they enter the patient’s airways, the
drug particles are separated from the carrier particles and reach the lungs while
the carrier particles impact on the throat (Telko and Hickey, 2005).
Newman suggests that the amount of drug particles depositing in the lungs as a
percentage of the metered dose of a DPI ranges from 5% to 40%, depending on the
design of the device, its formulation and the patient’s inhalation flow rate (Newman
and Busse, 2002). Those varying efficiencies can be seen in Table 1.3 gathered by
Newman and Busse (2002). DPIs are approximately 2.5 times more expensive to
produce than their pMDI equivalents. The cost of recycling is also higher for DPIs
than for pMDIs (Covar and Gelfand, 2008). This increased cost is relevant as DPIs






Rotahaler R© Sodium cromoglycate Slow (60 L·min−1) 6.2
Spinhaler R© Sodium cromoglycate
Fast (120 L·min−1) 13.1
Slow (60 L·min−1) 5.5
Diskhaler R© Salbutamol Not known 12.4
Turbuhaler R© Budesonide
Fast (58 L·min−1) 27.7
Slow (36 L·min−1) 14.8
Pulvinal R© Salbutamol
Fast (46 L·min−1) 14.1
Slow (28 L·min−1) 11.7
Easyhaler R© Salbutamol Fast (60 L·min−1) 28.9
Ultrahaler R© Nedocromil sodium
Fast (75 L·min−1) 13.3
Slow (42 L·min−1) 9.8
Clickhaler R© Budesonide 35 − 65 L·min−1 30.8
Taifun R© Budesonide
Fast (36 L·min−1) 34.3
Slow (21 L·min−1) 29.6
Cyclohaler R© Asthma NCE Fast (98 L·min−1) 19.1
Spiros R© Budesonide
Slow (15 L·min−1) 40.5
Fast (60 L·min−1) 30.4
Novolizer R© Budesonide
Fast (99 L·min−1) 32.1
Slow (54 L·min−1) 19.9
Table 1.3: Lung deposition of drugs from various DPIs, as percentages of metered
or capsule dose.
The strength of the DPI, (being actuated only upon inhalation) also represents its
main weakness. If the patient has a weak flow rate (which is often the case in the
treatment of obstructive lung diseases), the force used to aerosolise the drug might
not be sufficient to separate the carrier and drug particles, lowering dramatically
the device performance. A medium to high inspiratory flow rate is needed to remove
the API particles from the dose chamber or capsule and to separate them from the
carrier particles (Newman and Busse, 2002).
This is illustrated in Table 1.3 showing increased percentages deposition in the
lungs at higher inspiratory flow rates.
For this reason, many patients with lung diseases are unable to effectively gener-
ate an aerosol cloud from commercial dry powder inhalers (Burnell et al., 2001).
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DPIs are generally not recommended for children under 6, as their inspiratory
flow rate tends to be too low to adequately aerosolise the formulation (Bateman
and Fitzgerald, 2011). However, some brands are approved for younger children
(Turbuhaler R© is approved in most countries for 5 year-olds and the Diskus R© is
approved for 3 year-olds) (Bisgaard et al., 1998). As the efficiency of the devices is
dependent on patients inspiratory flow rates, DPIs have low dose uniformity (Telko
and Hickey, 2005). In order to overcome this issue, other actuation mechanisms
have been added to the patient inspiratory flow rate to aerosolise efficiently the
drug-carrier compound. The added component that produces the turbulence can
be an electronic vibrator, an impeller or a pneumatic power assisted device (Cop-
ley, 2009). Those “active” DPIs produce a sufficient level of turbulence and shear
stress to aerosolise efficiently the drug even at low inspiratory flow rates. In those
designs, the percentage drug deposition depends less upon patients inspiratory flow
rates which could lead to higher efficiencies and dose reproducibilities. However, as
those devices are more expensive than the traditional breath-actuated DPIs, they
are mainly used for the delivery of expensive systemic drugs such as insulin, for
which it is critical to deliver a specific drug amount to a precise deposition site.
Exubera R©, commercialised in 2006 by Pfizer, was the first inhaler to deliver insulin.
It was withdrawn from the market in 2007 due to poor sales. Aspirair R© is another
active DPI developed in 2007 by Vectura (Furness, 2006).
1.7.3 Inhaled drug delivery market
With an increasing number of people affected by pulmonary diseases, the market for
inhaled drug delivery has been constantly growing in the past 20 years (Fadl et al.,
2010). In 2011, the markets for the treatment of asthma and COPD achieved
sales of respectively 21.6 billion dollars and 12.9 billion dollars worldwide. The
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global prescription respiratory market was worth 64.6 billion dollars (AstraZeneca,
2011). As only 20% of people affected with COPD are believed to be diagnosed,
and as more patients gain access to treatments, market growth is set to continue.
PMDIs are believed to have a global market share of between 60% (Andersen et al.,
2010) and 80% (Telko and Hickey, 2005) with annual sales greater than 400 million
units (Sanders, 2007). The pMDIs segment generated almost 14.4 billion dollars in
2011 and is forecasted to reach 29.8 billion dollars by 2016 (BBC Research, 2012).
However, the number of units sold has slightly decreased between 2002 and 2009
due to the increasing market share of DPIs (Andersen et al., 2010). DPIs became
more commercially successful in the past twenty years after regulation caused the
decline of pMDIs. DPIs sales reached 14 billion dollars in 2008 and are forecasted to
continue increasing in the coming years (Clayborough and Simpson, 2010). DPIs
generally have the same price as pMDIs in developed countries. However, they
tend to be more expensive than pMDIs in developing countries. This is the reason
why although they account for one-third of the inhalation market by sold units,
they represent approximately half of the inhalation market in value (Lee, 2011)
The market share of DPIs is expected to achieve a higher growth compared with
pMDIs in the next few years. This is illustrated by the fact that for more than a
decade, the number of patents issued for DPIs devices has outgrown the number
of patents issued for pMDIs (Inhalation Report, 2009). However, as they remain
more expensive to produce, they are not expected to expand in developing countries




1.8 Pressurised Metered Dose Inhalers
1.8.1 Device components
pMDIs are devices that use compressed gases as a source of energy to aerosolise
drugs. They are composed of disposable and compact canisters containing be-
tween 100 and 400 doses (Oliveira et al., 2010). The canister needs to be strong to
withstand pressure from 3.5Patm to 10Patm but also needs to be light to be easily
carried. Therefore, it is often made of aluminium by a deep drawing process (Dun-
bar et al., 1997). Canisters typically have a volume of 15 mL to 30 mL (Oliveira
et al., 2010).
pMDIs also contain a propellant system, a metering valve, an actuator and a mouth-
piece. The actuation system is made of the metering chamber, the expansion cham-
ber, and two coupled valves placed on each side of the metering chamber at the level
of the interior orifice and the valve orifice (Swarbrick, 2007) as shown in Figure 1.7.
Figure 1.7: Schematic of the interior of a canister.
The metering valve (located at the interior orifice) aims to measure the metered
volume accurately and reproducibly. It should also be tightly sealed due to its high
pressure content. The metering valve contains a gasket, a ferrule and a valve stem
which connects the metering valve to the actuator as shown in Figure 1.8. The
expansion chamber represents the area between the valve orifice and the nozzle
orifice as seen in Figure 1.7. It is formed of the valve stem and actuator chamber
as shown in Figure 1.8.
67
Chapter 1
Figure 1.8: Components of a metering valve (Dunbar, 1996).
The expansion chamber’s main role is to leave sufficient time for the spray to start
atomising before reaching the nozzle orifice so that a liquid and vapour mixture is
already formed when exiting the device (Bar-Kohany and Sher, 2004).
Today, most APIs used in pMDIs are bronchodilators, corticosteroids and anti-
cholinergic drugs for the treatment of pulmonary diseases. The API represents at
most approximately 1% w/w of the total formulation (Fink, 2000) and an upper
limit of 2% w/w has been established in order to avoid the clogging of the valve
(Smyth, 2003). pMDIs also contain one or several types of substances to make the
API suitable for administration. The main component is the propellant.
Propellants are used as the source of energy to propel the formulation out of the
canister and aerosolise the flow into small inhalable particles. Propellants gener-
ally represent at least 80% w/w of the formulations (Fink, 2000). It was found
that formulations containing less than 80% w/w of propellant showed poor spray
properties (Ju et al., 2010). pMDIs might contain other substances referred to as
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excipients. There are two types of excipients: surfactants and cosolvents.
The surface active agents (surfactants) are often added to pMDIs’ formulations in
order to lubricate the valves and help stabilise suspension formulations. Cosolvents
can also be added to pMDIs formulations. Flavouring agents, stabilising agents,
dispersing agents and preservatives are also common components of pMDIs (Fink,
2000). For example, Alupent and Proventil contain respectively sorbitan trioleate
and oleic acid as stabilising agents (Berlin and McCarver, 1997).
1.8.2 Advantages of pressurised metered dose inhalers
pMDIs are the most commonly used inhalation devices for the treatment of res-
piratory diseases due to their low cost, robustness, portability and user-friendly
features (Kleinstreuer and Zhang, 2011). Contrary to DPIs, they do not depend
on patients’ flow rate to de-agglomerate the drug; which allows children younger
than 4 years old or patients with low inhalation flow rates to use them (Bate-
man and Fitzgerald, 2011). They also protect the drug from humidity and other
environmental conditions that can damage the API (Keller, 1999).
Their efficiency has improved, with 10% to 20% of the drug particles reaching
the lungs for pMDIs designed in the eighties compared to approximately 50% for
certain recent designs (Newman, 1985), (Stein and Myrdal, 2006).
1.8.3 Propellants used in pressurised metered dose inhalers
Originally, pMDIs were formulated with chlorofluorocarbon (CFC) propellants. In
1974, Molina and Rowland showed that CFCs cause degradation of the strato-
spheric ozone layer (Purewal, 1997). In 1987, the Montreal protocol banned CFC
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propellants because of their depleting effect on the ozone layer and ordered the
complete extinction of CFCs as propellants for aerosols by 2015 (Andersen et al.,
2010), (Anderson, 2005). Since Molina and Rowland’s discovery, efforts in finding
alternative propellant to replace CFCs have been continuous as there was no al-
ternative device as efficient as pMDIs available at the time. However, the effort of
finding new ozone-friendly propellants and reformulating each pMDI deterred some
industrials who preferred to focus their research on alternatives to pMDIs such as
propellant-free liquid methods and DPIs (Smyth, 2003). Because of the time and
cost of reformulation (which is believed to have been greater than 1 billion USD
(Andersen et al., 2010)), improving the performance of DPIs became more and
more appealing to pharmaceutical companies.
Scientists in charge of finding suitable alternative to CFCs analysed the toxicity
profile of other propellants, their solubility with APIs and surfactants, their vapour
pressure, their density, their taste and their odour. Chlorine free propellants were
investigated as chlorine was identified as the component harming the ozone layer.
Dimethyleter was considered but was expensive to manipulate due to its high
flammability and was dropped in favour of hydrofluoroalkanes (HFAs) (Swarbrick,
2007). HFA134a and HFA227ea distinguished themselves from other potential pro-
pellants and the International Pharmaceutical Aerosol Consortium for Toxicity
Testing (IPACT) conducted tests proving their safety and innocuity. Their only
side effect was sedation but it occurred at such high concentrations that the se-
dation was attributed to a lack of oxygen rather than to the HFAs. Some studies
also showed that HFA134a and HFA227ea were less likely to cause cardiac adverse
effects than some CFCs (Leach, 1995). HFA-based pMDIs proved to have a more
constant dosage than CFC-based pMDIs; which could be due to the fact that HFAs
are less sensitive to temperature changes (Clark, 1991). In addition, HFAs are not
flammable and seem to have similar physical and chemical properties as CFCs.
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All IPACT studies led to the conclusion that HFAs were as safe or safer than the
CFCs they were meant to replace. The main challenge remained the reformulation
of the existing CFC-based pMDIs with HFAs (Leach, 1995). The dissimilarities
between CFCs and HFAs that mainly affected the reformulation process were the
higher polarity and vapour pressure of the new HFA propellants (Smyth, 2003).
When comparing the deposition patterns of CFC and HFA driven pMDIs within
the lungs, it was found that HFA was spread more diffusely throughout the airways
while CFC remained in the central airways. Leach found that HFA-driven aerosols
lead to greater deposition of the aerosol within the lungs while also decreasing the
amount depositing at oropharyngeal level (80% to 90% of CFC-based pMDIs de-
posit in oropharyngeal region whereas HFA-based pMDIs deposit approximately
60% of the aerosol in the central lung region). As a result, a lower amount of
drug could be used when using HFA-driven aerosols. Using HFAs rather than
CFCs could also decrease the risk of throat inflammation associated with the re-
peated exposition of the oropharyngeal region to the propellant (Leach, 1995). In
his model, Kleinstreuer finds that CFC formulations lead to a lung deposition of
23.2% compared to 46.4% obtained with HFA formulations. Those findings might
be due to the fact that HFA propellants produce smaller droplets than CFC propel-
lants (Smyth, 2003). The sprays from HFA-based inhalers are found to be at least
twice slower than those of CFC-based inhalers (Hochrainer et al., 2005). It was
also found that HFA pMDIs have longer spray durations (0.21 s to 0.36 s for HFA
sprays compared with approximately 0.16 s for CFC sprays) (Hochrainer et al.,
2005). This could cause CFC-driven aerosols to increase coordination problems
compared to their HFA counterparts.
Nowadays, HFA134a and HFA227ea are the most common propellants for pMDIs
applications. One study showed that the MMADs of HFA227ea-driven sprays are
0.3µm to 0.4µm bigger than the MMADs of HFA134a-driven sprays (Purewal,
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1997). Brambilla et al (1999) found that the MMAD of a HFA134a formulation was
2.8µm compared to 3.5µm for an HFA227ea formulation. This could be explained
by the fact that HFA134a has a higher vapour pressure than HFA227ea (at 20◦C,
HFA134a has a vapour pressure of 570 kPa compared to 390 kPa for HFA227ea).
The vapour pressure corresponds to the pressure at which a substance’s vapour
and liquid phases are in equilibrium. A high vapour pressure will lead to a faster
evaporation as the propellant will start evaporating in the metering chamber when
the pressure is still relatively high. It is proven that a higher proportion of propel-
lant evaporating in the metering and expansion chambers leads to smaller droplets
in the aerosol (Purewal, 1997). This would imply that a high vapour pressure is
necessary for aerosol application as smaller droplets decrease the chance of oropha-
ryngeal impaction. However, it was also shown that droplets velocity increases at
high vapour pressures (William and Liu, 1998), which could enhance oropharyngeal
impaction. The high velocity of pMDIs sprays should be reduced as up to 80% of
particles issued from pMDIs impact on the throat (Fink, 2000). In order to reduce
the chances of oropharyngeal impaction due to high droplet velocity, HFA134a is
often mixed with a solvent of lower vapour pressure. This process is explained later
in this chapter.
Although pMDIs do not use CFC propellants anymore, they still have a weaker
ecological profile than DPIs as they contain propellants such as hydrofluoroalkanes
(HFAs) which exhibit greenhouse gas potential (Leach, 2005).
1.8.4 Pressurised inhalation formulations
Drugs in pMDIs can either be in solution formulations (dissolved in the propellant)
or in suspension formulations (drug and propellant are not miscible and stand in
two separate phases with drug particles suspended in the propellant). If the inhaler
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is a suspension type, the API and the propellant should have a low solubility as
partial solubility can induce crystal growth, increasing the risk of variations in
particle size and emitted dose (Smyth, 2003).
Suspension may lead to changed quantity of APIs in droplets due to particles aggre-
gation and flocculation (Smyth, 2003). Surfactants are often added to suspension
formulations to ensure the chemical stability of the formulation by preventing ag-
gregation of the API. They are also used to lubricate the valves in pMDIs (Smyth,
2003). Those surfactants were generally miscible with CFCs. This is the reason
why most CFC-based pMDIs were designed as suspension formulations. Com-
monly used surfactants such as sorbitan trioleate, oleic acid and lecithin have a
much lower solubility with HFAs (0.005% to 0.02% w/v) than with CFCs (0.1% to
2.0% w/v) (Smyth, 2003). The solubility of surfactants in HFAs is not sufficient to
ensure the chemical stability of the drug in suspension formulation (Smyth, 2003);
(Haynes et al., 2004). It can be increased by adding a cosolvent such as ethanol
in the formulation. However, adding a cosolvent to a formulation also increases
the solubility of the API in the propellant which must be avoided in suspension
formulations. This is the reason why solution type formulations became more pop-
ular with the development of HFA-based pMDIs. The main advantage of solution
formulations is that a constant quantity of drug is produced at each actuation.
However, they do not guarantee the chemical stability of the drug. If the inhaler is
a solution formulation, the API should have a sufficient solubility in the propellant
so that more API is delivered at each actuation and therapeutic effect is achieved
with a few actuations. Solution formulations might thus contain surfactants and/or
cosolvents to increase the solubility of the API in HFAs.
In solution formulations, the particle size is mainly governed by the percentage of
non-volatile components in the formulation, the vapour pressure of the formulation
as well as the device design. On the contrary, the minimum droplet size issued from
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suspension formulations is dictated by the size of the drug particles suspended in
the formulation. Most suspension formulations are composed of particles with
diameter ranging between 2µm and 5µm (Smyth, 2003).
1.8.5 The use of cosolvents in pressurised inhalation for-
mulations
Cosolvents are often used in HFA solution formulations to improve the solubility of
APIs and surfactants in HFA propellants, leading to the delivery of a greater ther-
apeutic dose by metered volume. They are also used to reduce the vapour pressure
of HFA134a leading to the aerosolisation of slower droplets. Adding ethanol to an
HFA-based formulation could therefore be thought to decrease oropharyngeal depo-
sition. It is also thought to prevent microbiological contamination (Smyth, 2006).
However, studies generally show that the efficiency of HFA solution formulations
decreases at high ethanol concentrations. When adding ethanol, the decrease in
vapour pressure can have several effects on the aerosolisation process. It might
increase the initial droplet mass median diameter and decrease the evaporation
rate of the aerosol. As a result, higher ethanol concentrations may lead to bigger
initial droplets which evaporate slower. The droplets would thus be bigger when
reaching the throat and a larger fraction of the aerosol would possibly impact on
the oropharynx (Stein and Myrdal, 2004). Even though high ethanol concentra-
tions lead to a greater amount of drug delivered (due to a greater solubility with
HFAs), it is necessary to estimate the net gain of adding ethanol. It was estimated
that the benefits of adding ethanol are cancelled when the percentage of ethanol
by weight is higher than 10% to 15% of the formulation. At higher concentrations,
significant deposition at the oropharynx not only decreases the percentage of drug
delivered to the lungs, but also increases the risk of systemic side effects and throat
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inflammation (Gupta et al., 2003).
1.8.6 Concentration of drug substance
The mass of API inside the metering chamber can vary from 20µg to 5000 µg
(Oliveira et al., 2010). The MMAD of aerosols was shown to increase with the
concentration of API in the formulation. For example, Polli et al (1969) investi-
gated two formulations with API concentrations of 0.175 mg·g−1 and 2.86 mg·g−1
and found MMADs of 3.2µm and 18µm respectively. When the drug concentration
increases, the quantity of propellant relatively decreases. As the propellant repre-
sents the source of energy which breaks up the liquid aerosol stream in particles, a
lower propellant concentration could result in a lower amount of energy available to
aerosolise the flow into small inhalable particles. A greater concentration of drug
substance also causes the molecules present in the formulation to be closer to each
other, increasing their force of attraction. As a result, when a formulation contains
a greater quantity of drug substance, a smaller source of energy is available to break
up a greater quantity of concentrate particles strongly bonded together, leading to
bigger droplets. The larger particles size could also be explained by the fact that
the propellant has the highest vapour pressure of all ingredients in the formulation.
Increasing drug substance concentration therefore decreases the vapour pressure of
the formulation. As mentioned previously, decreasing the vapour pressure of a for-
mulation results in greater MMAD (as the aerosol undergoes less flashing process
(Ashworth et al., 1991)). This may explain why formulations with a higher drug
amount have a larger MMAD and a lower FPF (Polli et al., 1969).
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1.8.7 Concentration of surfactant
As surfactants are non-volatile, it is also thought that they could be used to mod-
ulate the size of residual particles. When comparing a solution containing 1% and
5% w/w of pluronic l81, a study found that the 1% concentration leads to smaller
MMAD, higher FPF and deeper lung deposition. This may be due to the reduced
evaporative potential of droplets with higher concentration of pluronic l81 caused
by the strong hydrogen bond between pluronic l81 and HFA227ea (Saleem and
Smyth, 2009). Generally, excipients are used to increase the chemical stability of
the drug or to solubilise the drug in the propellant. As excipients are non-volatiles,
they will likely increase the size of residual particles and could therefore be used
to modify the site of deposition of the drug (Stein and Myrdal, 2004).
1.8.8 Patient-related issues in metered dose inhaler use
It is recognised that pMDIs performance is not consistent and this variability is
mainly caused by patient-related factors. Up to 2 out of 3 patients might not use
their pMDIs properly, thus reducing their efficiency (Fink, 2000). The handling
of the device includes the initialisation of the device and the inhalation technique.
Proper device handling can increase pMDIs’ performance. Alternatively, inappro-
priate handling of the device can reduce the treatment’s efficacy.
Initialisation of the device
Certain steps in the handling of the device are more critical than others. For
example the position of the device can influence the performance of the pMDI but
forgetting to prime the device can result in a complete failure of the drug delivery.
The initialisation varies from device to device. It generally consists in shaking and
priming the device (“firing a few shots”) before using it (Keller, 1999). Suspension
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type pMDIs need to be shaken prior to use, as the drug is not dispersed in the
propellant.
Patient force of actuation
pMDIs’ efficiency could also be compromised when patients are not able to apply
the required pressure on the pMDI actuator (e.g patient suffering from arthritis).
A force between 30 N and 40 N is necessary to overcome the resistance of the de-
vice and actuate conventional stem-type metering valves (MacMichael and Hearne,
2002). Those forces might be too high for pediatric and geriatric populations. One
study showed that only 29% of the participants could generate a sufficient force to
fire all marketed pMDIs with 36% of elderly participants in the study being un-
able to generate the minimum force to actuate any device (Armitage and Williams,
1988). Another study showed that the patients with the lowest hand strength were
unable to properly use pMDIs as they could not coordinate the actuation of the
device and the inhalation (Gray et al., 1996). pMDIs are therefore restricted to
patients able to actuate the device with sufficient strength.
Patient inhalation technique
One study reveals that 42% of the patients have inadequate inhalation technique
when using their pMDIs (Loh et al., 2004). Coordination is the main issue when
inhaling a pMDI dose, as the actuation of the device and the inhalation should occur
simultaneously. It is estimated that 50% of pMDIs’ users encounter coordination
problems when using pMDIs (Hickey, 2004). A lack of coordination increases the
risk of the actuated dose impacting on the back of the throat and therefore prevents
the total dose of drug from reaching the lungs (Marshall, 2010). It results in a
greatly decreased efficiency of pMDIs and currently represents their main drawback.
To overcome this problem, flow-triggered pMDIs actuated by a user’s inspiratory
flow rate i.e. breath-actuated pMDIs, were designed. For instance, the Autohaler is
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actuated when the flow detected is equal or superior to 30 L.min−1. The Autohaler
contains a lever on top of the device that needs to be lifted prior to use. This
loads a spring acting against a vane mechanism. Once the flow is superior to
30 L.min−1, the vane moves and causes the canister to be actuated (Fink, 2000).
The coordination problem can be solved by using spacer chambers. Those add-
on devices have a volume from 20 mL to 750 mL and are attached to the pMDI
mouthpiece (Newman, 2005). They delay the penetration of the spray into the
mouth by creating a distance between the pMDI and the patient. As a result the
need for synchronisation is greatly reduced if not eliminated. However, spacers are
bulky and render pMDIs less convenient to transport (Newman, 2005).
As mentioned earlier, it is believed that gravitational sedimentation increases with
decreasing airflow rates (Dolovich, 1991). A relatively low airflow rate of 30 L.min−1
should be adopted by pMDI users to optimise their device’s efficiency (Vincken
et al., 2010).
It was also shown that a deep inhalation followed by a breath-hold of 10 s maximises
the drug deposition in the lower part of the lungs (Kleinstreuer et al., 2008). As the
number of airborne particles subject to gravitational sedimentation decreases ex-
ponentially with time, a long inspiration followed by breath-holding might increase
the deposition of those particles on the lower airways (Agnew, 1984). Particles
depositing by diffusion are also more likely to deposit in the lower airways with
breath-holding than when the inhalation is followed immediately by an exhalation
as the latter tends to increase the exhalation of those submicron particles (Sanders,
1979). Patients therefore need to practice their inhalation technique adequately in
order to maximise their pMDI efficiency.
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Positioning of the device during inhalation
The angle at which users hold their pMDI was also found to have an effect on the
device’s efficiency. The efficiency was shown to be maximised at spray angles of
20◦ (Fadl et al., 2007). This might be because at a 0◦ angle, the spray impacts on
the tongue and the top of the spray is too far from the mouth ceiling to ensure a
sufficient friction to slow it down, leading to an increased throat deposition. At a
20◦ angle, the spray is at the ideal position, being located equidistantly from the
tongue and the mouth ceiling. As a result, shear stress contributed by the tongue
and the mouth ceiling can slow down the spray which as a result, does not impact
as much on the throat (Fadl et al., 2007).
1.9 Particle sizing methods for inhalation prod-
ucts
As mentioned in the beginning of this chapter, the size of the particles issued from
pMDIs determines partly their deposition location. For this reason, particle sizing
is of prime importance when designing inhalers. Aerosol particles can be measured
using several methods such as microscopy, inertial separation, laser diffraction,
image analysis, time-of-flight and phase Doppler analysis.
1.9.1 Laser diffraction analysis
Laser diffraction can be used to assess the size of particles in a flow. Several instru-
ments such as the Malvern 2600 R©, the Malvern Mastersizer R© E and S, the Malvern
Spraytec R© (Malvern Instruments, Inc., Southborough, MA) and the Sympatec R©
(Sympatec Inc., Lawrenceville, NJ) employ laser diffraction to assess the size of
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particles in different types of sprays. Laser diffraction represents a flow analysis
(vaporised formulations in the case of pMDIs) using a laser beam. When entering in
contact with a droplet, the laser light splits if the droplet is sufficiently small. The
laser diffraction is inversely proportional to the droplet size, allowing the droplet
size to be derived from the diffraction angle.
Algorithms used in laser diffraction analysis
In order to solve sprays particle size distributions, laser diffraction instruments can
use the Mie or the Fraunhofer scattering theories (Haynes et al., 2004). Fraun-
hofer theory represents a simplified version of the Mie theory, in which the optical
properties of the flow are not needed. It can be applied to opaque and spherical
particles of diameters much larger than the laser wavelength. It works best on
particles of diameter greater than 25µm (Mitchell et al., 2006). For particles with
smaller diameters such as pMDIs particles, it is recommended to use the Mie scat-
tering theory which takes into account the optical properties of the medium and
the spray although the latter might sometimes be difficult to assess (Xu, 2001).
Both medium and spray properties are needed as the angular diffraction pattern
depends on the ratio of the medium to the particles refractive index.
1.9.2 Inertial impaction analysis
Impactors separate particles according to their inertia. Particles with high iner-
tia deposit by inertial impaction on the impactor location corresponding to the
throat. The lowest the inertia of the particles, the further they can travel inside
the impactor, to reach locations representing the lower respiratory airways.
The two most common impactors are the Andersen cascade impactor (ACI) and
the next generation impactor (NGI). Impactors can generally measure particles
80
Chapter 1
with diameters ranging from 0.5µm to 35µm. Impactors are the most commonly
used instruments for aerosol particles sizing and are recommended by the United
States and the European pharmacopeias (Telko and Hickey, 2005).
One of the many advantages of impactors is that the determination of particle size
is aerodynamic so that it can take into account particles density and shape. They
can also provide chemical analysis of the particles, which is relevant as it allows the
determination of the amount of API of a particular size. Impactors can analyse the
whole spray issued from a pMDI and predict the deposition location of particles,
as a percentage of the total delivered dose.
However, impaction testing is labour intensive and time consuming. It is also
intrusive, as a sample of the spray is needed for the impactor to operate. Under-
estimation of particles size can occur as small droplets containing only propellant
are not filtered by impactors. However, this can be prevented by conducting a
chemical analysis following the impaction measurement. The size of the residual
particles can be overestimated compared to the size of the initial micronised API
when agglomeration of drug particles occurs inside the pMDI.
Michael et al (2001) indeed showed that the residual size of salmeterol xinafoate
and fluticasone propionate particles was higher than their initial size due to ag-
glomeration. Aggregation is reported to occur more in HFA-based pMDIs than in
CFC-based pMDIs (Michael et al., 2001).
Loss of particles on walls and on inter-stage surfaces can also reduce the accu-
racy of impactor devices. Impactor measurements significantly differ from in vivo
measurements. This might be due to the fact that the simulation throat used
in impactors experiments is not realistic. This problem can be reduced by using
anatomic throats (Smyth, 2003).
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Laser diffraction and impaction are the two most commonly used methods to mea-
sure the size of particles issued from inhalers. Other methods are described below.
1.9.3 Microscopy and particle imaging
The size of particles issued from pMDIs can be determined using microscopy. In
this method, the aerosol is fired on a plate treated to maintain the pattern of the
droplets. The main issue associated with this technique is that the concentration
of droplets should be sufficiently low to ensure that several droplets do not impact
at the same location as this would interfere with the size measurements. However,
the concentration should be sufficiently high to guarantee statistically significant
results (Dunbar, 1996).
1.9.4 Time-of-flight analysis
The time-of-flight analyser is an aerodynamic particle sizer (APS). It assesses the
residual size of particles by measuring the spray inside a large reservoir once all
its volatile components are evaporated. Time-of-flight analysers measure the time
of flight of particles as they travel through two laser beams. Particles velocities
are then converted to particles sizes. The APS R©3603 from TSI Inc. can measure
particles of size ranging from 0.2µm to 700µm (Mitchell and Nagel, 2004). The
APS R©3321, with an operating size range between 0.5µm and 20µm, is ideal for
the measurement of pMDIs sprays.
Haynes et al (2004) reported that time-of-flight analysers suffer from similar parti-
cles oversizing problems as the Malvern Spraytec R©. These problems may be due to
the fact that measurements occur while droplets are not fully evaporated. However,
Tiwari et al. (1998) showed that the Aerosizer R© gave lower particle size distribu-
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tions compared to the Malvern 2600 R© (Haynes et al., 2004). This might be due
to the fact that when using the Aerosizer R©, the particles were discharged in a 4 L
induction port before being measured (which would allow a more complete evapo-
ration of the particles) whereas when using the Malvern 2600 R©, the particles were
measured while still evaporating (Haynes et al., 2004). Mitchell et al. (2003) also
reported that the APS R© tend to undersize particles issued from pMDIs compared
with inertial impactors.
In this work, the size of aerosols particles will be measured using cascade impactors
and laser diffraction instruments as they remain the most commonly used instru-
ments for the assessment of aerosols particles size (Haynes et al., 2004). However,
as each method calculates particles sizes at different times and locations in the
aerosolisation process, using varying theories, it is advised not to compare directly
the particles size obtained with different apparatus.
1.10 Velocity measurements of emitted aerosols
A high velocity of droplets might increase their chance of inertial impaction and
thus reduce their ability to reach the lower respiratory tract (Hochrainer et al.,
2005).
However, at higher velocities, droplets might also be able to break up into smaller
secondary droplets due to increased aerodynamic forces applied to the spray. This
might result in their ability to reach lower parts of the respiratory tract (Finlay,
2001).
Velocity and size are considered the main factors influencing the deposition location




1.10.1 High-speed video recording
The velocity of an aerosol can be estimated by recording frames of the developing
spray and measuring the distance travelled by the front edge of the spray between
2 frames. Hochrainer et al (2005) used this method for HFA-based and CFC-
based sprays using a video camera with a 10 ms delay between each frame. The
evaporation of the spray enhances its deceleration as it causes particles to shrink
and therefore reduces their momentum. Hochrainer et al showed that the velocity
of HFA-based pMDIs decreased from an initial velocity of 10 ms−1 to 20 ms−1 to a
velocity of 2.0 ms− to 8.4 ms−1 at approximately 10 cm from the nozzle, depending
on the device tested.
1.10.2 Particle velocity measurements
Several quantitative methods can be used to measure particles velocity. The first
method was invented in the 18th century by the French engineer Henri Pitot. It
uses Pitot tubes to derive particles velocity from the pressure of the flow using
Equation (1.8) developed by Bernoulli.
U2flow
2




where Uflow is the flow velocity in m·s−1, g is the gravitational acceleration in
m·s−2, Z is the elevation of the point of measurement in m, Pflow is the pressure
at the point of measurement in kg·m−1·s−2 and ρflow is the density of the flow in
k·m−3.
In the 1920s, the implementation of hot wire anemometry improved the quality
of velocity measurements. Hot wire anemometers contain a fine metal wire at a
temperature above ambient temperature. Depending on the flow velocity, the wire
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cools to a certain extent, modifying its electrical resistance. The flow velocity can
thus be derived from the electrical resistance of the wire. Pitot tubes and wire
anemometers disturb the measured flow and can thus modify its behaviour and
characteristics (Wernet, 2003).
Laser Doppler anemometry (LDA), invented by Yeh and Cummins (1964), repre-
sents the first non-invasive (it does not interact physically with the flow) method
to measure 1D, 2D or 3D velocity components of a flow at one point. In LDA, sev-
eral laser beams are used; their cross-section, referred to as measurement volume,
is composed of dark and light fringes. The distance between the fringes is used





Figure 1.9: Drawing of the measurement volume showing the formation of fringes
(Devenport, 2006).
As the flow particles travel through the fringes, they scatter the laser light and
generate a modulation of the light intensity referred to as “a Doppler burst”. The
frequency of this scattering is used to determine the flow velocity. A lens helps to
measure the frequency by focusing the fluctuating light on a photodetector trans-
forming the light signals into voltage signals. A signal processor then determines
the frequency of this electrical signal which is used to derive the flow velocity using








where Sf is the distance between the fringes in m, λ is the wavelength of the laser
light in m and α is the angle of the intersecting beams in rad. The relationship






where f is the frequency of oscillations determined by the signal processor in Hz
and Up is the velocity of a particle in m·s−1.













Figure 1.10: Schematic of a single-component dual-beam LDA system (Devenport,
2006).
The two main disadvantages of LDA are that it can only measure particles velocity
at one point in the flow and can only assess the size of spherical particles. Particle
image velocimetry (PIV) on the contrary can provide particles velocity measure-
ments on one plane. This can be of benefit for the analysis of pMDIs sprays as




Pulsed light velocimetry is an umbrella term describing the analysis of particles
velocity using pulsed light. Varying laser techniques are used depending on the
flow density to be analysed. Laser speckle velocimetry (LSV) is a method designed
to measure the velocity of highly dense flows in which overlapping particles form
speckles in each interrogation spot (Pust, 2000). Particle tracking velocimetry
(PTV) is used to analyse low-density flows by tracking each particle individually.
Median density flows are generally measured using high image density PIV mode
(Pust, 2000). As sprays issued from pMDIs have a medium to high density de-
pending on the distance from the nozzle orifice at which they are measured, it was
thought PIV would be a suitable method to characterise their velocity (Crosland
et al., 2009).
1.10.3 Particle image velocimetry measurements
PIV is a technique in which two images are captured in a short lapse of time using
laser technology. Particles are recorded on several images and the flow velocity is
derived from their displacement during the short lapse of time between the images.
PIV can be used to calculate flow velocities ranging from millimetres per second
to several hundred meters per second (Adrian, 1991).
PIV is more common than LSV as it is estimated that most flows are not sufficiently
dense to produce speckles. It is also thought that the large amount of fine particles
needed to induce speckles produce less detectable images than the lower number
of larger particles needed for ideal PIV measurements (Adrian, 1991). The two
limits of PIV lie between particle tracking velocimetry for low-density flows and
high image density PIV for high density flows.
Hinsch classifies PIV methods according to parameters x, y and z where x cor-
responds to the number of velocity components calculated, y is the number of
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dimensions of the domain and z identifies whether the velocity measurements are
instantaneous (0) or continuous (1) (Prasad, 2000). The most common type of
PIV is of type (2, 2, 0) according to Hinsch’s classification. Obtaining 3D velocity
components in a 2D domain (3, 2, 1) is achievable with stereoscopic PIV and rep-
resents a popular form of PIV (Prasad, 2000). Holographic PIV (3, 3, 0) is difficult
and expensive to perform (Prasad, 2000) although cinematic holographic PIV (3,
3, 1) remains the most sophisticated and complex form of PIV. In recent years,
the most elaborate PIV techniques have become easier to perform thanks to the
development of digital recording (Gharib et al., 2002).
Lasers used in PIV measurements can be continuous wave lasers or pulsed lasers.
The laser should have a pulse with a sufficiently high frequency to ensure a good
resolution of the measurements. Pulses can be obtained on continuous wave lasers
using a chopper or by rapidly sweeping the laser beam over the domain (Prasad,
2000). Pictures recorded with pulses of higher frequency can assess the velocity of
faster particles. Pulsed lasers have a shorter pulse than continuous wave lasers (a
few nanoseconds for Yag lasers) and can therefore be used to measure the velocity
of faster particles (Adrian, 1991). It was thus decided to use a pulsed laser in the
PIV experiments conducted in this work.
During PIV measurements, particles in the flow reflect the laser light and this
scattered light is focused on a lens placed perpendicularly to the light sheet, before
being analysed by a computer. To carry out the velocity analysis, the image is
divided into small regions referred to as interrogation spots, the size of which
depends on the properties of the studied flow. If the flow velocity is high, the
interrogation spot should be of sufficient size to ensure that particles remain in
the area from one image to the next. If the flow is highly dense, interrogation
spots should be smaller to limit the number of particles in each interrogation zone.
Gaseous flows need to be filled with tracer particles in order for the laser light to be
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scattered. The tracer particles should ideally follow the flow streamlines without
important slip (Prasad, 2000).
Recording methods
The images can be recorded using a charged couple device (CCD) (used in the
present work), a film or holographic plates (when the domain studied is a volume)
(Gharib et al., 2002).
There are several PIV techniques, each involving different types of frame and pulse
recordings. The frames describe the images on which the particles positions are
recorded and correspond to the sequence of images captured by the camera or the
film. In single frame recordings, one frame is used to record images obtained with
several pulses. The term multiframe corresponds to a sequence of images that are
used at different time intervals to record particles positions. With this technique,
there is a record of particles motion in time.
Laser pulses are used to record an image at different time intervals. The time in-
terval between two pulses determines the maximum velocity that can be measured.
The time separation between two pulses can range from 1µs to 1 ms (Jahanmiri,
2011). The duration of the light pulse determines the sharpness of the picture
(Adrian, 1991).
The simplest recording method is the single frame method also referred to as streak
photography. This type of recording consists in lighting the particles with a long
pulse. It is similar to a certain extent to the single frame/multipulse method as
in both methods, the particles trajectories are almost continuous (Adrian, 1991).
Although streak photography is efficient for the analysis of two-dimensional flows,
the multipulse method is more accurate as it is easier to determine the location of
a particle from a dot than from a streak (Adrian, 1991). It is also thought that
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the energy of the laser concentrated on short pulses rather than on a long streak
leads to more intense scattering of the particles. The multipulse method therefore
allows the analysis of smaller particles than streak photography when using lasers
of similar power (Adrian, 1991).
The benefits of the multipulse set up are only obtained with pulsed lasers, not with
continuous wave lasers. This is due to the fact that continuous lasers have less light
intensity than pulsed lasers. Furthermore, their energy decreases as the duration
of the pulse decreases. For this reason, the multipulse method with continuous
wave lasers is mainly used to analyse slow flows or flows containing large particles
(Jahanmiri, 2011).
The single frame/double pulse technique is suitable for flows with low particles
density as it cannot deal with particles superposition. This technique also requires
a shifting of the image in order to identify the direction of the particles trajectory
(Adrian, 1991). As pMDIs flows have a medium to high density, the single frame
technique will not be used in the PIV analysis in Chapter 5.
In the multiframe method, the camera exposes particles displacement by producing
several shots of the interrogation spot. This technique can be used coupled with
single or multipulse laser illumination. The main advantages of multiframe mea-
surements are that the flow direction is determined directly and the time interval
between frames can be chosen independently of the time interval between pulses.
The lapse of time between pulses can therefore be chosen to satisfy velocity and
spatial requirements whereas the time between frames can be chosen to expose the
trajectory of the flow as required by the experiment (Adrian, 1991).
Multiframe/single pulse is the simplest type of multiframe techniques. In each
frame, the particles are exposed once. This method has several advantages such
as the clarity of the images in which particles do not superpose as each of their
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positions are exposed on one frame. This allows the particles images to be paired
more easily. For this reason, this technique was chosen in Chapter 5. When using
this method, the time interval between pulses must be equal or an integral multiple
of the time separation between frames.
Applications of different PIV methods
Varying particle imaging techniques, each with several frame and pulse specifica-
tions, are used depending on the type of flow to be analysed.
PTV, used for the analysis of low-density flows, is generally combined with single
frame/double pulse recordings. In the early age of PIV, the technique consisted
in illuminating particles with two pulses and capturing the two images on a single
frame. The distance travelled by each particle could then be determined easily
by pairing each pair of particles images. Today, the method is digitalised and
particle-pairing is computationally executed. The algorithms used must differen-
tiate particles images from noise. This is generally done by removing a certain
amount of noise from the picture, ensuring only bright pixels are computed. In
order to avoid particles overlapping, PTV should be used on relatively low-density
flows such as liquid flows with low seeding particle densities. In these flows, the dis-
tance between two neighbouring particles is generally larger than the displacement
of one particle between the two laser pulses (Prasad, 2000).
High density PIV is used to analyse flows in which more than one particle is present
in each interrogation spot. To ensure the presence of several particles in each
interrogation spot, a great care must be taken in the choice of the interrogation
spot size.
High image density PIV is the most accurate method for the analysis of particles
of diameter equal or smaller to 25µm corresponding approximately to the size of
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particles issued from pMDIs estimated by Dunbar at the nozzle orifice (Adrian,
1991), (Dunbar, 1996). High image density PIV was first used on liquid flows but
is also able to measure particles displacement in gaseous flows.
Algorithms
The algorithms used to assess particles displacement in PIV impact the level of
errors of the measurements. Several algorithms can be used to solve particles dis-
placement, the most common being the cross-correlation (CC) technique, the auto-
correlation technique, the particle tracking technique and particle image pattern
matching technique (PIPM) (Huang et al., 1997). The nearest neighbour approach
is a simple way to pair particles. It assumes that the nearest neighbour of the
particle corresponds to its pair (Adrian, 1991). This method can be made more
accurate by taking into account prior displacement of the particle to find its pair
(Adrian, 1991).
Correlation algorithms
Correlation algorithms are ideal to analyse particles in dense flows as they do not
match pairs of particles but small groups of particles. The algorithm analyses
all particles lying on one interrogation spot as one group and finds its match by
searching for groups with the most similarities (Adrian, 1991).
Using single frame/double pulse recordings, the auto-correlation algorithm results
in three peaks; the auto-correlation peak corresponding to the origin of the displace-
ment, the positive displacement peak corresponding to the correlation of the first
image with the second image and the negative displacement peak corresponding to
the correlation between the second image and the first image.
As the displacement peaks decrease in amplitude with the flow velocity, the auto-
correlation function is not advised for the analysis of high-velocity flows (Prasad,
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2000). In order for the method to capture appropriate displacements, the time
interval between the two pulses ∆t should be calculated according to the flow
velocity using Equation (1.13).
∆t ≤ 0.25 Li
PM Uflow
(1.13)
where Li is the length of the interrogation spot in m, PM is the magnification of
the recorded image and Uflow is the expected velocity of the measured flow in m·s−1
(Prasad, 2000). The following observations can be made from Equation (1.13):
• When the flow velocity increases, the lapse of time between pulses should be
shorter as the particles might leave the interrogation spot before the second
pulse can record the second picture.
• At high image magnifications, the lapse of time between pulses should be
short to ensure that particles remain in the interrogation spot between the
two pulses.
• Large time intervals between the two pulses can be used with large inter-
rogation areas as the probability that particles leave the interrogation spot
between pulses (referred to as in-plane loss of pairs phenomena) becomes
lower.
The accuracy of the auto-correlation algorithm can be improved by using mul-
tipulse techniques as they correlate a greater number of pairs, thus providing a
larger particles sample. When using single frame/multipulse recording, the lapse
of time between the pulses must be reduced to ensure that particles remain in the
interrogation area during each of the several pulses.
One of the weaknesses of the auto-correlation technique is that it cannot accurately
measure displacements smaller than a particle’s diameter as the auto-correlation
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peak is too large to recognise small displacements (Bastiaans, 2000). The auto-
correlation algorithm is also not advised to solve large displacements as they in-
crease the probability of in-plane loss of pairs. The signal to noise ratio starts
decreasing with displacements larger than a fourth of the length of the interroga-
tion spot (Prasad, 2000).
When using the auto-correlation algorithm, peaks smaller than the auto-correlation
and displacement peaks are obtained. They correspond to the noise caused by over-
lapping particles (Adrian, 1991). A noise peak may be larger than the displacement
peaks in which case it might be wrongly identified as a displacement peak. In or-
der to avoid this error, a feature specifying that the ratio of the displacement peak
to the next peak must exceed a detection threshold can be implemented (Adrian,
1991). It is also possible to look for a displacement peak within a certain region
based on neighbouring particles displacements. Post-interrogation techniques in
which the obtained displacements are compared with neighbouring particles dis-
placement can also be performed. If some displacements seem not to make sense,
the next highest peaks are analysed to determine if, when used, the particles dis-
placement is more in line with the displacement of neighbouring particles.
Another issue of the auto-correlation algorithm is due to the production of the two
displacement peaks, making the direct determination of the flow direction impos-
sible (Bastiaans, 2000). Various methods can be employed to resolve this problem.
For example, the camera can be translated during the experiments, causing the flow
to move at a velocity exceeding the counter flow. The velocity of the translation
is subtracted at the end of the experiment to find the real particles velocity. As
this method is labour-intensive, the auto-correlation technique should be limited to
flows with no reverse flow. As sprays issued from pMDIs are turbulent and contain
particles travelling in the opposite direction of the spray, auto-correlation is not
anticipated to be suitable in this work (Lee et al., 1991). The double frame/single
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pulse recording technique can identify directly the flow direction as both images
are stored on two different recording frames. This method leads to the more so-
phisticated CC technique (Bastiaans, 2000).
CC is used with multiframe/single pulse techniques. As the particles are recorded
on at least two frames, the directional ambiguity of auto-correlation algorithms is
removed (Bastiaans, 2000). Contrary to auto-correlation, CC only produces one
displacement peak.
Errors in digital PIV
The level of error depends on the flow to be analysed, the experimental procedure
and the algorithm used. The three main types of errors in digital (DPIV) are
outliers, mean-bias and root-mean-square (RMS) errors (Huang et al., 1997).
Some errors are easier to identify than others. For instance, “outliers” which cor-
respond to mismatched particles are generally easy to detect as they are larger
than one pixel. The outliers arise from different sources such as three-dimensional
motion, large velocity gradients or poor particle seeding (Huang et al., 1997).
Mean-bias errors occur during the determination of particles displacement. They
represent the difference between actual and measured displacements and can be
due to errors in the determination of the beginning and/or the end of particles
displacement. As the reference point corresponds to the centre of the image, mean-
bias errors often occur when particles deform or rotate (Adrian, 1991). They can
also be due to the fact that particles displacement is not determined with sub-pixel
accuracy but always rounded to the nearest pixel integer value. There is no bias
error if the particle’s displacement corresponds to an integer number of pixels. This
type of error referred to as peak locking depends mainly on the size of particles to
be analysed. It is accentuated for particles diameter smaller or equal to one pixel
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and minimised for particles diameter of approximately two pixels (Pust, 2000).
Bias errors decrease with pixel sizes and with increasing particle size and can be
reduced by increasing the image resolution, which leads to a larger particle to pixel
ratio.
Velocity bias occurs as faster particles generally have less chance of being identified
correctly as they might have left the interrogation area between recordings. This is
particularly the case in the presence of high velocity gradients as the PIV system
might be set up to record low velocities and might therefore not be able to record
big displacements. This might lead to a velocity bias in which small displacements
are overestimated (Bastiaans, 2000). This is problematic for low image density
DPIV in which the failure of one measurement can be significant due to the small
numbers of pairs per interrogation spot (Adrian, 1991). Bias errors decrease with
the increasing number of samples and with decreasing particles displacements.
Gradient error is another common type of error due to deformation or rotation
within an interrogation area. This can reduce the accuracy of the measurements
sometimes leading to false velocity results. However, this problem might be solved
by retransforming the images according to their velocity gradients before perform-
ing the cross-correlation (Prasad, 2000), (Weng et al., 2010). When gaseous flows
are studied, tracking errors can arise due to the inability of the tracer particles to
follow the flow without slip (Prasad, 2000). This type of error is not of relevance
to this work as tracer particles were not used. Finally, random errors due to noise
in the recorded images are unavoidable. Random errors are proportional to the
particle image diameter and are given by Equation (1.14) developed by Prasad
(2000).
σ = e dpi (1.14)
where σ is the random error, e is a coefficient varying between 0.05 to 0.10 depend-
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ing on the experimental settings and dpi is the particle image diameter. The size
of the interrogation spot also has an effect on the level of measurements errors as
small interrogation spots tend to increase spatial resolution but also increase the
level of random error as they contain a smaller sample of particles (Fincham and
Spedding, 1997).
The camera and its cable might increase the RMS error although this can be
reduced using a digital camera as was done in this work (Huang et al., 1997). Even
with those error types, PIV remains one of the most accurate methods to determine
the velocities of unsteady transient flows such as pMDIs sprays (Weng et al., 2010).
1.10.4 Phase Doppler Anemometry
Phase Doppler anemometry (PDA) is the most comprehensive technique to char-
acterise pMDIs sprays as it can measure the velocity of particles as well as their
size and concentration.
In PDA measurements, a laser beam is split and focused around a zone referred
to as measurement volume. When the spray reaches the measurement volume, the
light scattered by particles is focused on photo-detectors by means of a lens placed
between the measurement volume and the photo-detectors. The light scattered by
each particle produces a Doppler burst signal used to assess the characteristics of
the particle such as size and velocity.
Particles velocity is as important as particles size when determining the efficiency of
a pMDI. Particles velocity is difficult to determine at the nozzle orifice using optical
measurements as the evaporation of the propellant causes a blur. For this reason,
the velocities reported at the nozzle orifice vary tremendously in the literature.
The highest pMDI spray velocities were found by Dunbar (1997) and Kleinstreuer
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et al (2007) who reported velocities between 150 ms−1 and 225 ms−1 at the nozzle
orifice using computational simulations. The velocity of the liquid spray exiting the
pMDI is 15 ms−1 (as cited by Fink (2000)). Hochrainer et al (2005) found velocities
of 2.0 ms−1 to 8.4 ms−1 when measuring CFC-based and HFA-based pMDIs sprays
at a distance of 10 cm from the nozzle orifice using high-speed video recording.
They reported higher velocities for CFC-based pMDIs compared to HFA-based
pMDIs.
According to Newman et al (1982), the initial spray velocity is approximately
30 ms−1 which agrees with the data obtained by Clark (1996) using a phase Doppler
particle analyser (PDPA). In their PIV measurements, Crosland et al (2009) re-
ported a nozzle orifice velocity of between 50 ms−1 and 60 ms−1. Wigley et al (2002)
found a peak velocity of 90 ms−1 using PDA.
The large differences observed might be due to the fact that the velocity decays
extremely rapidly and might vary significantly if not measured at the exact same
moment and at the exact same location. Furthermore, varying measurement tech-
niques use different principles, which might also contribute to those variations in
velocity. It is therefore recommended to only compare velocity data obtained using
similar experimental techniques and measured at similar times and locations.
1.11 Aims and objectives
pMDIs suffer from inconsistency of the drug deposition location which is mainly
due to a poor control over the size and velocity of the aerosolised droplets. The aim
of this thesis will therefore be to study those two parameters at several times and




Patient-related factors might lead to different aerosol characteristics. As pMDIs
perform optimally at low inhalation flow rates, they are commonly recommended
for patients who cannot achieve the high inhalation flow rates necessary for DPI
use. It is suggested that many of these patients are young children or elderly
patients with weak hand strength and might not be able to actuate their pMDI
properly. The aim of this work will be to identify the effect of the actuation force
on the size and velocity of the particles.
As pMDIs are used globally, the impact of environmental conditions on the aerosol
properties is of interest. For this reason, variations in temperature and their effect
on the size and velocity of droplets will also be studied.
A one-dimensional Matlab-based model will be developed in order to calculate the
size and velocity of the particles at the nozzle orifice where experimental measure-
ments are difficult to obtain.
Residual droplets size of sprays aerosolised under varying experimental conditions
will be assessed using a NGI. PIV, Sympatec R© and Malvern Spraytec R© measure-
ments will be conducted to evaluate the velocity and size of pMDI sprays during
their trajectory.
In both the computational and experimental parts of this work, formulation and
device design will be modified in order to understand how they can be used to




Development of a computational
simulation of pMDI discharge
2.1 Introduction
2.1.1 Actuation mechanisms
The actuation process of pMDIs comprises several steps designed to aerosolise the
formulation into fine droplets. Before the actuation of the canister, the valve stem
is in a position which allows the formulation to enter and circulate in the metering
chamber. The canister is in an inverted position with the inner valve located below
the container. This design allows the metering chamber to fill naturally under
gravity (Newman, 2005). Because of its fixed volume, only a certain amount of
formulation (the metered dose) can enter the metering chamber. When the user
actuates the device, the valve stem is pushed inside the metering chamber, sealing
it and preventing any more formulation from entering the metering chamber. At
the same time, the formulation is released through a valve orifice separating the
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metering and expansion chambers into the expansion chamber which consists of the
valve stem and the actuator pit (Oliveira et al., 2012). From there, it is aerosolised
into droplets when being propelled out of the expansion chamber through the nozzle
orifice (Swarbrick, 2007). The actuation mechanism is described in Figure 2.1.
Figure 2.1: Actuation mechanism of a pMDI.
(Lewis, 2007)
In his work on cosmetic aerosols, York defined the spray formation process as the
succession of four processes: primary atomisation occurring inside the expansion
chamber and at the nozzle orifice, secondary atomisation occurring downstream
of the nozzle orifice, evaporation and entrainment (Dunbar, 1996). During the
primary atomisation, the formulation breaks into ligaments or large droplets (Ver-
steeg et al., 2006). The droplets then disintegrate into smaller droplets during the
secondary atomisation phase. Finally they evaporate and are displaced by the gas
phase outside the pMDI.
The aim of this chapter was to develop a model simulating the discharge of the
flow issued from a pMDI from the metering chamber to the nozzle orifice, which
corresponds to the primary atomisation.
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2.1.2 Description of the flow in a pressurised metered dose
inhaler
Sequences of the aerosolisation process
Versteeg et al (2006) studied the internal flow inside a pMDI using time-resolved
laser-based high-speed imaging. Their observations are described below.
Before the actuation of the canister, the metering chamber contains liquid propel-
lant at a certain temperature and at the corresponding saturated vapour pressure.
In the first 1 ms to 2 ms of the actuation, the metered dose is forced under pressure
into the expansion chamber containing air at atmospheric pressure. When the high-
pressured liquid propellant comes in contact with the comparatively low-pressured
air, the liquid formulation becomes superheated which causes flash evaporation,
producing initially a vapour-only spray.
The flashing of the formulation occurs primarily in the expansion chamber where it
is responsible for the initial disintegration of the liquid jet into particles (Sanders,
1979). Flash evaporation represents one of the main processes of primary atomisa-
tion (Wigley et al., 2002).
After its initial vapour state in the expansion chamber and at the nozzle orifice, the
flow becomes a liquid-rich mixture as the formulation starts filling the expansion
chamber (Versteeg et al., 2006).
Simultaneously, the formulation remaining in the metering chamber starts to evap-
orate to fill the void left by the mass of propellant discharged in the expansion
chamber. As a result, the temperature and pressure decrease in the metering
chamber. The pressure decrease in the metering chamber combined with the pres-
sure increase in the expansion chamber lead to a decrease in the mass flow rate
through the valve orifice (Shaik, 2009).
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In the next 5 ms to 10 ms, the expansion chamber is filled with a two-phase foamy
mixture. The quality of the formulation (ratio of the total mass of gas, including
air, to the total mass of the formulation) therefore increases. The spray exiting the
expansion chamber is now a vapour/liquid mixture (Versteeg et al., 2006). This
step corresponds to the fully developed phase of the spray and lasts between 60 ms
and 70 ms. The spray exiting the pMDI during this phase is dense and composed
of very small droplets (Versteeg et al., 2006).
During the terminal 60 ms to 70 ms of the aerosolisation process, the spray density
decreases and the size of the droplets emitted increases, particularly at the edges
of the nozzle orifice (Versteeg and Hargrave, 2002). This is due to the fact that
the mass of propellant decreases, reducing the amount of energy available to break
up the droplets forming the spray. At the end of the atomisation, a spring located
within the valve returns the actuator to its initial position. The valve orifice is
closed and the formulation in the body of the canister can again enter the metering
chamber to form a new therapeutic dose.
Flow regimes
Upon actuation, the flow at the valve orifice is critical due to the high pressure
gradient between the metering and expansion chambers. This means that the
mass flow rate is at its maximal value and cannot be increased further by lowering
the pressure in the expansion chamber. The discharge of the propellant from the
metering chamber into the expansion chamber, which results in a pressure drop in
the metering chamber and a pressure increase in the expansion chamber, causes the
flow to become subcritical. The flow is subcritical when Equation (2.1), described





where Racrit defined later in this chapter is the critical ratio which depends on
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thermodynamic properties of the flow, Pds and Pus are respectively the pressures
downstream and upstream of an orifice in Pa.
At the nozzle orifice, the flow is initially subcritical as there is no pressure gra-
dient between the expansion chamber and the exterior environment (the pressure
is atmospheric at both locations). Once the pressure increases in the expansion
chamber, the pressure gradient across the nozzle orifice increases to critical ratio,
leading to a critical flow. As the metering chamber is depleted of formulation, the
pressure in the expansion chamber decreases again, leading to a subcritical flow.
Primary atomisation process
Although little work has been conducted on primary atomisation in pMDIs, re-
search on this subject has been carried in other areas such as the automotive and
chemical industries. Diesel injection systems, leaks in “high-pressured” vessels and
refrigeration systems are some of the systems that have been extensively researched
(Serras-Pereira et al., 2010), (Beychok, 1998), (Gorokhovski and Herrmann, 2008).
Those systems can be of help to understand the primary atomisation in a pMDI as
they all undergo liquid evaporation due to a sudden pressure drop. This process is
referred to as “flash boiling atomisation”. Flash boiling atomisation occurs when a
liquid is submitted to superheated conditions due to a drop of pressure inside the
system. York (1957) assumed that as a result, the liquid would evaporate instanta-
neously during an adiabatic process corresponding to a mass transfer between the
liquid and gas phases (as there would be no time for heat transfer between the two
phases during this instantaneous evaporation process) (Dunbar, 1996).
In reality, the liquid evaporation is not instantaneous. As the discharge of the flow
from a pMDI is extremely rapid, the liquid starts boiling and parts of it evaporate.
When the heat transfer with the exterior environment is negligible, the vapour
evaporation energy is taken from the liquid causing the temperature inside the
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system to decrease. However, as in many transient processes, the liquid does not
have the time to regain equilibrium and remains in a state of instability (Shaik,
2009).
In the expansion chamber, flash boiling atomisation is generally followed by nucle-
ation, fast bubbles growth and liquid atomisation (Sher et al., 2008).
Nucleation defines the formation of vapour nuclei inside a formulation during flash
boiling atomisation and the filling of those nuclei by evaporating propellant. Nu-
cleation starts at the valve orifice due to a sudden pressure drop and heterogeneous
surface (Sher et al., 2008). In order to grow and not to collapse, the nuclei must have




9 γ mg TbRs
8pi St
(2.2)
Where rcrit is the critical radius of the bubble in m, γ is the heat capacity ratio
coefficient of the propellant vapour inside the bubble, mg is the mass of gas in the
bubble in kg, Tb is the bubble temperature in K, Rs is the specific gas constant in
K−1·kg−1 and St is the surface tension in kJ·m−2.
Nucleation can be homogeneous if it occurs in the entire volume of the superheated
liquid or heterogeneous if it occurs at the boundaries between the superheated liquid
and foreign surfaces such as drug particles or the surface of the canister. In pMDIs,
nucleation sites are generally located at the surface of the expansion chamber walls.
In suspension formulations, nucleation can also occur at the surface of drug particles
(Finlay, 2001).
Dunbar reported that bubble growth does not occur in the expansion chamber
as the generated vapour nuclei are continuously destroyed by the incoming flow
discharged from the metering chamber and as a result do not reach the critical
bubble size. This could be due to the fact that the energy available to develop the
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vapour nuclei into bubbles is not sufficiently high (Dunbar, 1997). However, since
Dunbar’s work, Versteeg et al (2006) have proven the existence of bubbles within
the expansion chamber through pMDIs visualisations.
Finlay (2001) reported that bubble growth occurs for stable nuclei in the region
immediately after the valve orifice where the pressure drop occurs. This region is
referred to as “recirculation zone”. The boiling flow remains longer in the sub-
pressurised recirculation zone than it remains in the non-recirculation region. Due
to this increased residence time, the bubbles in the recirculation region become
larger. When a pack of bubbles grows, some of them collide and explode; this
corresponds to the inception of the flashing process (Shaik, 2009). The growth
of the remaining bubbles causes an expansion of the recirculation zone until it
obstructs the flow. At this point the recirculation zone is propelled downstream.
A new recirculation zone is created and this cycle continues until the end of the
atomisation process. The generation and expulsion of the recirculation zone at
the nozzle orifice contribute to the oscillating nature of the spray with a frequency
between 500 Hz and 800 Hz (Finlay, 2001). Versteeg et al (2006) observed dense
and lean spray oscillations of frequency between 500 Hz and 1000 Hz in the exiting
spray (Figure 2.2).
Figure 2.2: Density wave of a spray issued from a pMDI




In the expansion chamber, most of the liquid propellant is concentrated on the
walls; whereas the vapour core is mainly located on an axis aligned with the centre
of the nozzle orifice. In the literature, this phenomenon, referred to as “annular flow
regime” characterises “the vapour core surrounded by the foamy liquid covering the
chamber walls” (Versteeg and Hargrave, 2002). Versteeg et al (2006) were able to
visualise the annular shape of the flow in a sequence of images of the expansion
chamber taken from a high-speed video recording. The annular pattern of the
flow caused a slip between the liquid and vapour phases. During the aerosolisation
process, the liquid phase observed on the walls of the expansion chamber enters the
nozzle orifice where it is elongated into ligaments. Upon contact with stagnant air,
the ligaments are broken into droplets which exit the nozzle orifice (Versteeg and
Hargrave, 2002). This process, referred to as “shear-thinning” is, with flashing, the
other main mechanism of primary atomisation inside pMDIs (Smyth, 2003). As
the pressure gradient across the nozzle orifice diminishes towards the end of the
aerosolisation process, shear-thinning is reduced and the outer liquid layer forms
big droplets at the edges of the spray (Versteeg and Hargrave, 2002).
2.1.3 Previous investigations on flows similar to pMDIs
flow
Fraser et al (2002) investigated the influence of the flashing location on the mass
flow rate of critical flows. They established that the mass flow rate decreased as
the flashing location was moved further upstream of the nozzle orifice (as cited by
(Shaik, 2009)).
When studying short capillary tubes, systems relatively similar to the design of
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pMDIs, Pasqua (1953) observed that the liquid core of the flow diminishes towards
the tube exit (Shaik, 2009). When investigating a propellant mixture through twin-
orifices, Fletcher (1975) observed a correlation between the mass flow rate and the
product of the valve orifice diameter by the nozzle orifice diameter. Fletcher found
that the propellant was under metastable conditions in the expansion chamber (as
cited by Shaik, (2009)).
Clark (1991) studied experimentally the continuous and metered-dose discharges
of propellant through twin-orifices. As his findings were used throughout the nu-
merical simulation, they are summarised later in the chapter.
2.1.4 Models simulating the discharge of turbulent and tran-
sient flows
Flows in the expansion chamber are turbulent with a Reynolds number in the range
of several hundred thousands (Finlay, 2001). They are also unsteady and multi-
phase which makes them challenging to model. Several models have been developed
to simulate the aerosols issued from inhalers. Models can describe the flow trajec-
tory inside the pMDI, the flow properties at the nozzle orifice, the aerosolisation
of the formulation and the deposition of the aerosol inside the respiratory tract.
One-dimensional models are generally used to describe the discharge upstream of
the nozzle whereas computational fluid dynamics (CFD) models are mainly used to
simulate the flow downstream of the nozzle. CFD models simulating the trajectory
of aerosols downstream of the nozzle orifice and their deposition in the respiratory
airways are not studied in this work which focused on the properties of the spray




The homogeneous equilibrium model (HEM) was introduced by Strakman et al
(1964). This approach assumes that there is no slip between the liquid and gaseous
phases as the flow is assumed to be a continuous “pseudo-fluid” mixture of liquid
and vapour bubbles. In the HEM, the liquid and vapour velocity are therefore
equal at one location and they follow the law of a single component system with
average properties of liquid and gaseous phases (i.e. a pseudo-fluid). The liquid and
vapour phases therefore have the same pressure and temperature and the mixture
is assumed to be in thermal equilibrium (Dunbar, 1996), (Shaik, 2009).
Escanes et al (1995) and Wongwises et al (2001) used the HEM to model transient
and steady flows in long capillary tubes and found data matching experimental
results (Shaik, 2009). This might be due to the fact that in long tubes, the flow
has time to reach the equilibrium conditions assumed in the HEM. However, this
approach cannot be adapted to simulate flows in pMDIs as in those transient sys-
tems, the flow does not have time to reach equilibrium conditions and therefore
remains in a constant state of metastability. The HEM was found to underestimate
the choking flow rate in short tubes (Shaik, 2009).
Non-homogeneous equilibrium model
The non-homogeneous equilibrium model (NEM) was developed by Moody in 1965
(Elias and Lellouche, 1994). It resembles the HEM but takes into account the
slip between the gas and liquid phases. In the NEM, the vapour phase has a
higher velocity than the liquid phase. The NEM assumes adiabatic conditions
and thermodynamic equilibrium. This approach simulates more realistically the
annular flow inside pMDIs, in which the gaseous core has a higher velocity than




In the separated flow model (SFM), developed by Richter in 1981, varying equa-
tions are used to describe the behaviour of each phase within the flow (Elias and
Lellouche, 1994). The TFM was used by Yang and Zhang (1995) to describe the
behaviour of a two-phase critical propellant flow in short tubes (Shaik, 2009). They
assumed different velocities and temperatures for each phase. It was found that the
predictions from the SFM for this type of flow were more in line with experimental
findings than the HEM which underestimated the mass flow rate by approximately
20 % (Shaik, 2009).
2.1.5 Models simulating the internal flow of a pMDI
Clark was the first to model the behaviour of flows inside pMDIs. His model
assessed the velocity, the mass flow rate and the size of the droplets forming the
aerosol at the nozzle orifice. Clark calculated droplet diameters ranging from 20µm
to 30µm and droplet velocities of approximately 30 m·s−1 (Clark, 1991). Clark also
conducted experimental work and used a Dantec phase Doppler particle analyser
(PDPA) to measure particles velocity at a distance of 5 cm from the nozzle orifice
and reported a 35 m·s−1 velocity. He also measured a volume median diameter
between 5µm and 10µm at this location using a Malvern laser diffraction system
(Clark, 1996). The increasing distance from the nozzle orifice might explain the
reduction in droplets sizes assessed computationally and experimentally.
Clark developed two models. In the first model, he studied the discharge of a
continuous flow through a twin orifice. The pressure in the metering chamber was
therefore assumed to be constant and the flow propelled from the metering chamber
was pure liquid during the whole aerosolisation process. This type of flow discharge
is composed of four stages.
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First, the saturated liquid exits the metering chamber through the valve orifice.
This process depends on the pressure gradient between the metering and expansion
chambers, the density of the propellant and the geometry of the valve orifice. The
flow then undergoes evaporation in the expansion chamber leading to the expansion
of the propellant until the propellant vapour fills the expansion chamber.
The two-phase flow then exits the expansion chamber through the nozzle orifice.
This stage is more complex as it is influenced by the flow conditions in the expansion
chamber (quality, temperature, pressure). The flow is then aerosolised outside the
canister.
This model assumes that the flow reaches equilibrium when the mass flow rates at
valve and nozzle orifices are equal. It could be applied to simulate the discharge
from pMDIs if the volume of the expansion chamber in pMDIs was negligible com-
pared to the volume of the metering chamber. This would be the case in a pres-
surised canister containing no metering chamber, in which the formulation flows
directly from the body of the canister to the expansion chamber. This model has
shortcomings as in reality the metering and expansion chambers have comparable
volumes. For example, Clark used a canister with a metering chamber volume of
100µL and an expansion chamber volume of approximately 125µL (Shaik, 2009).
Clark refined his model and took into account the fact that the metering chamber
empties during the aerosolisation process. In this second model, a pressure drop
occurring inside the constant metering chamber volume simulates the discharge of
the pre-metered volume. As soon as the aerosolisation process begins, the pressure
in the metering chamber decreases. During the discharge of the formulation, the
metering chamber pressure is assumed to drop below the saturated vapour pressure
corresponding to the metering chamber temperature. This leads to the discharge
of a two-phase flow from the metering chamber (Clark, 1991). The present model
was inspired by the second simulation from Clark.
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Dunbar (1996) also conducted experimental and theoretical work to characterise
the aerosols issued from pMDIs. He developed a model for the discharge of a pure
propellant two-phase flow. In his model, Dunbar used a metering chamber volume
of 63µL, an expansion chamber volume of 17.6µL, a valve orifice diameter of
0.7 mm with a discharge coefficient of 0.61 and a nozzle orifice diameter of 0.5 mm
with a discharge coefficient of 0.78. He assumed that the velocities of the gas and
liquid phases were equal. He calculated a peak velocity of 225 m·s−1 and a mass
median diameter between 7.9µm to 20µm at the nozzle orifice. He found that the
discharged formulation was composed of approximately 80% by weight of liquid
(Dunbar et al., 1997).
Ju et al (2010) improved Dunbar’s model by implementing a feature to simulate a
multi-component two-phase flow. Their numerical approach assumed that:
• the aerosolisation duration was divided in small time units referred to as time
steps
• the velocity remained constant at both valve and nozzle orifices during each
time step
• the liquid phase was incompressible
• the flow was adiabatic (no transfer of heat occurred between the formulation
and the device or the atmosphere)
• the conditions in the metering chamber remained saturated during the whole
discharge process
• the liquid and gas phases did not have similar velocities
• the discharge coefficients were constant throughout the discharge process
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To match Dunbar’s experimental setting, Ju et al (2010) used a nozzle orifice diam-
eter of 0.5 mm when simulating the discharge of pure HFA134a. They calculated
exit velocities of 15 m·s−1 to 19 m·s−1 at the nozzle orifice depending on the concen-
tration of non-volatile components. Those velocity values are considerably lower
than Dunbar’s. They calculated spray durations of approximately 0.1 s, which is
half of that found by Dunbar. These differences could be due to the fact that Ju
et al calculated separately the characteristics of the liquid and gas phases whereas
Dunbar calculated them using similar equations.
Shaik and Versteeg (2008) developed a model simulating the discharge of a pMDI.
They calculated the properties of the flow along the axis of the valve and nozzle
orifices. They found that the pressure and temperature across the expansion cham-
ber were constant but decreased across the valve and nozzle orifices as the latter
represent sudden constrictions. Their work also showed that the quality of the flow
in the expansion chamber slightly increased towards the nozzle orifice compared to
the area near the valve orifice. They found that the saturated liquid spray leaving
the metering chamber becomes metastable upon entering the expansion chamber
due to the extremely transient nature of the discharge and the large pressure drop
across the valve orifice. This means that while in the expansion chamber, the for-
mulation is made of a metastable liquid, a saturated liquid and a saturated vapour
phases (Vacek and Vins, 2009). Shaik and Versteeg also assumed that the flow was
a steady state one-dimensional adiabatic flow and that the velocity of the liquid
and vapour phases were equal.
A numerical simulation from Aamir and Watkins (2000) modelled the leak of
propane from a high-pressured vessel. As the leak is more likely to occur at a
draw off pipe, this scenario was studied. The vessel could be compared to the




In their model, Aamir and Watkins (2000) assumed that the discharge coefficient
was constant and that the flow was quasi-steady which means that it was steady
over the duration of each time step. This system assumed different velocities for
the gas and liquid phases. The velocity of subcritical liquid and gas phases was
determined using the Bernoulli equation. They found a gas velocity and a liquid
velocity of approximately 225 m·s−1 and 40 m·s−1 respectively and a weighed av-
erage of approximately 100 m·s−1 at the nozzle orifice. This value compares well
with Wigley et al ’s maximum value of 90 m·s−1 at the nozzle orifice using phase
Doppler anemometry (PDA) (Wigley et al., 2002). However, it is higher than the
maximum values of 60 m·s−1 to 70 m·s−1 found experimentally by Crosland et al
(2009) using particle image velocimetry (PIV) at the nozzle orifice.
2.1.6 Models simulating the aerosolisation of sprays down-
stream of the nozzle orifice
The flow characteristics obtained from the models discussed above can be used
as inputs conditions for models simulating the aerosolisation process downstream
of the nozzle orifice. The latter information is useful as it is difficult to obtain
accurate experimental data at the nozzle orifice.
For example, in order to simulate the aerosolisation of the spray issued from a vessel
containing highly pressurised liquid propane, Aamir and Watkins (2000) used the
outputs such as the quality and velocity of the flow obtained from their simulation
described in Section 2.1.5. They found velocities of approximately 22 m·s−1 and
mean diameters of 15µm at a distance of 5 cm from the nozzle orifice. This value
is in agreement with the experimental value of 20 m·s−1 obtained by Allen when
studying propane jets (Aamir and Watkins, 2000).
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Stein et al (2012) built a model simulating the aerosolisation of suspension for-
mulations. Most of their work focused on the size of the residual droplets from
suspension formulations. For example, their model can calculate the effect of drug
concentration, size of the suspended drug particles and size of the initial droplets
on the residual size of the droplets in suspension formulations. It can also predict
the probability of droplets containing zero, one or more drug particles. The model
can take into account the geometric standard deviation (GSD) of the formulation
and several geometric characteristics of the pMDI such as the volume of the me-
tering chamber and the size of the valve orifice. The limitations of this model are
that it uses samples of 10 000 droplets containing drug particles although tens to
hundreds of millions are produced in reality. It is also restricted to the simulation
of aerosols containing one type of drug.
The inputs needed to run Stein et al ’s simulation include the properties of the
formulation, the size distribution of the micronised drug particles and the size
distribution of the initial droplets. Stein et al deemed models calculating the initial
droplets size too computationally intensive and questioned their accuracy on such
volatile formulations. They also judged that experimental measurements would not
be sufficiently accurate at the nozzle orifice to calculate the initial droplets size.
For those reasons, they developed a semi-empirical model using Equation (2.3)









where MMDin and MMDre are respectively the mass median diameters of the
initial and residual droplets in µm, ρin and ρre are respectively the densities of the
initial and residual droplets in kg·m−3 and CNV is the concentration of non-volatiles
(weight fraction). Equation (2.3) fails to account for all elements of secondary
atomisation, which could lead to a poor accuracy of the initial droplets size.
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Using Equation (2.3) to calculate initial droplet diameters while changing several
experimental conditions, Stein et al obtained Equation (2.4) correlating the size of
the initial droplets to several formulation and design parameters.
MMDin = 6.90 + 0.0441× Vmc + 23.6× CEtOH − 63.8× C2EtOH
+ 24.7× CEtOH × dno − 0.129× CEtOH × Vmc (2.4)
where Vmc is the volume of the metering chamber in µL, CEtOH is the concen-
tration of ethanol (weight fraction) and dno is the nozzle orifice diameter in mm.
Equation (2.4) was initially developed by Stein et al (2004) to characterise the
initial droplets size of solution formulations. As it was used by Stein et al (2012)
to assess the initial droplets size of suspension formulations, their determination of
the initial droplets size might not be accurate.
2.1.7 Aims and objectives
pMDI flows are complex to study as they involve turbulence, phase changes, density
changes as well as pressure fluctuations (Sher et al., 2008). The nozzle orifice is
very small with a length of about 1 mm and a diameter smaller than 1 mm, the flow
exiting the nozzle has a very high velocity and lasts only a fraction of second. As a
result, experimental measurements of the flow properties outside the nozzle orifice
are difficult to realise. Experimental measurements of the flow as it exits pMDIs
consist mainly of visualisation of the flow inside the expansion chamber and at the
nozzle orifice (Versteeg et al., 2006).
Numerical solutions are of great interest as they represent a mean to obtain quan-
titative information on the flow at the nozzle orifice. Flow characteristics at this
location are useful as they can be used as inputs to models describing the aerosoli-
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sation of the flow downstream of the nozzle orifice.
The aim of this chapter was to create a computational model simulating the be-
haviour of the flow inside a pMDI upon actuation of the device. The flow was
assumed to be one-dimensional and the flow properties were calculated at the noz-
zle orifice which was assumed to be two-dimensional. It was thus decided that a
three dimensional computational fluid dynamics model was not necessary to sim-
ulate the discharge of a pMDI formulation and a one-dimensional Matlab-based
simulation was designed.
This simulation could represent a fast and easy way to study the effect of certain
parameters on the exit properties of the flow at the nozzle orifice. This chapter
outlines the equations used in the simulation. The results and novel features of the
model will be shown in the next chapter.
2.2 Assumptions
Some of the assumptions reported in previous work from Clark (1991), Dunbar
(1996), Aamir and Watkins (2000) and Ju et al (2010) were used in the present
model.
• As pMDIs containing solely propellant were studied, a one-component model
was used.
• The flow inside the pMDI was assumed to be steady over each time step.
This assumption is valid if short time steps are used which was the case in
the present model (dt <0.0005 s, where dt is a time step).
• The flow was assumed to be one-dimensional. A 50µL non-continuous valve
from Valois (Valois pharmaceutical division, 780160 Marly Le Roi, France)
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was measured with a Mitutoyo Dial Caliper 150 mm with a resolution of
0.01 mm. The length of the expansion chamber was found to be 8.05 mm.
As the nozzle orifice of diameter <0.5 mm is relatively small compared to the
length of the expansion chamber, the assumption of a one-dimensional flow
is reasonable.
• The valve and nozzle orifices were assumed to be two-dimensional. As they
have small lengths (<1 mm) compared to the metering and expansion cham-
bers, this assumption was deemed reasonable (Shaik, 2009).
• The Bernoulli equation was assumed valid at the first time step to describe
the discharge of the propellant from the metering chamber. This is a valid
assumption as the flow is an incompressible liquid at initial conditions.
• The Bernoulli equation was also assumed valid for 2-phase flows at sub-critical
conditions. This assumption was also used in the model developed by Aamir
and Watkins (2000).
• At each time step, a state of equilibrium was assumed so that the principle
of mass and energy conservation could be used in the system.
• In the metering chamber, the two phases were assumed to be in saturated
conditions during the whole aerosolisation process.
• The flow properties were assumed to be constant across the expansion cham-
ber. This is not completely accurate as Shaik and Versteeg showed that
several properties changed as the flow travelled along the expansion cham-
ber. For example, the quality of the flow increased closer to the nozzle orifice.
However, pressure and temperature were evenly distributed across the expan-
sion chamber (Shaik and Versteeg, 2008). As the aim of this chapter was to
build a one-dimensional simulation, the variation of properties within the ex-
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pansion chamber was not possible to model and was beyond the scope of the
current research.
• The pressure in the expansion chamber was calculated by assuming that the
gas propellant was an ideal gas.
• The effect of gravity was neglected.
2.3 Initial conditions
• The initial temperature in both the metering and expansion chambers corre-
sponded to ambient temperature.
• The metering chamber was filled with HFA134a at the saturated vapour pres-
sure corresponding to the initial temperature. It follows that as soon as the
pressure dropped (due to propellant discharge) the void caused by the emp-
tying of the metering chamber was filled with gaseous propellant. As a result,
the flow exiting the metering chamber contained both a gaseous and liquid
phases throughout the aerosolisation process except at the onset of the actu-
ation.
• The initial specific enthalpy and density of the propellant in the metering
chamber were set to the value of saturated liquid HFA134a enthalpy and
density at the specified room temperature.
• At initial conditions, the expansion chamber was filled with air at atmospheric
pressure.
• The initial specific enthalpy and density in the expansion chamber were set
to the value of air enthalpy and density at the specified room temperature




The Matlab-based model initiates upon actuation of the device and runs until the
pressure in the expansion chamber equals atmospheric pressure (at which point the
propellant is no longer propelled out of the device).
At initial conditions, the metering chamber contained pure liquid and became a
2-phase flow system at the subsequent time step. For this reason, a loop was
designed that contained all calculations except the calculation of metering chamber
properties at initial conditions and mass flow rate at the valve orifice at the onset
of the actuation.
Once the mass flow rate at the onset of the actuation was calculated, the program
entered the loop that re-iterated calculations until the pressure in the expansion
chamber equalled atmospheric pressure. Inside the loop, the program calculated
the system’s thermodynamic properties in the expansion chamber, then in the
metering chamber.
In both chambers the temperature was calculated using energy equations. In the
metering chamber, the pressure and other thermodynamic properties were calcu-
lated as a function of the temperature as the propellant was assumed to be under
saturated conditions. In the expansion chamber, the pressure was calculated as the
sum of air pressure and propellant vapour pressure.
The pressure gradient at both orifices was used to determine whether the flow was
critical or subcritical (depending on whether the ratio of downstream to upstream
pressures was higher or smaller than the critical pressure ratio) at each time step.
The velocities and mass flow rates at both orifices were then determined based on
the state of the flow (critical or subcritical), during the time step interval.
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Once the loop was finished the program went back into the loop to calculate the
thermodynamic properties at the subsequent time step. Those calculations contin-
ued until the pressure in the expansion chamber equalled atmospheric pressure.
2.5 Program step by step
2.5.1 Metering and expansion chambers at initial condi-
tions
Figure 2.3 representing a canister, shows specific dimensions used in the simulation.
Figure 2.3: Schematic of a canister where dmc is the diameter of the metering
chamber in m, dvo is the diameter of the valve orifice in m and dno is the diameter
of the nozzle orifice in mm.
The geometrical properties of the pMDI such as the valve and nozzle orifice diam-
eters, the discharge coefficients at both orifices and the metering and expansion
chamber volumes were listed at the beginning of the simulation and are presented
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in Table 3.1 in Chapter 3.
The properties inside the expansion and metering chambers at initial conditions
were defined.
Tec = Tamb (2.5)
where Tec is the temperature in the expansion chamber and Tamb is the ambient
temperature in K.
Pec = Patm (2.6)
where Pec is the pressure in the expansion chamber and Patm is the atmospheric
pressure in Pa.
Equations (2.7), used to calculate air density, was computed based on thermody-
namic tables from Rogers and Mayhew (1995) using Matlab and is listed in the
Appendix.
ρec = ρair = f(Tec) (2.7)
where ρec is the density in the expansion chamber and ρair is the density of air in
kg·m−3 (Rogers and Mayhew, 1995).
hec = hair = Cpa Tec (2.8)
where hec is the specific enthalpy in the expansion chamber in kJ·kg−1, hair is the
specific enthalpy of air in kJ·kg−1 and Cpa is the specific heat capacity of air at con-
stant pressure in kJ·kg−1K−1. It was assumed that Cpa was constant which is rea-
sonable as its value varies from 1.0023 kJ·kg−1·K−1 at 175 K to 1.0063 kJ·kg−1·K−1
at 325 K (Rogers and Mayhew, 1995).
It was assumed that the metering chamber was entirely filled with HFA134a pro-
pellant at saturated conditions. For this reason, the pressure, density and enthalpy
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were assumed to be a function of the temperature in the metering chamber as
shown in Equations (2.10), (2.11), (2.12).
Tmc = Tamb (2.9)
where Tmc is the temperature in the metering chamber in K.
Pmc = f(Tmc) (2.10)
where Pmc is the pressure in the metering chamber in Pa.
ρmc = f(Tmc) (2.11)
where ρmc is the density of the propellant in the metering chamber in kg·m−3.
hmc = f(Tmc) (2.12)
where hmc is the specific enthalpy of the propellant in the metering chamber in
kJ·kg−1. Several equations determining thermodynamic properties of HFA134a
were studied. For example, for the calculations of the pressure and density of
HFA134a, the equations from Tan and Shua (2003) and equations from Dupont’s
technical report were compared to the Klea134a thermodynamic tables (Dupont,
2004), (Klea134a, 2011). Equations (2.10) to (2.12) are listed in the Appendix.
2.5.2 First time step
At the onset of the actuation, the flow was assumed to be incompressible (single
phase fluid). The Bernoulli equation could therefore be applied between the me-
tering and valve orifice to calculate the velocity of the flow at the valve orifice. The
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where ρlpmc and ρlpvo are respectively the liquid densities of HFA134a in the meter-
ing chamber and at the valve orifice in kg·m−3, Umc and Uvo are the flow velocities
in the metering chamber and at the valve orifice respectively in m·s−1 and Pvo is the
pressure at the valve orifice in Pa. The pressure at the valve orifice was assumed
to be equal to the pressure in the expansion chamber so that Equation (2.13) be-
came Equation (2.14). As the valve orifice was assumed to be two-dimensional,












As the mass flow rate was assumed to be constant between the metering chamber
and the valve orifice over each time step, Equation (2.15) was assumed valid for









where dmc is the diameter of the metering chamber and dvo is the diameter of the
valve orifice in m (as shown in Figure 2.3). As the flow is incompressible at the
onset of the actuation, it was assumed that ρlpmc and ρlpvo were equal. As a result,










where ρl is the density of the propellant at room temperature in kg·m−3.
dmc
2 Umc = d
2
vo Uvo (2.17)




































The distances dmc and dvo were measured and were found to have values of respec-


















The mass flow rate out of the metering chamber at the onset of the actuation was
calculated using Equation (2.22).
m˙pvo = ρl Uvo Avo (2.22)
where m˙pvo is the mass flow rate of propellant at the valve orifice in kg·s−1 and
Avo is the valve orifice area in m
2. By replacing Uvo into Equation (2.22) using
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Equation (2.21), Equation (2.23) was obtained.





When simplifying Equation (2.23), Equation (2.24) was obtained.
m˙pvo =
√
2ρl (Pmc − Pec) Avo (2.24)










where Cdvo is the discharge coefficient of the valve orifice. Discharge coefficients





where m˙real is the real mass flow rate in kg·s−1 and m˙ideal is the ideal mass flow
rate in kg·s−1. The ideal mass flow rate does not take into account the limit of
mass flow due to the vena contracta effect shown in Figure 2.4.
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Figure 2.4: Schematic of a flow going through a constriction.
Discharge coefficients are used when a flow passes through a constriction, which is
the case between the metering chamber and the expansion chamber.
The difference of pressure after a constriction such as the valve orifice causes the
area of the flow to become smaller after the constriction. The point of minimum
area is referred to as vena contracta. The size of the vena contracta depends on
the velocity, the viscosity and the density of the fluid. In this work, the discharge
coefficients enabled the model to take into account the flow constrictions at the
valve and nozzle orifices. Discharge coefficients at the valve orifice were shown
to range from 0.4 to 0.8 for pMDIs with valve orifice diameters values between
0.259 mm and 1.066 mm (Clark, 1991).
2.5.3 Iterative calculation loop
After the calculation of the liquid propellant velocity at the onset of the actuation
from the metering chamber to the expansion chamber, the program enters a loop
calculating the conditions in the entire system (i.e. the metering and expansion




The loop states that:
• the model continues running only if Pec ≥ Patm
• if Pmc > Pec the flow velocity between the metering and expansion chambers
must be calculated otherwise it must be set to zero, assuming there is no
back flow into the metering chamber.
2.5.3.1 Expansion chamber
After the discharge of the propellant from the metering chamber at the onset of the
actuation, the conditions inside the expansion chamber are updated. The mass of
each phase (liquid and vapour) in the expansion chamber corresponds to the mass
at the previous time step plus the mass coming from the metering chamber minus
the mass leaving the expansion chamber in that time step. The masses of the liquid








where mlpec corresponds to the mass of liquid propellant in the expansion chamber
in kg, m˙lpvo is the mass flow rate of the liquid phase at the valve orifice in kg·s−1,
m˙lpno is the mass flow rate of the liquid phase at the nozzle orifice in kg·s−1, dt
corresponds to the time step in s and the superscripts “o” and “n” refer to the
previous and current time step values respectively.
mvpnec = mvp
o
ec + ( ˙mvp
o
vo − ˙mvpono) dt (2.28)
wheremvpec corresponds to the mass of propellant vapour in the expansion chamber
in kg, ˙mvpvo is the mass flow rate of the propellant vapour phase at the valve orifice
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in kg·s−1 and ˙mvpno is the mass flow rate of the propellant vapour phase at the
nozzle orifice in kg·s−1.
The mass of air in the expansion chamber was calculated by subtracting the mass
of air leaving the expansion chamber from the mass of air at the preceding time
step as shown in Equation (2.29).
manec = ma
o
ec − m˙ano dt (2.29)
where maec corresponds to the mass of air in the expansion chamber in kg and
m˙ano is the mass flow rate of air at the nozzle orifice in kg·s−1.
The total enthalpy in the expansion chamber is calculated using Equation (2.30).
Hnec = H
o
ec + (m˙pvo dt hmc)
o − (m˙no dt hec)o (2.30)
where Hec is the total enthalpy in the expansion chamber in kJ, hmc and hec are the
specific enthalpies in the metering and expansion chambers respectively in kJ·kg−1
and m˙no is the total mass flow rate at the nozzle orifice in kg·s−1.
The total enthalpy in the expansion chamber defined in Equation (2.30) is also equal
to the sum of liquid propellant, vapour propellant and air enthalpies as shown in
Equation (2.31).
Hec = Hlpec +Hvpec +Haec = mlpec hlpec +mvpec hvpec +maec haec (2.31)
where Hlpec, Hvpec, Haec are the total enthalpies in the expansion chamber of
the propellant liquid phase, propellant vapour phase and of air respectively in kJ
and hlpec, hvpec, haec are the specific enthalpies in the expansion chamber of the
propellant liquid phase, propellant vapour phase and of air respectively in kJ·kg−1.
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In order to find the temperature and flow characteristics in the expansion chamber
at the new time step, the specific enthalpy of the liquid and vapour phases in
Equation (2.31) are respectively replaced by Equations (2.32), and (2.33) with
unknown constant u from the Mexichem Fluor website (Klea134a, 2011).








where A1, B1, C1, D1, E1, A2, B2, C2, D2 and E2 correspond to the coefficients of
the specific liquid and vapour enthalpy equations listed in the Appendix and u is







where Tcrit corresponds to the critical temperature of the propellant in K.
The thermodynamic properties in the expansion chamber were then calculated
based on the new temperature. The density of the liquid propellant in the expansion
chamber was calculated using Equation (2.11) listed in the Appendix (Klea134a,
2011).
The volume of the gas phase in the expansion chamber was calculated using Equa-
tion (2.35).
V vec = Vec − mlpec
ρlpec
(2.35)
where V vec is the total volume of the vapour phase (i.e. including air and propel-
lant) in the expansion chamber in m3, Vec is the volume of the expansion chamber
in m3 and ρlpec is the density of the liquid phase of the propellant in the expansion
chamber in kg·m−3. The density of the total vapour phase (taking into account
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where ρvec is the density of the vapour in the expansion chamber in kg·m−3.






where ρec is the average density inside the expansion chamber in kg·m−3. The
quality in the expansion chamber was calculated based on the new masses in the





where qec is the quality of the flow in the expansion chamber. The pressures of the
vapour propellant and air phases were calculated by assuming that both propel-









where Pvpec is the pressure of the propellant vapour in the expansion chamber in
Pa, Ru is the universal gas constant in kJ·K−1kmol−1 and Mp is the molecular







where Paec is the pressure of air in the expansion chamber in Pa and Ma is the
molar mass of dry air in kg·kmol−1 (Rogers and Mayhew, 1995).
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The total pressure in the expansion chamber is the sum of the air pressure and
vapour propellant pressure and was calculated as shown in Equation (2.41).
Pec = Paec + Pvpec (2.41)
The flow exiting the expansion chamber can exhibit two behaviours which are crit-
ical and subcritical. The equations used to determine the gas and liquid velocities










where Cp is the specific heat capacity of the vapour phase in kJ·kg−1·K−1
calculated as a function of the new temperature in the expansion chamber. The















When the flow is subcritical, the Bernoulli equation can be applied and the liquid















where Uvno is the velocity of the vapour phase at the nozzle orifice in m·s−1.
At critical conditions, (Racrit ≤ PatmPec ), the Bernoulli equation cannot be used
because the velocity no longer depends on downstream conditions. From Equa-
tion (2.44), Patm = Racrit Pec, one obtains Equation (2.48) for the calculation of











Equations (2.48) and (2.49) were also used by Aamir and Watkins (2000) in their
simulation of high-pressured propane leakage.
The liquid and vapour mass flow rates were calculated using Equations (2.50)
and (2.51) respectively.
m˙lpno = Ano (1− qec) ρec Ulno (2.50)
m˙vno = Ano qec ρec Uvno (2.51)
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where m˙vno is the total mass flow rate of the vapour phase at the nozzle orifice
in kg·s−1. The total mass flow rate at the nozzle orifice was calculated using
Equation (2.52).
m˙no = m˙lpno + m˙vno (2.52)
Clark attempted to correlate the size of particles exiting the nozzle orifice to dif-
ferent factors such as vapour pressures, orifice diameter ratios and surfactant con-
centrations (Clark, 1991). He measured the residual size of the particle in a large
volume holding chamber 5 s after actuating the pMDI. From the residual size of
the droplets, he worked back the theoretical initial particle size. He then developed
Equation (2.53), correlating the initial particles size to the quality and pressure in








where MMD is the mass median diameter of the formulation in µm. This corre-
lation is consistent with experimental results using CFC and HFA134a propellants
(Smyth, 2003). However Equation (2.53) cannot be used at the onset and at the
end of the discharge process, as when Pec → Patm, MMD → ∞. The size of the
particles at the nozzle orifice was therefore calculated only during the first half
of the spray duration. Equation (2.53) also assumes that the initial size of the
droplets is not influenced by the size of the nozzle orifice, which might not be a
valid assumption (Berry et al., 2003).
2.5.3.2 Metering chamber
The quality of the flow and other thermodynamic properties were then determined
in the metering chamber. The mass of the propellant in the metering chamber
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corresponds to the mass of propellant in the metering chamber at the previous time
step minus the mass that left the metering chamber as shown in Equation (2.54).
mpnmc = mp
o
mc − m˙povo dt (2.54)
where mpmc is the mass of propellant in the metering chamber in kg. The metering
chamber contains a liquid and a vapour phase. The masses of each phase can be
calculated using Equations (2.55) and (2.56) respectively.
mlpmc = mpmc (1− qmc) (2.55)
where mlpmc is the mass of liquid propellant in the metering chamber in kg and
qmc is the quality of the propellant in the metering chamber.
mvpmc = mpmc qmc (2.56)
where mvpmc is the mass of vapour propellant in the metering chamber in kg.




mc − (m˙pvo dt hmc)o (2.57)
where Hmc is the total enthalpy in the metering chamber in kJ.
The new total enthalpy in the metering chamber can also be calculated from the
specific enthalpies of the propellant as shown in Equation (2.58).
Hmc = mlpmc hlpmc +mvpmc hvpmc − (mvpmc −mvpomc)hlvpmc (2.58)
where hlpmc, hvpmc and hlvpmc are respectively the specific enthalpies of the liquid
phase, the vapour phase and the specific enthalpy of vaporisation of the propellant
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in the metering chamber in kJ·kg−1.
As in the expansion chamber, the temperature was found by replacing each spe-
cific enthalpy by its polynomial form in the energy equation. The program im-
plemented the 4th order equations of state with unknown constant u as shown in
Equations (2.59), (2.60) and (2.61).

















When Equation (2.58) was implemented in Matlab with each enthalpy term re-
placed by its approximation equation (Equations (2.59), (2.60) and (2.61)), u was
calculated and used to find the new metering chamber temperature.
As the formulation in the metering chamber was assumed to be under saturated
conditions, its pressure, its density and its enthalpy could be solved as functions of
the temperature using the equations listed in the Appendix.




hvpmc − hlpmc (2.63)
As in the expansion chamber, the specific heat capacity of the propellant and γ
were calculated in order to determine the flow regime at the valve orifice.
Similar types of calculations as for the nozzle orifice were repeated to find the veloc-








The velocities of the gas and liquid phases at the valve orifice at subcritical condi-












where Uvvo is the velocity of the propellant vapour at the valve orifice in m·s−1
and ρvpmc is the propellant vapour density in the metering chamber in kg·m−3.
At critical conditions, (Racrit ≤ PecPmc ), Equations (2.67) and (2.68) were used for










The liquid and vapour mass flow rates were calculated using Equations (2.69)
and (2.70) respectively.
m˙lvo = Avo (1− qmc) ρmc Ulvo (2.69)
m˙vvo = Avo qmc ρmc Uvvo (2.70)
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The total mass flow rate at the valve orifice was calculated using Equation (2.71).
m˙vo = m˙lvo + m˙vvo (2.71)
Once the flow characteristics were calculated throughout the system, the simula-
tion went back into the loop until the pressure in the expansion chamber became
atmospheric. A flow chart of the model can be seen in Figure 2.5.




A one-dimensional Matlab model simulating the discharge of a pMDI spray was
developed. Since the current model calculates two different flow velocities for the
vapour and liquid phases, it may offer greater accuracy than previous simulations.
The model was used to calculate spray characteristics such as velocity, mass flow
rate and particles size at the nozzle orifice. The results and novel features obtained
from the simulation will be discussed in the next chapter.
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Theoretical analysis of metered




3.1.1 Effects of different parameters on the properties of
pMDIs sprays at the nozzle orifice
In Chapter 1, it was seen that the behaviour of pMDI sprays might be influenced
by several factors such as device design, formulation design, exterior conditions and
handling of the device. In this chapter, the role of certain parameters on the spray
properties was investigated using the model developed in Chapter 2.
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Models developed by Clark (1991), Dunbar (1996), Ju et al (2010), (2012) simu-
lating the aerosolisation of a pMDI formulation give highly variable results. This
might be because the modelling of the discharge from pMDIs is complex and vary-
ing assumptions might cause significant differences in the results. The present
model was inspired from and compared with those previous models. The parame-
ters studied and their effects on the sprays issued from pMDIs are described below.
Effect of temperature on spray characteristics
When measuring the size of particles issued from pMDIs using a Malvern Spraytec R©,
Haynes and coworkers (2004) found that an increase in temperature led to the
aerosolisation of droplets with a greater initial velocity and with a smaller residual
diameter. Pu et al (2011) obtained similar findings in their Sympatec R© experi-
ments.
In their inertial impaction experiments, Polli et al (1969) also reported this trend
(albeit with CFC propellants) and observed a dramatic decrease in the MMAD at
higher temperatures. The market for pMDIs is expanding in third world countries
where temperatures might differ from temperatures in Europe. In some countries,
the large differences between outdoor and indoor temperatures could modify the
properties of pMDIs sprays. The study of the temperature effect on the spray
characteristics is therefore critical. To the best knowledge of the author, the ef-
fect of temperature was never incorporated into a simulation although it could be
useful in order to develop formulations which behaviours would not be affected by
temperature changes. Depending on the formulation, a specific temperature might
be required for optimum drug deposition at the target location.
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Effect of nozzle and valve orifices diameters on spray characteristics
Nozzle orifice diameters could influence the particle size of aerosols issued from
pMDIs. Common nozzle diameters range from 0.2 mm to 0.5 mm (Swarbrick, 2007).
Although one might think that smaller orifices might lead to the aerosolisation
of smaller droplets, Ashworth et al (1991) found that the lung deposition was
independent of the nozzle orifice diameter.
Conversely, a study from Berry et al (2003) revealed that the amount of fine parti-
cles was inversely related to the nozzle orifice diameter. This relationship was also
shown by Ganderton et al (2003) who plotted the MMAD and the fine particle dose
(FPD) obtained using an impactor as functions of the nozzle orifice diameter. They
showed that the nozzle orifice had a significant effect on the FPD which decreased
from approximately 85µg to 30µg as the nozzle orifice diameter increased from
0.22 mm to 0.42 mm. The results of Ganderton et al are reproduced in Figure 3.1.
Figure 3.1: Fine particle dose and MMAD plotted as functions of the nozzle orifice
diameter (Ganderton et al., 2003).
The results in Figure 3.1 show that the nozzle orifice only has a slight effect on
142
Chapter 3
the size of the particles. This could be due to the fact that small nozzle orifice
diameters do not reduce the number of big droplets produced in a spray so that
the MMAD remains relatively constant across the range of nozzle orifice diameters
tested. However, large nozzle orifice diameters hinder the capacity of the flow to
aerosolise into fine droplets so that the FPD value greatly decreases across the
range of nozzle orifice diameters tested.
Another explanation for the relatively constant MMAD values could be that the
MMAD is only determined from the aerosol reaching the sizing stages of the im-
pactor. As a result, large droplets issued from pMDIs with large nozzle orifices
would not reach those stages and the MMAD would not increase significantly.
Another experimental work showed that using a nozzle orifice diameter of 0.25 mm
instead of 0.5 mm improved the performance of the inhaler tested (Kleinstreuer
et al., 2007). From those results, it would seem beneficial to use nozzle orifices with
smaller diameters although they are blocked more frequently than nozzle orifices
with bigger diameters (Swarbrick, 2007). The ratio of the nozzle and valve orifices
is also important as it might influence the moment in the aerosolisation process
when the flow becomes critical and thus affect the exit velocity of the flow.
Effect of force of actuation on spray characteristics
As discussed in Chapter 1, users might have varying actuation forces. The role of
the actuation force on the spray characteristics was deemed worth of study, as it
was believed to affect the opening rate of the valve orifice. This is illustrated in
Equations (3.1) to (3.6).




where Sc is the distance travelled by the canister during its actuation in m, Uin c
is the initial velocity of the canister in m·s−1, ac is the acceleration of the canister
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in m·s−2 and t is the valve orifice opening time in s. As the initial velocity is 0,





Applying Newton’s second law on the canister, Equations (3.3) and (3.4) are ob-
tained.





where F is the force applied to the canister in N and mc is the mass of the canister











As Sc and mc are constant, it results that F is proportional to the square of the
valve orifice opening rate. To the best knowledge of the author, the role of the
actuation force and, consequently, the role of the valve opening rate on the spray
properties have not been investigated. It was decided to modify the valve orifice
opening rate in the simulation in order to observe its effect on the exit properties
of sprays issued from pMDIs.
3.1.2 Aims and objectives
The aim of this chapter was to validate the model by comparing the velocity of the
spray, its duration, its quality as well as the particles size at the nozzle orifice with
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results obtained from other models and experimental data. After validation of the
model, the main objective was to understand the effect of several parameters on
the exit properties of the spray.
For example, the effect of the nozzle and valve orifices diameters on the size and
velocity of the exiting droplets was studied and helped to validate the model as the
results obtained could be compared with the literature.
As mentioned in Chapter 1, the minimum force required to actuate a pMDI might
represent an issue for elderly users and other weak users. As the actuating force
affects the valve orifice opening rate, the latter was modified in the simulation and
its effect on the spray characteristics was assessed.
The model was also modified to simulate the discharge of suspension formulations
containing fluticasone propionate (FP). This is relevant as the simulation could
thus be used to investigate certain commercial suspension formulations.
Finally, through the monitoring of the spray in the metering and expansion cham-
bers, the aim of the chapter was to investigate the effect of different factors on the
evolution of the flow inside the device.
3.2 Methods
The model was developed on Matlab as described in Chapter 2. It was then modi-
fied to take into account the velocity of the valve opening orifice and the presence
of FP in the formulation.
The default settings of parameters used in the simulation listed in Table 3.1 were




Present Dunbar Ju et al
work (1996) (2010)
Valve orifice diameter (mm) 0.7 0.7 0.7
Nozzle orifice diameter (mm) 0.5 0.5 0.5
Metering chamber volume (µL) 63 63 63
Expansion chamber volume (µL) 17.6 17.6 17.6
Discharge coefficient at valve orifice 0.61 0.61 0.61
Discharge coefficient at nozzle orifice 0.78 0.78 0.5
Temperature (K) 293 295 293.15
Table 3.1: List of parameters used in the simulation.
3.3 Results
3.3.1 Effect of temperature on spray characteristics
Effect of temperature on velocity
Figures 3.2 and 3.3 respectively show the liquid and vapour phases velocity at the
nozzle orifice at several temperatures.




Figure 3.2 shows that the velocity of the liquid phase increases at higher temper-
atures. The peak velocity was approximately 17 m·s−1 at 293 K compared with a
peak of approximately 23 m·s−1 at 313 K.
The aerosolisation process had longer durations at higher temperatures (approxi-
mately 0.16 s at 293 K, 0.175 s at 298 K and 0.225 s at 313 K).
Figure 3.3: Velocity of the vapour phase of the spray at the nozzle orifice at several
temperatures.
In Figure 3.3, the initial velocity peak occurs immediately at the onset of the
actuation as the spray exits the nozzle orifice. The vapour phase velocity then
decreases as more liquid-rich propellant enters the expansion chamber. As the
liquid propellant starts evaporating, the flow at the nozzle orifice becomes critical.
It remains critical until a sharp drop in the velocity occurs towards the end of the
atomisation process due to a lower expansion chamber pressure as the metering
chamber becomes depleted of formulation. The velocity then decreases until the
end of the discharge process.
Figures 3.2 and 3.3 show that at all temperatures, the vapour phase, with a max-
147
Chapter 3
imum velocity of 200 m·s−1 was much faster than the liquid phase which had a
maximum velocity of approximately 23 m·s−1.
The velocity of the vapour phase also increases at higher temperatures. The peak
velocity is approximately 180 m·s−1 at 293 K compared with a peak of approxi-
mately 200 m·s−1 at 313 K.
The higher velocities observed at higher temperatures could be explained by a




Figure 3.4: Pressure in the metering and expansion chambers when the formulation
and the room temperatures are set to 293 K, 298 K and 313 K.
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Figure 3.4 shows that the pressure in the metering chamber decreases from the
saturated vapour pressure at the specific temperature at which the simulation is
run, to atmospheric pressure. The expansion chamber pressure is initially atmo-
spheric before increasing to almost the level of the metering chamber pressure as
the propellant is discharged from the metering chamber. Towards the end of the
aerosolisation process, the expansion chamber pressure decreases to atmospheric
pressure as the formulation is discharged from the device.
Effect of temperature on mass flow rate and residual mass
Figure 3.5 shows the total mass flow rate of the propellant at the nozzle orifice.
Figure 3.5: Total mass flow rate of the propellant at the nozzle orifice at several
temperatures.
The mass flow rate curves follow broadly the expansion chamber pressure curves.
The maximum mass flow rate was approximately 2.3 g·s−1 at 313 K compared with
1.7 g·s−1 at 293 K.
As the mass flow rate was higher and the duration of the spray was longer at
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higher temperatures, a greater quantity of propellant would be expected to be
discharged. This agrees with Figure 3.6, showing the mass of propellant remaining
in the metering chamber when the pMDI was actuated at several temperatures.
Figure 3.6: Residual mass of propellant in the metering chamber when the formu-
lation and the room temperatures are set to 293 K, 298 K and 313 K.
Figure 3.6 shows that the residual mass inside the metering chamber at the end of
the actuation, was lower at higher temperatures as it represented approximately
70% of the initial mass of the metering chamber formulation at 293 K compared to
50% at 313 K.
Effect of temperature on mass flashing and droplet size
Figure 3.7 shows the fraction of the formulation that could potentially evaporate







where fractionmflash represents the fraction of liquid formulation that could flash
at the nozzle orifice, hlpec is the specific enthalpy of the liquid propellant in the
expansion chamber in kJ·kg−1, hlpwb is the specific enthalpy of the liquid propellant
at the wet bulb temperature in kJ·kg−1 and hlvpwb is the specific enthalpy of
vaporisation of the propellant at the wet bulb temperature in kJ·kg−1.
Figure 3.7: Fraction of the formulation that could evaporate at the nozzle orifice
at 293 K, 298 K and 313 K.
Figure 3.7 shows that at all temperatures, the fraction of propellant that can evap-
orate decreases during the actuation process which is expected as the energy avail-
able for the evaporation of the propellant and the temperature in the expansion
chamber decrease.
The fraction of liquid propellant that can evaporate increases at higher tempera-
tures, potentially leading to the formation of smaller droplets. The effect of tem-
perature on the mass median diameter (MMD) of the droplets emitted at the nozzle
orifice is shown in Figure 3.8.
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Figure 3.8: MMD of the spray at the nozzle orifice at several temperatures.
In Equation (2.53), developed by Clark and defined in Chapter 2, it can be seen








For this reason, the value of the MMD at the onset and the end of the actuation
were not taken into account in all MMD graphs and the maximum diameter shown
was 500µm as this is the maximum droplet size reported for pMDIs aerosols in the
literature (Hochrainer et al., 2005).
The MMD, with a minimum value of approximately 85µm at 293 K compared
to 45µm at 313 K is seen to greatly decrease at increasing temperatures. From
Equation (2.53), lower MMD values could be explained by a higher pressure build
up in the expansion chamber or a higher expansion chamber quality. The increasing
pressure in the expansion chamber at higher temperatures was shown in Figure 3.4
and the increasing quality at higher temperatures can be seen in Figure 3.9.
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Figure 3.9: Quality in the expansion chamber at 293 K, 298 K and 313 K.
The quality in the expansion chamber has a value of 1 at initial conditions as
the expansion chamber is filled with gaseous air. It then decreases due to the
replacement of dry air by propellant. As the propellant starts evaporating, the
quality increases. It then decreases which could be due to a drop in enthalpy
towards the end of the atomisation process as the mass of propellant entering
the expansion chamber decreases. This enthalpy decrease would in turn cause a
decrease in temperature, resulting in a lower quality.
At 313 K the increasing quality of the propellant in the expansion chamber from
approximately 0.03 s to 0.1 s after the onset of actuation might arise from the
increasing quality of the propellant coming from the metering chamber. As the
metering chamber empties, the quality would indeed increase at a high temperature
at which the latent heat of vaporisation is lower than at low temperatures.
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3.3.2 Effect of the valve and nozzle orifices diameters on
spray characteristics
Effect of nozzle to valve orifices ratios on the pressure build up in the
expansion chamber
The ratio of the nozzle orifice to the valve orifice diameters was 0.71 when using the
nozzle and valve orifices diameters used by Dunbar (1996) presented in Table 3.1.
The valve orifice diameter of a metering valve and the nozzle orifice diameters from
two mouthpieces, employed for experimental work in subsequent chapters, were
measured using a travelling microscope.
The valve orifice of a 50µL non-continuous valve from Valois (Valois pharmaceutical
division, 780160 Marly Le Roi, France) was found to have a diameter of 0.55 mm.
The nozzle orifice of an Alvesco R© mouthpiece (Takeda Pharmaceuticals Interna-
tional GmbH, Zurich, Switzerland) had a diameter of 0.20 mm. The mouthpiece
from Flixotide R© had a nozzle orifice diameter of 0.50 mm, which is similar to the
diameter used by Dunbar (1996). Those two mouthpiece diameters, each combined
with the 50µL non-continuous valve orifice diameter were investigated. Dunbar’s
valve and nozzle orifices diameter values were also run in the simulation. All the
combinations of valve and nozzle orifices diameters studied are listed in Table 3.2
in which the orifice diameter ratio (ODR) corresponds to the ratio of the nozzle
orifice to the valve orifice diameters.
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Valve orifice Nozzle orifice
ODR










Table 3.2: List of the combinations of valve and nozzle orifices diameters investi-
gated.
The effect of the nozzle orifice and valve orifice diameters on the expansion chamber
pressure can be seen in Figure 3.10.
Figure 3.10: Expansion chamber pressures for several nozzle and valve orifices
diameter combinations, where dvo and dno are respectively the valve and nozzle
orifices diameters in mm.
At a specific valve orifice diameter, a smaller nozzle orifice diameter leads to a
greater pressure build up in the expansion chamber. More generally, it shows that
when the ODR decreases, the pressure in the expansion chamber increases.
Effect of the nozzle orifice diameter on the discharge duration
When keeping a constant valve orifice diameter and running the simulation at
293 K, the effect of the nozzle orifice diameter on the duration of the discharge
process was investigated and is shown in Table 3.3.
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Table 3.3: Effect of the nozzle orifice diameter on the duration of the discharge
process.
A smaller nozzle orifice leads to a longer aerosolisation process, which seems logical
as a lower amount of formulation could be discharged at each time step.
Effect of the nozzle orifice diameter on the size and velocity of the par-
ticles at the nozzle orifice
In Figures 3.11 and 3.12, the valve orifice diameter was kept constant at a value
of 0.7 mm, the size of the nozzle orifice was modified and its effect on the size and
velocity of the aerosolised particles was investigated.
Figure 3.11 shows that the minimum MMD had a value of approximately 50µm
when a nozzle orifice diameter of 0.2 mm was used compared to a value of approx-
imately 90µm when a nozzle of orifice diameter of 0.6 mm was used.
Figure 3.11: MMD values at the nozzle orifice for several nozzle orifice diameters.
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Figure 3.12: A. Velocity of the liquid phase at the nozzle orifice for several nozzle
orifice diameters. B. Velocity of the vapour phase at the nozzle orifice for several
nozzle orifice diameters.
Figure 3.12 shows that the velocity of the propellant increased at lower nozzle orifice
diameters. The liquid phase had a peak velocity of approximately 18 m·s−1 at a
nozzle orifice diameter of 0.2 mm compared to 16 m·s−1 at a nozzle orifice diameter
of 0.6 mm. The vapour phase had a peak velocity of approximately 220 m·s−1 at a
nozzle orifice diameter of 0.2 mm compared to approximately 170 m·s−1 at a nozzle
orifice diameter of 0.6 mm.
It was believed that the ratio of the maximum expansion chamber pressure to the
maximum metering chamber pressure might depend upon the ratio of the nozzle
to valve orifices diameters. In order to investigate this relationship, several nozzle
orifice diameters were tested for one valve orifice diameter. The nozzle diameters
studied varied from 0.1 mm to 0.5 mm in steps of 0.1 mm. This set of simulations




Figure 3.13: Maximum expansion chamber to metering chamber pressure ratios as
a function of the nozzle orifice to valve orifice diameter ratios.
Figure 3.13 shows that the maximum expansion to metering chambers pressure
ratio decreases almost linearly with the nozzle to valve orifices diameter ratio. The
pressure in the expansion chamber can be seen to reach almost 90% of the metering
chamber pressure at low nozzle to valve orifices diameter ratios.
3.3.3 Effect of the valve orifice opening rate
Subroutine simulating the opening rate of the valve orifice
In the current work, the valve orifice area was varied in function of time to render
the actuation more realistic. Figure 3.14 helps to understand the calculation of the
opening of the valve orifice area as a function of the actuation time.
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Figure 3.14: Geometry of the valve orifice allowing the calculation of the valve
orifice opening as a function of the actuation time where w corresponds to the
displacement of the canister in m at a certain time and A′, B′ and C ′ refer to the
specific hatched areas in m2, C ′ being the valve orifice opening area at a certain
time.
The subroutine modifying the valve opening area as a function of the actuation
time and canister velocity was developed using Equations (3.8) to (3.17).









where dvo represents the diameter of the valve orifice and where θ represents the

























(θ − sin θ) (3.13)
as










where w corresponds to the displacement of the canister at a specific time t in s as
shown in Figure 3.14, and is calculated using Equation (3.16).
w = Uc t (3.16)
where Uc is the velocity of the canister in m·s−1.






When replacing θ in Equation (3.9) one obtains Equation (3.18) which was imple-



















The velocity of a canister actuated by a “healthy” female adult and a “weak”
and inexperienced female research team member was studied in order to identify
whether diverse actuation types might influence the actuation mechanism and sub-
sequently the spray characteristics.
The velocity of an aluminium canister (Bespak, UK) crimped to a 50µL non-
continuous valve from Valois (Valois pharmaceutical division, 780160 Marly Le
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Roi, France) was measured during actuation using a linear variable differential
transformer (LVDT). The LVDT output was captured on a computer by means
of a USB 6211 analog to digital converter (National Instruments, Berkshire, UK)
at a sampling frequency of 1 kHz. The actuation profiles of the “healthy” and the
“weak” female users can be seen in Figure 3.15.


























Figure 3.15: Actuation profile of a “healthy” adult female user and a “weak” female
user.
The opening rate of the valve orifice for the “weak” inexperienced female user
was approximately 1.9 mm·s−1. The actuation velocity varied between 1.7 mm·s−1
to 1.9 mm·s−1 for five actuations. The opening rate of the valve orifice for the
“healthy” female was 21 mm·s−1. The actuation velocity varied between 21 mm·s−1
and 27 mm·s−1 for five actuations.
Figure 3.15 shows that the “healthy” female and the “weak” inexperienced female
have highly different actuation profiles. The time during which the valve orifice is
fully open, although it greatly differs between the “healthy” female and the “weak”
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female users, is not believed to affect spray characteristics as in both cases, the valve
remains open for a longer time than the duration of the discharge process.
In the simulation, it was found that valve opening rates higher than approximately
2 mm·s−1 led to similar velocity and MMD results as instantaneous openings of
the valve orifice. For this reason, the valve opening rate of the “healthy” female
user was not implemented in the simulation. The valve opening rates of the “weak”
inexperienced female were tested and compared to the instantaneous opening of the
valve orifice. The effect of several valve opening rates on the expansion chamber
pressure is shown in Figure 3.16.
Figure 3.16: Expansion chamber pressure at several valve orifice opening rates.
Figure 3.16 shows that at instantaneous opening of the valve orifice, the pressure in
the expansion chamber is higher than at lower valve opening rates. It was believed
that a higher pressure build up in the expansion chamber might translate into the
aerosolisation of smaller droplets. The MMD values of the spray at various valve
opening rates were therefore investigated and are shown in Figure 3.17.
163
Chapter 3
Figure 3.17: MMD at the nozzle orifice at several valve orifice opening rates.
Figure 3.17 shows that the opening rate of the valve orifice has an effect on the
MMD of the aerosolised particles. When the valve orifice opens instantaneously,
the minimum MMD has a value of approximately 70µm compared to a value of
approximately 90µm at the lowest tested valve opening rate of 1.5 mm·s−1.
3.3.4 Effect of a suspended drug on spray characteristics
The model was modified to take into account the presence of fluticasone propionate
(FP) in the HFA134a formulation. As FP and HFA134a are not soluble and are
commonly used as a suspension formulation (e.g. Flixotide R©), it was assumed that
the drug would not interact with the propellant and would not modify its thermody-
namic properties. The properties of FP, found in the Chemical Book website were
assumed not to change as a function of temperature (chemicalbook.com, 2008).
The FP particles were treated as homogeneously dispersed in the formulation and
it was assumed that the same mass of FP was carried by the liquid phase and
the vapour phase of the propellant. The model calculated the mass of the drug
in the expansion chamber as a percentage of the mass of gas and liquid phases.
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The volume of the gas phase in the expansion chamber was calculated after de-
termining the volume occupied by the drug and the liquid phase. The presence
of FP therefore decreased the amount of propellant present in the system at each
actuation.
It was assumed that the presence of the drug particles did not affect the discharge
coefficients of both valve and nozzle orifices. In commercially available pMDIs, a
limit of 2% API by weight has been reported in order to avoid blockage of the
nozzle orifice (Smyth, 2003). However, concentrations of up to 10% by weight were
investigated in the following figures, to better demonstrate the effect of an increased
weight concentration of FP on the spray characteristics. Figure 3.18 shows the
effect of the drug concentration on the pressure in the expansion chamber.
































Figure 3.18: Expansion chamber pressure at varying FP concentrations.
The expansion chamber pressure decreases from a peak of 425 kPa at 0% FP to
250 kPa at 10% FP. As the expansion chamber pressure decreases at increasing
FP concentrations, the velocity at the nozzle orifice is also expected to decrease.
Figures 3.19 and 3.20 respectively show the exit velocity of the liquid and vapour
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phases of the formulation at several FP concentrations.
































Figure 3.19: Velocity of the liquid phase at the nozzle orifice at varying FP con-
centrations.

































Figure 3.20: Velocity of the vapour phase at the nozzle orifice at varying FP con-
centrations.
Figures 3.19 and 3.20 show that the velocity of the formulation decreases from
approximately 16 m·s−1 to 12 m·s−1 for the liquid phase and from approximately
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180 m·s−1 to 165 m·s−1 for the gas phase when the FP concentration increases from
0% to 10% by weight.
Figure 3.21 shows the MMD of the formulation at varying FP concentrations.
Figure 3.21: MMD of the suspension formulation at varying FP concentrations.
Figure 3.21 shows that the minimum MMD increases from approximately 70µm
to 100µm as the FP concentration increases from 0% to 10% by weight.
3.4 Discussion
3.4.1 Effect of temperature on spray characteristics
Effect of temperature on velocity
The velocities obtained when the simulation was run at the same temperature as
Dunbar and Ju’s models were 17 m·s−1 and 170 m·s−1 for the liquid and vapour
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phases respectively (Dunbar, 1996), (Ju et al., 2010).
The model developed by Ju et al (2010) calculated a peak velocity of approximately
19 m·s−1 for a HFA134a spray although it is not clear if they refer to the liquid or
gas phase velocity. It is therefore not possible to compare their velocity values to
other work including the present simulation.
In the model of Wigley et al (2002), two velocity peaks of approximately 60 m·s−1
each were obtained at the nozzle orifice for the mixture of the gas and liquid phases
during the actuation of a HFA134a-based pMDI. Wigley’s velocity results are shown
in Figure 3.22.
Figure 3.22: Temporal profile of propellant velocity (Wigley et al., 2002).
The first velocity peak in Figure 3.22 is believed to correspond to the high quality
flow exiting from the nozzle orifice at the beginning of the discharge. The velocity
then reduces due to the fact that the quality of the flow decreases. Towards the
end of the spray, the formulation undergoes more intense evaporation due to the
emptying of the metering and expansion chambers, leading to the second velocity
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peak (Wigley et al., 2002). The present work cannot be directly compared to
Wigley’s work as the velocity of the liquid and vapour phases were calculated
separately.
In his simulation, Dunbar obtained a peak velocity of 225 m·s−1 for both the liquid
and vapour phases. As velocity values from simulations range from 19 m·s−1 to
225 m·s−1, it is not possible to validate the current model’s velocity profiles using
only modelling data so that experimental data were also investigated (Dunbar,
1996), (Ju et al., 2010), (Wigley et al., 2002).
The value of 225 m·s−1 reported by Dunbar (1996) for the velocity of both liquid
and vapour phases of a HFA134a spray seems very high compared to experimental
velocity measurements in the literature. For example, Wigley et al (2002) found
a maximum velocity of approximately 90 m·s−1 in the vicinity of the nozzle orifice
when using phase Doppler anemometry (PDA) for HFA134a sprays.
In his PDA measurements, Dunbar measured velocity of approximately 60 m·s−1 for
a HFA134a spray at a distance of 25 mm from the nozzle orifice. This is in line with
the findings of Crosland et al (2009) who obtained a maximum velocity of 60 m·s−1
in their particle image velocimetry (PIV) measurements of a HFA134a-based pMDI
at a location of 1 mm from the extremity of the mouthpiece (approximately 25 mm
from the nozzle orifice).
The lower velocity obtained by Dunbar compared to Wigley might be explained
by the fact that Wigley measured the velocity of the droplets closer to the nozzle
orifice (Dunbar, 1996), (Wigley et al., 2002). However as it is thought that PDA
measurements should only be taken at a minimum distance of 10 mm from the noz-
zle orifice for maximum measurement accuracy due to the high spray concentration
closer to the nozzle orifice, Wigley’s PDA results (shown in Figure 3.22) might not
be as reliable as Dunbar’s.
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The variations of the spray exit velocity observed from simulations and experimen-
tal work might be due to the small size of the nozzle orifice and, as pMDI sprays
are extremely transient, turbulent, fast and dense at this location, their properties
are difficult to measure or to calculate. However, the velocities found in the present
simulation are within the range of velocities quoted from the literature.
The higher velocities observed at higher temperatures might be due to the fact
that an increased temperature led to a higher vapour pressure of the formulation,
increasing the pressure gradient between the formulation and the atmosphere, thus
producing a spray exiting the device at a higher velocity. This was illustrated in
Figure 3.4 which showed that the pressure in both the metering and expansion
chambers increased at higher temperatures.
Clark (1991) measured the pressure in the metering and expansion chambers of a
pMDI containing CFC-12 propellant using a pressure sensor and observed a slightly
longer duration of the discharge process compared to the current simulation (0.20 s
compared to 0.16 s in the current work). As both CFC-12 and HFA134a have
approximately similar vapour pressures, the type of propellant is not believed to
be responsible for the durations difference (Smyth and Hickey, 2011). The longer
duration in Clark’s work could be attributed to the fact that they used a bigger
metering chamber (100µL compared to 63µL in the current simulation). Clark’s
experimental measurements shown in Figure 3.23 reveal a similar shape of the
pressure curves in the metering and expansion chambers compared to the curves
obtained in Figure 3.4.
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Figure 3.23: Measured pressure inside the metering and expansion chambers for a
CFC-12 spray (Clark, 1991).
The similarity between Clark’s measured pressure profiles and those simulated in
this work (Figure 3.4) provides some evidence towards the validation of the velocity
profiles obtained in Figures 3.2 and 3.3.
Effect of temperature on mass flow rate, residual mass and spray dura-
tion
Figure 3.4 also provides an explanation for the varying durations obtained at dif-
ferent temperatures. The long discharge processes observed at high temperatures
could indeed be due to the fact that the metering chamber containing high pressure
formulation might take a longer time to reach atmospheric pressure.
The model developed by Wigley et al stops after 0.08 s (Wigley et al., 2002). How-
ever, when measuring pMDIs sprays using PDA, they observed an aerosolisation
duration of between 0.15 s and 0.20 s. This is to be expected as the PDA set
up measures particles moving or standing in the air until they evaporate whereas
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simulation models stop running as soon as the pressure in the device becomes
atmospheric.
However, Dunbar (1996) calculated an actuation duration of 0.215 s when using his
simulation of a HFA134a-based pMDI which is in the same range as the duration of
0.195 s obtained from his PDA measurements (Dunbar, 1996). Dunbar’s values are
comparable to the duration of approximately 0.16 s obtained in the current work
with similar room temperature and nozzle orifice diameter.
When using similar initial conditions, Ju et al (2010) found a discharge of ap-
proximately 0.1 s with both their numerical simulation and experimental results
obtained with the dual laser beam method. The difference in duration between Ju
et al and Dunbar is attributed to the calculation of a significantly higher mass flow
rate in Ju’s model compared to Dunbar’s model. The mass flow rates from both
works are shown in Figure 3.24.
Figure 3.24: Total mass flow rates at nozzle orifice as a function of time (Ju et al.,
2010).
The peak mass flow rate of 2 g·s−1 obtained by Ju et al is 4 times greater than
the maximum mass flow rate of 0.5 g·s−1 obtained by Dunbar (1996) although both
simulations used similar device geometries. This difference might be due to the fact
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that Ju et al assumed different velocities for the vapour and liquid phases whereas
Dunbar assumed both phases had a similar velocity.
In this work, when the simulation was run at 293 K, the maximum mass flow rate
was 1.7 g·s−1 which is relatively similar to Ju et al ’s value although the duration
is twice as long as Ju et al ’s duration. As the current simulation uses the same
metering chamber volume and propellant as Ju et al and Dunbar’s simulations, it
is believed that the simulations of Ju et al and Dunbar are not suitable to describe
the entire discharge process in their models, as a significant proportion of the
formulation is not discharged. It is expected that the residual mass of formulation
remaining in the device in Ju et al and Dunbar’s simulations would be higher than
any of the residual masses shown in Figure 3.6.
The residual mass was shown to decrease at increasing temperatures. This might
be due to the fact that at low temperatures, the vapour pressure of the propellant
is too low to provide a sufficient amount of energy to discharge the entire metered
dose. This is of interest as patients using their pMDIs in different environments
could obtain varying amount of drug per metered dose. This might affect the
efficacy of pMDIs treatments and might hinder the potential of pMDIs for the
delivery of certain drugs such as insulin, for which the amount of drug delivered
must be accurate.
The residual mass in the simulation might seem high (up to 70% at 293 K). How-
ever, the simulation does not take into account the heat transfer from the sur-
roundings. If the user maintained the pMDI in the actuated position and therefore
the valve orifice open, evaporation of the metering chamber formulation would take
place due to heat transfer with the surroundings. As a result, the pressure in the
metering chamber would increase, causing a prolonged discharge of the formulation
and, therefore, a lower residual mass of the formulation in the metering chamber.
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Effect of temperature on mass flashing and droplet size
Reports on droplets size at the nozzle orifice in the literature vary tremendously.
More´n and Andersson (1980) estimated that the particles at the nozzle orifice
have a diameter of approximately 35µm using holographic microscopy. High-speed
photography measurements from Wigley et al (2002) showed that large droplets of
30µm to 60µm diameters are issued from pMDIs at the beginning of the actuation.
Hochrainer et al (2005) reported sizes in the range of the nozzle orifice diameter
(approximately 200µm to 500µm). In the present simulation, one can only quote
the minimum MMD as, when using Equation (2.53) developed by Clark (1991),
the MMD →∞ at the beginning and at the end of the discharge process.
When using Equation (2.53), Dunbar (1996) obtained a minimum MMD of 8µm
compared to approximately 85µm in the present simulation when using similar
experimental parameters. Dunbar’s value seems low compared to data in the liter-
ature.
In Equation (2.53), MMD values depend solely on the pressure and quality in the
expansion chamber (respectively Pec and qec). In order to understand the difference
between the MMDs in the present work and Dunbar’s values, the pressure and
quality obtained from the current simulation and from Dunbar’s simulation were
compared. The pressure and quality calculated by Dunbar and Ju et al in the
expansion chamber are shown in Figure 3.25.
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Figure 3.25: A. Pressure in the expansion chamber. B. Quality of the propellant
in the expansion chamber (Ju et al., 2010).
Dunbar’s expansion chamber pressure is similar to the curve obtained at 293 K
in Figure 3.4 although the sharp edge of the pressure peak is not present in the
pressure graph in the current work. The experimental pressure measurements from
Clark (1991) shown in Figure 3.23 and the pressure calculations from Ju et al ’s
simulation shown in Figure 3.25 did not reveal such a sharp pressure rise at the
beginning of the actuation which would suggest that the present simulation is more
in line with literature findings.
The quality in the expansion chamber shown in Figure 3.9 greatly differs from
Dunbar’s quality shown in Figure 3.25.
The quality in the expansion chamber in Ju et al ’s model is below 0.1 at the end
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of the actuation compared to a value of 0.5 calculated by Dunbar and 0.009 in
the present simulation. The quality in the expansion chamber in the current work
shown in Figure 3.9 has a lower magnitude compared to Ju’s simulation. However,
the shape of the quality plot in Ju et al ’s simulation is more similar to the quality
plot in Figure 3.9 than to Dunbar’s quality plot which has an exponential shape.
The value of the expansion chamber quality in the present simulation is more similar
to the quality value in the simulation of the discharge of a HFA134a spray by Shaik
(2009). Shaik obtained a qec smaller than 0.02 in the expansion chamber when using
a pMDI with a valve orifice diameter of 0.42 mm and a nozzle orifice diameter
of 0.48 mm compared to a valve orifice diameter of 0.7 mm and a nozzle orifice
diameter of 0.5 mm in the present simulation. The bigger valve orifice diameter
in the present work might explain the lower quality values compared to Shaik’s
results as a bigger valve orifice area would allow a higher mass of wet propellant
to be discharged from the metering chamber in the expansion chamber.
Dunbar (1996) calculates a quality of 0 at the onset of actuation in the expansion





where qec is the quality in the expansion chamber, mvp is the mass of vapour
propellant in kg, mlp is the mass of liquid propellant in kg and ma is the mass of air
in kg. As at initial conditions the expansion chamber is filled with air and contains
no propellant, the quality in the expansion chamber should be 1. It is therefore not
clear how Dunbar obtained a value of 0 for the quality in the expansion chamber
at initial conditions.
Dunbar’s low MMD value of 8µm could be due to his extremely high expansion
chamber quality calculations. As the quality and pressure plots in the present
176
Chapter 3
simulation are more similar in magnitude and shape to other works, the MMD
values obtained from the model developed in Chapter 2 might be more reliable.
Figure 3.7 shows that at higher temperatures, a higher proportion of the formula-
tion could evaporate at the nozzle orifice. This is expected as, when the formulation
is heated at increased temperatures, the propellant would have more energy to evap-
orate and because the surrounding air would also be at a high temperature, less
energy of evaporation would be required. A temperature increase should also lead
to a greater formulation pressure inside the device, leading to the aerosolisation of
smaller droplets. This was illustrated in Figure 3.8.
3.4.2 Effect of the valve and nozzle orifices diameters on
spray characteristics
Effect of nozzle to valve orifices ratios on the pressure build up in the
expansion chamber
Figure 3.10 showed there was a greater expansion chamber pressure build up at
lower nozzle orifice to valve orifice diameter ratios which is to be expected as more
formulation would enter the expansion chamber and a lower amount of formulation
would be discharged from the expansion chamber.
Figure 3.12 showed that the velocity of the propellant increased at lower nozzle
orifice diameters. As one of the roles of the expansion chamber is to reduce the
speed of the spray in order to reduce the risk of drug particles impacting on the
back of the user’s throat, small nozzle orifices might not be optimal for an efficient
pMDI drug delivery. However, Figure 3.11 also showed that smaller nozzle orifices
promote the formation of smaller droplets which impact less on the throat and
penetrate more efficiently into the lungs (Finlay, 2001).
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Smaller nozzle orifice diameters were shown to lead to the aerosolisation of smaller
and faster droplets, which was due to a higher expansion chamber pressure build
up. This finding is in agreement with Berry et al (2003) who showed that the
amount of fine particles was inversely related to the nozzle orifice diameter.
Several valve orifice diameter plots could be added to Figure 3.13 and could be
used when choosing the valve and nozzle orifices diameters of the pMDI according
to the expansion chamber pressure build up to be achieved.
As the ratio of the twin orifice diameters was shown to affect the velocity of the
spray, it is of importance to remind pMDI users that mouthpieces are not inter-
changeable and cannot be coupled with any canister.
Effect of the nozzle orifice on the aerosolisation duration
In their simulation, Ju et al (2010) calculated a discharge of approximately 0.1 s to
0.28 s depending on the formulation and nozzle orifice used. The shortest duration
was obtained with a 0.5 mm nozzle orifice diameter when simulating the discharge
of pure HFA134a (similar to the nozzle orifice in the current work and Dunbar’s
work). The longest duration was obtained with a 0.3 mm nozzle orifice diameter
when simulating the discharge of multi-component formulations. This agrees with
Lewis (2007), who showed that the duration of a spray decreased when mouthpieces
with higher nozzle diameters were used.
In the present work, the duration of the discharge process also decreased at in-
creasing nozzle orifice diameters as was shown in Table 3.3.
However the difference observed across the range of most commercially available
nozzle orifice diameters was relatively small (0.017s) (Swarbrick, 2007). As a re-
sult, it is believed that smaller nozzle orifices could not be used to improve users
coordination process by providing a longer spray discharge.
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3.4.3 Effect of the opening rate of the valve orifice on spray
characteristics
In the work of Clark (1991), Dunbar (1996), Aamir and Watkins (2000) and Ju et
al (2010), the valve orifice area was assumed constant throughout the actuation
process. This assumption is unrealistic as the valve orifice does not open instanta-
neously and the simulation showed that the time it takes to fully open might affect
the MMD of the particles at the nozzle orifice.
The opening rate of several users was measured. The opening rate of a “weak”
inexperienced female user resulted in a lower pressure build up in the expansion
chamber, leading to higher MMD values compared with instantaneous openings
of the valve orifice. This can be explained by the fact that when the valve opens
slower, the area of the valve which is available for discharge is smaller for a longer
time, allowing a lower amount of propellant to enter the expansion chamber, which
in turn would comparatively reduce the expansion chamber pressure. As the valve
orifice opening rate is related to the force of actuation, this finding might mean
that pMDI users with low actuation forces would aerosolise larger droplets than
users with high actuation forces.
In order to resolve this issue, a smaller valve orifice diameter could be used in order
to reduce the time needed to open the valve orifice fully for users with low rates
of valve orifice opening. Figure 3.13 could also be used in order to determine the
optimal nozzle orifice diameter to be combined with a small valve orifice diameter




3.4.4 Effect of a suspended drug on spray characteristics
The lower vapour pressure calculated at high drug concentrations can be attributed
to the lower mass of propellant discharged from the metering chamber to the ex-
pansion chamber. As the propellant mass is smaller, the enthalpy in the expansion
chamber decreases, leading to a lower expansion chamber temperature and thus
to a decrease in the expansion chamber pressure. The lower expansion chamber
pressure, in turn, leads to a decrease in the velocities of both the liquid and vapour
phases of the spray.
In their simulation of suspension formulations, Ju et al (2010) obtained similar
velocity profiles when simulating several formulations containing varying amount
of non-volatile components and HFA134a. They calculated velocities decreasing
from 19 m·s−1 at 100% HFA134a to 18 m·s−1 at 90% HFA134a.
The increase in MMD values calculated at increasing FP concentrations was due to
the lower expansion chamber pressure but also to a lower quality in the expansion
chamber that would be expected as FP is a non-volatile and would therefore reduce
the proportion of vapour phase forming in the device. Those results are in line
with Polli et al ’s experimental data as they found that the MMD of formulations
increased with the concentration of API (Polli et al., 1969).
However in the present simulation, Equation (2.53) only takes into account the
pressure and quality in the expansion chamber to calculate the MMD at the nozzle
orifice whereas, in reality, the size of aerosolised droplets would also increase with
the size of the drug particles present in the formulation and with their tendency
to aggregate (Smyth, 2003), (Murnane et al., 2008). As Equation (2.53) fails to





The simulation presented in Chapter 2 was validated by comparing the results to
diverse experimental work and simulations (Clark, 1991), (Dunbar, 1996), (Wigley
et al., 2002) and (Ju et al., 2010).
The main findings from the model were that the force of actuation might affect the
size of the aerosolised particles, which means that weaker patients would potentially
aerosolise larger droplets and would therefore risk having a lower amount of drug
particles reaching their lungs.
High nozzle to valve orifices diameter ratios were found to lead to a smaller pres-
sure build up in the expansion chamber and consequently to the formation of larger
droplets of lower velocity at the nozzle orifice. Higher temperatures were found to
increase the initial velocity and reduce the MMD of the discharged sprays, which
would translate into a varying performance of pMDIs when exposed to diverse en-
vironments. Higher temperatures were also found to reduce the mass of propellant
remaining in the metering chamber after the discharge process.
When studying the effect of FP particles on the characteristics of the spray, it was
found that increasing the concentration of FP led to a reduced initial velocity and
higher MMD values which is in line with the literature.
After comparing the model to the literature, it was found that some of the results




Experimental studies on the
actuation of metered dose inhalers
4.1 Introduction
The aerosolisation process is divided into two distinctive phases. The primary
atomisation, which is the process involved in the transformation of the liquid for-
mulation into discrete droplets, occurs in the pMDI. Once the spray exits from the
nozzle orifice, the secondary atomisation begins. Secondary atomisation describes
the behaviour and the transportation of the droplets downstream of the nozzle
orifice. The aim of the numerical model was to simulate the behaviour of the flow
from the metering chamber to the nozzle orifice, which corresponds to the primary
atomisation of the spray. In this chapter, the droplets size was measured during
their secondary atomisation downstream of the nozzle orifice.
Secondary atomisation represents the evaporation of the spray occurring outside
the pMDI. This atomisation is thought to be a 2-phase gas/liquid process in which
the liquid ligaments attached to the gaseous propellant are teared apart by aero-
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dynamic forces, causing the aerosolisation of the liquid phase of the spray. The
evaporation of the spray starts during the flashing phase of the propellant dur-
ing the primary atomisation and continues during the transportation of the spray,
leading to the reduction of droplets size.
The size of particles has been shown to influence their deposition profiles within
the respiratory tract. In in vivo studies by Leach et al (2002), a HFA-based formu-
lation containing beclamethasone dipropionate with a mass median aerodynamic
diameter (MMAD) of 0.9µm was compared to a CFC-based formulation contain-
ing beclamethasone dipropionate with a MMAD of 3.5µm. The oropharyngeal
deposition obtained when testing the CFC formulation was 4 times higher and the
total lung deposition was more than 10 times lower than the values obtained for
the HFA-based formulation. When testing another CFC-based formulation with
a MMAD of 2µm, the oropharyngeal deposition was lower and the lung deposi-
tion was higher than the values obtained with the CFC-based formulation with a
MMAD of 3.5µm (Leach et al., 2002). This shows that particles size significantly
influences the spray deposition pattern.
Due to the transient and metastable nature of the flow inside the device, the
droplets size and velocity vary during the actuation of the pMDI as was shown
in the mathematical simulation in Chapter 3. The droplets velocity also decreases
during their trajectory as the spray loses kinetic energy. The size of droplets issued
from pMDIs decreases during their trajectory between the nozzle orifice and the
oropharynx due to the volatile nature of their propellant. Once the volatile compo-
nents have completely evaporated, the particles reach their residual size. The size
of particles issued from pMDIs can be measured using several experimental tech-
niques such as laser diffraction and impaction techniques described in Chapter 1.
Impaction is currently the preferred technique for both the industry and academia
as it is the only method directly measuring the active pharmaceutical ingredient
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(API) mass-weighted size distribution and the fraction of the spray depositing by
impaction on the back of the throat. It also provides consistent results (Mitchell
and Nagel, 2004).
The mechanism of impaction can be illustrated by the Stokes number described in






where Stk is the Stokes number, ρp is the density of the particle in kg·m−3, dp is
the particle diameter in m, Up is the velocity of the particle in m·s−1, η is the air
viscosity in kg·m−1·s−1 and r is the airway radius in m. The Stokes number can
be defined as the ratio of the stopping distance of the particle to the diameter of
the obstacle. When the Stokes number increases, the particles have greater inertia
and are more likely to impact on the oropharynx or on other points of bifurcation
in the airways (Clark, 2009).
The inertia of a particle is proportional to its velocity and to the square of its
diameter (Dunbar, 1996). As a result, large and fast particles tend to deposit more
at the biggest bifurcation of the respiratory tract, which is located at the throat.
The high size and velocity of particles therefore affect the efficiency of pMDIs as
they reduce the amount of drug that can reach the lungs. The velocity of the
particle increases with the inhalation flow rate of the patient. pMDI users with
high inhalation flow rates might therefore have a higher throat deposition than
users with low inhalation flow rates. Impaction apparatus are able to simulate the
effect of inhalation flow rate on throat deposition which is an advantage compared
to laser techniques.
Impaction measurements separate particles according to their inertia by making
them follow an airflow through various impaction stages. Each stage plate con-
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tains jets with different cut-off diameters which depend upon the flow rate drawn
through the device. The particles with the largest aerodynamic diameter have a
higher inertia. As a result, they are not able to adapt their trajectory to the sin-
uous airways and impact on the first plates. The smallest particles, which do not
impact on the first plates, reach stages with smaller cut-off diameter jets. The
first stages represent the upper respiratory tract whereas the last stages represent
the lower respiratory tract. Impactors designs may vary with different number of
stages, number of jets per stages and jet dimensions. The next generation im-
pactor (NGI) has 7 stages with cut off diameters of 11.72µm, 6.40µm, 3.99µm,
2.30µm, 1.36µm, 0.83µm and 0.54µm respectively when operating at a flow rate
of 30 L·mn−1 (Copley, 2012). A picture of a NGI can be seen in Figure 4.1.
Figure 4.1: Open view of a NGI showing nozzles and collection cups (Copley, 2012).
The efficiency of pMDIs is defined as the percentage of drug delivered to the lungs.
It can be assessed using several measures such as the percentage of particles reach-
ing the lungs for each actuation. It can also be defined using the fine particles
fraction (FPF) discussed in Chapter 1. The efficiency of pMDIs depends on many
factors such as the formulation design, the device design and the way the device is
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handled (e.g. users often have difficulties to coordinate the actuation of the device
with the inhalation of the spray). Those parameters have an effect on the depo-
sition location within the respiratory tract. Variations in one or several of those
parameters will therefore influence the quantity of particles reaching the lungs.
4.1.1 Literature review of factors determining aerosol size
distribution
Many articles have focused on the effect of parameters such as formulation and
device designs on the deposition patterns of particles in the respiratory tract. For
example, Polli et al (1969) investigated the effect of drug particles size inside the
formulation, drug and surfactant concentration, propellant vapour pressure, pro-
pellant temperature and nozzle orifice diameter on particles residual size.
Pu et al (2011) compared the particle size measurements using a Sympatec R© and
an Andersen cascade impactor (ACI). They found that both methods give simi-
lar fine particle fractions and mean diameter values for formulations containing a
low concentration of non-volatiles. They showed that the residual size of aerosol
droplets increased for suspension formulations containing drug particles compared
to pure propellant formulations. They also found that the size of residual particles
increased with the size of the API used in the formulation.
For their investigation, Pu et al (2011) automatically actuated the pMDIs using
a Sprayer device from Sympatec R©. This device can be used to control the accel-
eration, velocity, stroke length or force of the actuation piston (Sympatec, 2010).
They did not control the force of the piston but its actuation velocity.
Other systems have been used to provide the automatic actuations of canisters
such as the SprayVIEW MDx automated actuator (Proveris Scientific Corporation,
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Marlborough, MA), controlled by Proveris Viota software (Version 5.2.1) used by
Liu et al (2012). However, the effect of those actuations have not, to the best
knowledge of the author, been investigated or compared with manual actuations.
Murnane et al (2008) studied the behaviour of drugs in suspension formulations.
They noticed that in suspension formulations, certain drugs such as fluticasone pro-
pionate (FP) were prone to aggregation and as a result, did not disperse efficiently
in the propellant.
Aggregates forming in suspension formulations can be retrieved in the residual
droplets, after all propellant has evaporated. Michael et al (2001) showed that
the size of the aggregates increased with the concentration of the API. This phe-
nomenon is shown for FP particles in HFA134a in Figure 4.2.
Figure 4.2: Effect of increasing suspension concentrations on average aggregates
size of fluticasone propionate in HFA134a (Michael et al., 2001).
As the size of residual particles issued from suspension formulations corresponds
to the size of the aggregates, aggregation of drug particles could reduce the FPF
187
Chapter 4
of suspension formulation (Murnane et al., 2008).
Pu et al (2011) also found that the FPF of formulations decreased with the in-
creasing size of the API particles.
Brambilla et al (1999) investigated the effect of non-volatiles concentration on the
residual particles size. They showed that adding non-volatile components increased
significantly the size of the particles issued from pMDIs.
Lewis (2007) reported that pMDIs with small nozzle orifices led to a higher FPF
than pMDIs with large nozzle orifices. Later in this chapter, those findings are
compared to the NGI results in order to determine the influence of the pMDI
design on the pattern of the aerosolised sprays.
Stein et al (2012) studied the evaporation mechanisms of aerosols issued from
pMDIs. They also showed that residual droplets size increased at higher drug
concentrations and that the initial particles size increased with the diameter of the
nozzle orifice, the metering chamber volume and the concentration of non-volatiles
in the formulation.
Haynes et al (2004) compared the particle size measurements using a Malvern
Spraytec R© and an ACI. They found that the Malvern Spraytec R© overestimated
the size of HFA-based aerosols compared to the ACI. This might be due to the fact
that the sprays are not fully evaporated when measured by the Malvern Spraytec R©.
They showed that it was possible to obtain comparable results with both methods
for a solution formulation when placing a 20 cm simulation throat between the
pMDI and the Malvern Spraytec R© measurement zone as it would allow a more
complete evaporation of the aerosol before its measurement. They also noticed
that particles size decreased at high temperatures. Their results on FPF and D50
obtained with the Spraytec R© are in line with the measurements of Pu et al (2011)
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with the Sympatec R©.
4.1.2 Aims and objectives
As the actuation force is not constant among different types of populations and
might influence the behaviour of the spray, it was decided to investigate the impact
of varying forces on the velocity and size of particles issued from pMDIs. The aim
of this study was to identify whether the actuation force affected the deposition
pattern of several formulations and if so, for which formulation it had a stronger
impact. The influence of the actuation force on the API fraction depositing in the
throat was assessed. This work has, to the best knowledge of the author never
been conducted before. In order to identify the potential effect of actuation force
on spray characteristics, the performance of each formulation under normal adult
actuation was studied. A method was also developed to allow the automated
actuation of the cylinder under several actuation forces.
This chapter studies the deposition pattern of a suspension and two solution formu-
lations aerosolised using two mouthpieces of varying nozzle orifice diameters. The
suspension and solution formulations contained similar FP concentrations. The
two solution formulations contained varying excipients at similar concentrations.
This has, to the best knowledge of the author never been studied before.
It has been shown in Chapter 3 that varying nozzle orifice diameters, formulation
designs and valve opening rates may affect the velocity and size of initial particles
at the nozzle orifice. In this chapter, the role of formulation design, mouthpiece




4.2 Materials and methods
4.2.1 Materials and equipment
• Solkane R© 134 (inhalation grade) (Solvay Florides Inc., Hanover, Germany)
• polyethylene glycol 400 (PEG400) (pharmacopoeial quality) from Fluka (Sigma-
Aldrich Chemie GmbH, Industriestrasse 25 CH-9471 Buchs SG Switzerland).
• ethanol (pharmacopoeial quality) (Fisher Scientific, Loughborough, UK)
• fluticasone propionate (pharmacopoeial quality) (LGM Pharma, Boca Raton,
Florida, USA); (Batch number 458763)
• aluminium canisters (Bespak, Norfolk, UK)
• transparent polyethylene terephthalate (PET) canisters
• a filling crimping machine (Pamasol, Switzerland)
• 50µL non-continuous valves from Valois (Valois pharmaceutical division,
780160 Marly Le Roi, France)
• a high-pressure liquid chromatography (HPLC) apparatus Agilent 1260 In-
finity chromatograph (S/N DEAAV01717) (Agilent Technologies UK lTD.,
Edinburgh, UK)
• a Kinetex 2.6µm particle size reversed-phase column (XB-C18 - 50 mm x 30
mm (Serial 557858.3, Phenomenex, Macclesfield, UK))
• HPLC grade methanol for the preparation of mobile phase and washing so-
lution (Fisher Scientific, Loughborough, UK)
• Hipersolv R© grade ammonium acetate for the preparation of the mobile phase
and washing solution (Lab3 Ltd, Bristol, UK)
190
Chapter 4
• water from a laboratory water purification unit (Purite, GDF-Suez, France)
• analar grade methanol for washing (Fisher Scientific, Loughborough, UK)
• a dosage unit sampling apparatus (DUSA) for pMDIs (Copley Scientific, Not-
tingham, UK)
• glass fibre filters to prevent drug particles from escaping the DUSA (What-
man, Kent, UK)
• a DFM3 Flow Controller (Copley Scientific, Nottingham, UK)
• a high capacity pump Model HCP5 (Copley Scientific, Nottingham, UK)
• a critical flow controller Model TPK (Copley Scientific, Nottingham, UK)
• a NGI containing a throat, 7 stages and a micro-orifice collector (Copley
Scientific, Nottingham, UK)
• a rotary mixer (Sandrest, East Sussex, England)
• a silicone device/NGI adaptor, manufactured in-house
• a Flixotide R© mouthpiece (Allen and Hanburys Ltd, Middlesex, UK)
• an Alvesco R© mouthpiece (Takeda Pharmaceuticals International GmbH, Zurich,
Switzerland)
• an experimental aluminium rig connected to a switch providing automated
actuation of the canisters (built and designed in-house from De Montfort
University)
• a pneumatic cylinder (SMC CD85N12-10S-B) (SMC, Buckinghamshire, UK)
• a drying oven Type VT6 (Thermo Fisher Scientific, MA, United States)
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4.2.2 Manufacture of test formulations
Size measurements of FP particles using liquid dispersion laser diffrac-
tion (Jaffari et al., 2013)
The size measurements of the FP particles were conducted by Jaffari. Her method
and findings are reported below.
Laser diffraction particle sizing was carried out using a Malvern Mastersizer R© X
(Malvern Instruments Ltd, UK) fitted with a 100 mm focal length lens (0.5µm
to 180µm) and an MS7 magnetically stirred cell. Saturated solvent dispersants
were sonicated for 30 mn and stirred overnight. Approximately 1 mg of powder was
added to 2 mL filtered dispersant (0.2µm cellulose acetate syringe ffilter, Gema
Medical S.L., Spain) and sonicated (Sonicleaner, DAWE, Ultrasonics Ltd, USA).
A background reading was taken and the suspension was added to the sample cell
until obscuration was between 10% and 30%. Following equilibration (30 s to 60 s),
ten individual measurements were taken for n=3 samples to obtain particle size
measurements (Dv10, Dv50, Dv90, volume mean diameter; VMD) calculated using
Fraunhofer theory.
The size characteristics of the FP particles are shown in Table 4.1.
Powder Dv10 (µm) Dv50 (µm) Dv90 (µm) VMD (µm) Span
FP 1.09±0.02 2.76±0.03 4.97±0.11 2.94±0.04 1.41
Table 4.1: Size characteristics of the FP particles.
Manufacture of solution formulations
Solvents are often added to HFA-based formulations in order to better dissolve the
APIs in HFA134a. In this work, one solution formulation contained ethanol and
the other solution formulation contained both ethanol and PEG400.
It has been shown that the efficiency of a pMDI decreased at ethanol concentrations
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greater than 15% w/w (Gupta et al., 2003). It was thus decided to put 15% w/w
of ethanol in the formulation.
In order to determine the solubility of FP in the HFA134a and ethanol solution,
the formulations were manufactured in clear PET canisters. FP was first weighed
and disposed in the transparent canister. Ethanol was added at the end in order
to avoid its evaporation. A magnetic stirrer of 8 mm was added before crimping
the canisters using the filling crimping machine (Pamasol, Switzerland). HFA134a
was forced under pressure in the canisters until they contained 15 g of formulation.
The formulations were stirred overnight on a platform shaker at 150 rpm.
Several concentrations of FP were tested until the final concentration of 0.05% w/w
allowed the complete dissolution of FP in the formulation. The final formulation
therefore contained 0.05% w/w of FP, 15% w/w of ethanol and approximately 85%
w/w of HFA134a. This formulation is referred to as HEF. Several metal canisters
containing the HEF formulation were prepared from a large batch of FP+ethanol
in order to improve the accuracy of the process. Ethanol was added before closing
the recipient. The recipient was then plunged into an ultrasound bath until the
drug was dissolved in the ethanol. The canisters were filled from the batch and
crimped immediately using the filling crimping machine in order to prevent ethanol
evaporation. HFA134a was then forced under pressure in the canisters.
PEG400 is a hydrophilic cosolvent helping APIs to dissolve in propellants. PEG400
was used in the second solution formulation. The same type of procedure was un-
dertaken for the manufacture of this formulation containing 0.05% w/w of FP, 10%
w/w of ethanol, 5% w/w of PEG400 and approximately 85% w/w of HFA134a. This
formulation is referred to as HPEF. The HEF and HPEF formulations contained
similar FP and cosolvents concentrations in order to allow direct comparisons be-
tween those two formulations. However, the filling crimping machine could not
193
Chapter 4
force the exact same mass of propellant into each canister, resulting in slightly
different compositions between canisters for each formulation. The four canisters
with the most similar compositions were chosen for each formulation.
Manufacture of a suspension formulation
FP is often used in HFA134a-based suspension formulations such as Flixotide by
Allen and Hanburys Ltd and Flovent by Glaxosmithkline (Murnane et al., 2008).
For this reason, a FP suspension containing HFA134a and 0.05% w/w FP for-
mulation was investigated in this work. The 0.05% w/w FP concentration was
chosen to allow direct comparisons with the HEF and HPEF formulations. This
formulation is referred to as HF. To manufacture this formulation, the drug was
weighed and deposited into the canisters which were then crimped and filled with
approximately 15 g of HFA134a using the filling crimping machine. However, the
filling crimping machine could not force the exact same mass of propellant into
each canister, resulting in slightly different compositions between canisters. The
three canisters with the most similar compositions were chosen for the study of the
HF formulation.
The composition of the three formulations studied are summarised in Table 4.2.
Names of the formulations
HF HEF HPEF
FP 0.05% 0.05% 0.05%
HFA134a ' 99.95% ' 84.95% ' 84.95%
Ethanol - 15% 10%
PEG400 - - 5%
Table 4.2: Composition of the studied formulations.
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Table 4.3 shows an inventory of the formulations manufactured.
Formulation crimped with Number of
a Valois 50µL valve canisters
Solution HEF 26
formulations HPEF 35
Suspension formulation HF 5
Table 4.3: Inventory of the manufactured formulations.
4.2.3 Device dimension characterisation
For the suspension formulation, a Flixotide R© mouthpiece with a length of 25 mm
and a nozzle orifice diameter of 0.50 mm was used. The Flixotide R© mouthpiece was
chosen as it is designed for a commercial suspension formulation.
For the two solution formulations, an Alvesco R© mouthpiece with a length of 37 mm
and a nozzle orifice diameter of 0.20 mm was used. The Alvesco R© mouthpiece was
chosen as it is designed for a commercial solution formulation.
The solution formulations were also aerosolised with the Flixotide R© mouthpiece for
comparative purposes. Both nozzle diameters were determined using a travelling
microscope.
4.2.4 High performance liquid chromatography analysis
HPLC was used to determine the concentration of FP depositing at each stage of
the NGI.
Mobile phase




• 35% ammonium acetate 0.6% (w/v)(aq.)
The washing solution had the following composition:
• 75% methanol
• 25% ammonium acetate 0.6% (w/v)(aq.)
The mobile phase and the washing solution were manufactured using a similar
procedure. Purite water was used as impurities can affect the results of HPLC
measurements. After 0.6% (w/v) aqueous ammonium acetate solution was mixed
with the methanol, the mixture was degassed using a sonicator for approximately
60 s. It was then filtered in a vacuum filtration device using filters of cutoff diameter
2.5µm (Whatman, Kent, UK) before being sonicated again for 30 mn.
Calibration standards
HPLC vials with several known concentrations of FP were analysed to obtain a
calibration curve. The nominal concentrations of FP in mobile phase for the cal-
ibration curves were 50µg·mL−1, 25µg·mL−1, 10µg·mL−1, 5µg·mL−1, 1µg·mL−1
and 0.5µg·mL−1.
A stock solution was prepared by accurately weighing 2.5 mg of FP with a weigh-
ing scale (Mettler Toledo, UK), transferring it into a 50 mL volumetric flask and
bringing the solution to volume with mobile phase.
The stock solution was used to prepare a calibration series by pipetting the volumes
shown in Table 4.4.
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Theoretical Volume of Final volume






5 (of the 1 µg·mL−1 solution
10
prepared above)
Table 4.4: Volume of stock solution required to prepare a calibration series range
of 0.5µg·mL−1 to 50µg·mL−1.
The above solutions were transferred into HPLC vials for analysis by HPLC. A
linear regression analysis was conducted, using the LINEST function on Microsoft
Excel, to establish the relationship between the peak area determined by the HPLC
analysis and the drug concentration in the HPLC vials.
Sensitivity
The limit of area detection (LODarea) and limit of area quantification (LOQarea),
both in mAU·s−1, were calculated using Equations (4.2) and (4.3).
LODarea = Yintercept + 3SD (4.2)
LOQarea = Yintercept + 10SD (4.3)
where SD is the standard deviation of the Yintercept from the linear regression
analysis in mAU·s−1.
The limit of concentration detection (LODconcentration) and limit of concentration
quantification (LOQconcentration), both in µg·mL−1, were calculated using Equa-












In the experiments below, the mobile phase flow rate was 0.5 mL·mn−1 and the
temperature of the column was set to 40 ◦C. A UV wavelength of 240 nm was
used to detect the FP. Under those conditions, the retention time for FP was
approximately 3 mn.
Precision
The precision of the machine was assessed using the standard deviation of several
injections of the same vial. The standard deviation of three injections of 20µL
was calculated for each vial and, as it always laid below 2% of the mean, it was
considered that three injections were sufficient to ensure an acceptable precision
level.
Repeatability
In order to check the accuracy and repeatability of the method above, 5 accuracy
standards of concentration 10µg·mL−1 were prepared for each calibration curve.
For each standard, 2 mg of FP was weighed accurately into a 20 mL volumetric
flask. Mobile phase was added until the level of the liquid almost reached the
volume mark on the flask. The flask was then sonicated for a few minutes before
being finally brought to volume. The final solution was transferred into a HPLC vial
for analysis by HPLC. The amount of FP was then calculated using the calibration
curve. This process was repeated five times for each calibration curve.







4.2.5 Emitted dose analysis of formulations
The dose content of each canister for each formulation was determined using a
dosage unit sampling apparatus (DUSA) of the British Pharmacopoeia (2007 261
/id). Four doses determinations were performed for each canister used in the ex-
periments. An airflow of 30 L·mn−1 was drawn through the DUSA using a vacuum
pump in order to simulate an inhalation of 3.25 L and lasting 6.5 s (Copley Scien-
tific, Nottingham, UK).
The DUSA was branched to the mouthpiece on one side and a rubber fitting helped
to form a tight seal between them. On the other side the DUSA was branched to
the vacuum pump and the connection was sealed using Parafilm M flexible film.
A glass fibre filter by Whatman was inserted inside the apparatus to avoid drug
particles escaping on the side of the DUSA branched to the vacuum pump.
The airflow was adjusted to 30 L·mn−1 using the DFM3 flowmeter (Copley Scien-
tific, Nottingham, UK) before each experiment. The canister was placed inside a
mouthpiece and was shaken for 5 s with one shot fired to waste before inserting
the mouthpiece in the rubber fitting. The pump was activated for 5 s prior to
pMDI discharge. Each formulation was actuated 4 times into the DUSA, allowing
a sufficient amount of drug to be quantified by the HPLC method (Section 4.2.4).
Between each actuation, the mouthpiece was removed and the canister was shaken.
There was a pause of approximately 10 s between each discharge.
After the 4 actuations, the DUSA was opened and the glass fibre filter was placed in
a 50 mL beaker. Approximately 40 mL of the washing solution prepared in Section
4.2.4 were transferred into the beaker. The beaker was then sonicated for a couple
of minutes in order to dissolve the drug particles deposited on the glass fibre filter.
The content of the beaker was transferred to a 50 mL volumetric flask and brought
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to volume with washing solution.
After each use, the DUSA, mouthpiece, canister and rubber fitting were first washed
with water then with methanol prior to further testing. The dose content analysis
was realised for the three formulations and for a commercial Flixotide R© formulation.
4.2.6 Inertial impactor testing of emitted aerosol dose
The NGI was connected to a vacuum pump set at 30 L·mn−1. The connection
was sealed using Parafilm M flexible film. The flow rate through the NGI was
monitored using the DFM3 Flow Controller (Copley Scientific, Nottingham, NG4
2JY). The throat was fitted with a silicone mouthpiece adaptor to form a tight
seal around the mouthpiece. Prior to each run, all stages of the NGI were rinsed
with 100% (v/v) methanol followed by 100% purite water and dried in an oven at
40 ◦C. Before each NGI run, the vacuum pump was switched on for approximately
5 s and the canister was shaken for around 10 s and fired once. For each NGI test,
the canister was actuated 8 times into the NGI. Between each actuation, there was
a pause of 10 s during which the pMDI was shaken for 5 s.
After the experiment, the device (including the mouthpiece, the stem of the canister
and the mouthpiece adaptor) was washed with the washing solution then trans-
ferred into a 20 mL volumetric flask. It was then sonicated before being brought
to volume.
The throat was washed with the washing solution then transferred into a 50 mL
volumetric flask. It was then sonicated before being brought up to volume.
Volumes of washing solution of 10 mL were measured with a pipette and transferred
into each of the first 5 stages of the NGI. Volumes of washing solution of 5 mL were
measured with a pipette and transferred into each of the last 3 stages of the NGI.
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All stages were placed on a rocker for approximately 5 mn in order for the FP to
dissolve completely in the washing solution.
The device volumetric flask, throat volumetric flask and the 8 stages were each
transferred into separate HPLC vials. The concentration of FP in the different
parts of the NGI was determined by HPLC using the linear regression discussed
in Section 4.2.4. The amount of drug deposited on each stage was subsequently
calculated (i.e. mFP = FP concentration× Volume of washing solution).
4.2.7 Experimental implementation of varying actuation
forces
As the actuation force is inversely related to the valve orifice opening time as
seen in Equation (3.6) in Chapter 3, it was of interest to investigate the effect of
several actuation forces on spray deposition patterns. An aluminium rig shown
in Figures 4.3 and 4.4 was designed to this effect. A pneumatic piston with an
aluminium “thumb” provided the actuation. The “thumb” always stayed in contact
with the pMDI in order to avoid any shock with the canister. The pneumatic
piston, located on the upper part of the rig, was connected to an automated switch
designed to send a signal to activate the piston.
In order to assess the force needed to actuate the 50µL valve from Valois used
in this work, different forces were applied to the canisters until actuation. The
50µL valve required approximately 30 N to be actuated which is in line with the
minimum forces of 30 N to 40 N reported in the literature for the actuation of stem-
type metering valves (MacMichael and Hearne, 2002). Forces of 30 N and 50 N were
applied to the canister by modifying the pressure in the pneumatic piston and their
effect on spray characteristics were investigated using a NGI.
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Figure 4.3: Front view of the experimental rig.
Figure 4.4: Side view of the experimental rig.
4.2.8 Statistical analysis
The significance of all data obtained in this work was determined using a one-
way analysis of variance by Tuckey’s comparison test. The statistical analysis
was conducted using the software SPSS Statistics 20. The results were considered
significantly different based upon 95% probability values (p<0.05).
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4.3 Mathematical prediction of dose performance
4.3.1 Emitted mass calculation
The theoretical mass of FP delivered per actuation with the Flixotide device is
known and could therefore be compared to the mass retrieved using the DUSA.
For the other formulations, the theoretical mass of FP delivered per actuation
had to be calculated using the density of the formulation and the volume of the
metered valve. The density of the HF suspension formulation was assumed to be
equal to the density of a pure HFA134a formulation as the content of FP was non-
significant (0.05% w/w). The density of each solution formulation was calculated




where ρformulation is the density of the formulation in g·mL−1, Cx is the percentage
by weight of each component of the formulation and ρx is the density of each
component of the formulation in g·mL−1. The mass of formulation in each actuation
of the 50µL valve was calculated using Equation (4.8).
mformulation = Vmc × ρformulation (4.8)
where mformulation is the mass of formulation delivered per actuation in g and Vmc
is the metering chamber volume in mL. The mass of FP delivered per actuation
was calculated using Equation (4.9).
mFP = mformulationCFP (4.9)
203
Chapter 4
where mFP is the mass of FP delivered per actuation in g, and CFP is percentage
by weight of FP in each formulation.
In this chapter, the amount of drug recovered on each stage was expressed as a per-
centage of the total recovery. This was decided as the total mass delivered varied
from one NGI test to another. This was particularly the case in the section compar-
ing different actuation forces. In this part of the experimental work, the pneumatic
piston was used to simulate several forces and the actuation was sometimes not
achieved properly. As there was no mean to determine whether the metered dose
was discharged completely in the NGI, more actuations were conducted to ensure
a sufficient amount of drug would be deposited on each stage of the NGI to allow
quantification by the HPLC instrument.
4.3.2 Droplet size distribution calculation
Stein et al (2012) found a relationship between the initial and residual size of








where MMDin and MMDre are the mass median diameters of initial and residual
particles respectively in µm, ρin and ρre are the densities of the initial and residual
droplets respectively in kg·m−3 and CNV is the weight fraction of non-volatiles.
They also showed that the initial size of particles issued from pMDIs increased
with the diameter of the nozzle orifice, the metering chamber volume and the
concentration of ethanol in the formulation.
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This is illustrated in Equation (4.11) (presented in Chapter 2) which is valid for
HFA134a-based solution formulations containing ethanol.
MMDin = 6.90 + 0.0441× Vmc + 23.6× CEtOH − 63.8× C2EtOH
+ 24.7× CEtOH × dno − 0.129× CEtOH × Vmc (4.11)
where Vmc is the volume of the metering chamber in µL, CEtOH is the weight frac-
tion of ethanol and dno is the nozzle orifice diameter in mm.
Lewis (2007) developed Equation (4.12), illustrating that for HFA-based solution
formulations, the MMAD is primarily influenced by the concentration of non-
volatiles in the formulation.




where CNV is the weight fraction of non-volatiles in the formulation.
4.3.3 Respirable dose calculation
Lewis (2007) developed Equation (4.13) that calculates the emitted FPF of HFA134a
solution formulations containing ethanol according to certain mouthpiece charac-
teristics.
FPFED ≤ 5 = 2.1× 10−5 dno−1.5 Vmc−0.25CHFA134a3 (4.13)
where FPFED ≤ 5 corresponds to the amount of particle with a diameter smaller
than 5µm expressed as a percentage of the emitted dose, dno is the nozzle orifice
diameter in mm, Vmc is the metering chamber volume in µL and CHFA134a is the
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weight fraction of HFA134a.
4.4 Results
4.4.1 HPLC assay of fluticasone propionate
Linearity
The relationship between the concentration of FP and the peak area obtained
for each of the three calibration curves can be seen in Equations (4.14), (4.15)
and (4.16).
y = 87.303x− 26.040 R2 = 0.99989 (4.14)
y = 92.989x− 17.744 R2 = 0.99973 (4.15)
y = 92.087x− 2.223 R2 = 0.99999 (4.16)
Equation (4.16) was chosen as it had the highest linearity and when x=0, y had
the closest value to zero of Equations (4.14), (4.15), (4.16).
Towards the end of the experimental work, a new Kinetix 2.6 micro (50 X 3.0
mm) column was used and a new calibration curve was produced. Equation (4.17)
corresponds to this calibration curve.
y = 88.171x+ 3.786 R2 = 0.99997 (4.17)
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The calibration curve represented by Equation (4.17) can be seen in Figure 4.5.
Figure 4.5: Peak area (mAU·s−1) as a function of concentration of FP (µg·mL−1).
Precision
For Equation (4.16), the LODconcentration was 0.04µg·mL−1 and the LOQconcentration
was 0.13µg·mL−1.
For Equation (4.17), the LODconcentration was 0.09µg·mL−1 and the LOQconcentration
was 0.3µg·mL−1. These low values indicate a high-sensitivity of the method at low
concentrations of FP.
Accuracy
In order to determine whether the experimental method allowed the recovery of a
satisfactory percentage of the drug, a commercial formulation of known FP dosage
was analysed. The formulation used was Flixotide R©125 which is a suspension
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formulation containing HFA134a and FP at a dose of 125µg per metered dose.
The aerosolisation of Flixotide R©125 in the NGI was performed as discussed in
Section 4.2.6.
All the NGI tests reported in this section were performed on the same Flixotide R©125
canister. As Flixotide R© delivers 125µg per actuation and 5 actuations were fired for
each NGI, the theoretical recovery dose used to calculate the percentage recovery












Total recovery (µg) 537.11±77.52
Percentage recovery (%) 85.94 ±12.40
Table 4.5: Amount of FP recovered for a mean of 4 NGIs performed on one
Flixotide R© canister.
4.4.2 Emitted dose analysis
The theoretical dose content per actuation of each formulation determined in Sec-
tion 4.3.1 were used to calculate the percentages recovery of FP for the 4 DUSA
tests realised for each formulation as described in Section 4.2.5. The results are
presented in Table 4.6.
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Dose content per actuation
35.36±7.20µg 23.27±0.32µg 25.62±0.65µg
Canister 1 (n=4)
Dose content per actuation
33.93±3.82µg 24.28±2.03µg 26.32±5.73µg
Canister 2 (n=4)
Dose content per actuation
33.53±3.75µg 24.45±0.69µg 28.90±5.69µg
Canister 3 (n=4)






Mean percentage recovery 113.68±3.20% 84.90±2.63% 97.43±10.30%
Table 4.6: Percentages of FP recovered for 4 DUSA tests performed on the three
formulations.
4.4.3 Aerosolisation of fluticasone propionate suspensions
The MMAD and FPFs calculated as a percentage of the emitted dose and recovered
dose were derived from the deposition of the aerosol on the stages of the NGI. The
recovered dose of FP represents the total amount recovered on all stages of the NGI,
on the throat and on the device whereas the emitted dose of FP corresponds to the
total amount of FP recovered from the NGI, excluding the amount of FP recovered
from the device. As both measures are used in the literature, the amount of fine
particles with a diameter smaller than 5µm was expressed both as a percentage
of the recovered dose (FPFRD ≤5 (%)) and as a percentage of the emitted dose
(FPFED ≤5 (%)) (Brambilla et al., 1999), (Lewis, 2007). Those data are shown for






Device (%) 4.31±0.74 7.19±1.55
Throat (%) 35.37±4.97 38.69±2.50
FPFED ≤5 (%) 48.04±2.74 50.54±2.03
FPFRD ≤5 (%) 45.96±2.57 46.90±1.71
FPFED ≤2.5 (%) 26.74±0.68 34.49±1.59
MMAD (µm) 2.89±0.16 2.09±0.07
Table 4.7: Deposition and size characteristics of the Flixotide R© and HF formu-
lations using the Flixotide R© mouthpiece. Mean of n≥4 determinations for each
formulation.
The MMAD of the Flixotide R© formulation was significantly higher than the MMAD
of the HF formulation (p<0.05). The FPFED ≤2.5 (%) of Flixotide R© was signifi-
cantly lower than the FPFED ≤2.5 (%) of the HF formulation (p<0.05). The other
characteristics were similar for both formulations (p>0.05).
The FPF values of the Flixotide R© and HF formulations in this work are in line
with the results of Feddah et al. (2000) obtained on a Flixotide R©250 formulation.
The FPFRD ≤5 of 45.96% obtained on Flixotide R©125 in this work is higher than
the FPFRD ≤4 of 32.67±2.1% measured by Feddah et al (2000); these data are
expected as the percentage of particles smaller than 4µm should be lower than
the percentage of particles smaller than 5µm. It could also be due to the fact
that Feddah et al (2000) analysed a formulation containing twice as much FP in
the metering chamber compared with the Flixotide R©125 in this work. This could
accentuate aggregation of the FP particles in the canister and ultimately lead to
the aerosolisation of bigger particles (Murnane et al., 2008).
The FPFRD ≤5 of 46.9±1.7% found in Table 4.7 is higher than the value of Pu et
al (2011). They obtained a FPFRD ≤4.7 of 38.0±2.0% when testing a suspension
formulation containing an API of particle diameter of 1.77µm. This difference
could be attributed to the use of an ACI by Pu et al instead of a NGI in this work.
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It could also be due to the fact that they measured a FPFRD ≤4.7 instead of a
FPFRD ≤5.
Although in Europe, the FPF represents the fraction of particles with a diameter
≤5µm, the value of 4.7µm is also quoted as the upper size limit for FPF as it
corresponds to the cut-off diameter of the 3rd stage of the ACI (Mitchell and
Nagel, 2004).
The 38% throat deposition obtained with the HF formulation is in line with the
findings of Gabrio et al (1999). They measured a throat deposition of 42% for
a HFA134a and beclamethasone dipropionate formulation with a mouthpiece of
similar nozzle orifice diameter (0.50 mm).
4.4.4 Effect of formulations on aerosolisation
The characteristics of the HF, HEF and HPEF formulations using the Flixotide R©
mouthpiece are shown in Table 4.8. The aerosolisation data of the Flixotide R© and
HF formulations previously presented are again reported.
Formulation
Flixotide R© HF HEF HPEF
Mean±SD Mean±SD Mean±SD Mean±SD
Device (%) 4.31±0.74 7.19±1.55 6.23±0.85 5.07±1.50
Throat (%) 35.37±4.97 38.69±2.50 77.04±3.17 86.38±1.02
FPFED ≤5 (%) 48.04±2.74 50.54±2.03 14.43±2.64 5.15±0.42
FPFRD ≤5 (%) 45.96±2.57 46.90±1.71 13.51±2.47 4.90±0.45
FPFED ≤2.5 (%) 26.74±0.68 34.49±1.59 11.86±2.11 2.90±0.26
MMAD (µ m) 2.89±0.16 2.09±0.07 1.29±0.22 4.12±0.37
Table 4.8: Deposition and size characteristics of the Flixotide R©, HF, HEF and
HPEF formulations using the Flixotide R© mouthpiece. Mean of n≥6 determinations
for each formulation.
The deposition of the three formulations in the NGI using the Flixotide R© mouth-
piece is shown in Figure 4.6.
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Figure 4.6: In vitro deposition profile of the three formulations using the Flixotide R©
mouthpiece. Mean of n=6 determinations for the FP formulation and mean of n=7
determinations for the HEF and HPEF formulations.
Table 4.8 and Figure 4.6 show that the deposition pattern of particles varies ac-
cording to the formulation tested. The throat deposition, fine particle fraction and
MMAD differ significantly for each formulation (p<0.05).
The throat deposition was 38.69±2.50% for the HF formulation compared to
77.04±3.17% for the HEF formulation and 86.38±1.02% for the HPEF formulation.
The MMAD of the suspension formulation was 2.09±0.07µm compared to




4.4.5 Effect of mouthpiece design on aerosolisation
NGI results of the HEF and HPEF formulations with two mouthpiece
designs
In the previous experiments, all formulations were tested with the Flixotide R©
mouthpiece, designed for a FP suspension formulation. In this set of experiments,
both solution formulations were tested with the Alvesco R© mouthpiece, designed for
a solution formulation.
The Flixotide R© mouthpiece has a length of 25 mm and a nozzle orifice diameter
of 0.50 mm. In comparison the Alvesco R© mouthpiece has a length of 37 mm and
a nozzle orifice diameter of 0.20 mm. The depositions of the HEF and HPEF
solution formulations using the two mouthpieces are shown in Figures 4.7 and 4.8
respectively.
Figure 4.7: In vitro deposition profile of the HEF formulation using the Alvesco R©
and Flixotide R© mouthpieces. Mean of n=7 determinations for the Flixotide R©
mouthpiece and mean of n=4 determinations for the Alvesco R© mouthpiece.
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Figure 4.8: In vitro deposition profile of the HPEF formulation using the Alvesco R©
and Flixotide R© mouthpieces. Mean of n=7 determinations for the Flixotide R©
mouthpiece and mean of n=4 determinations for the Alvesco R© mouthpiece.
The characteristics of the HEF and HPEF formulations with the two mouthpieces
are presented in Table 4.9.
HEF HPEF
Mouthpiece Flixotide R© Alvesco R© Flixotide R© Alvesco R©
Mean±SD Mean±SD Mean±SD Mean±SD
Device (%) 6.23±0.85 17.97±1.09 5.07±1.50 19.96±3.44
Throat (%) 77.07±3.21 40.98±0.92 86.38±1.02 52.58±5.42
FPFED ≤5 (%) 14.41±2.66 46.98±1.28 5.15±0.42 19.72±2.98
FPFRD ≤5 (%) 13.51±2.47 38.54±1.43 4.90±0.45 15.71±1.66
FPFED ≤2.5 (%) 11.85 ± 2.11 41.91±1.00 2.90±0.26 10.76±1.74
MMAD (µm) 1.29±0.22 0.74±0.05 4.12±0.37 4.16±0.19
Table 4.9: Summary of the deposition and size characteristics for the HEF and
HPEF formulations with the Flixotide R© and Alvesco R© mouthpieces. Mean of n=7
determinations for the Flixotide R© mouthpiece and mean of n=4 determinations for
the Alvesco R© mouthpiece.
For the HEF formulation, the FPFED ≤5 was 46.98±1.28% with the Alvesco R©
mouthpiece compared to 14.41±2.66% with the Flixotide R© mouthpiece (p<0.05).
The throat deposition was 40.98±0.92% with the Alvesco R© mouthpiece compared
to 77.07±3.21% with the Flixotide R© mouthpiece. The MMAD was 0.74±0.05µm
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with the Alvesco R© mouthpiece compared to 1.29±0.22µm with the Flixotide R©
mouthpiece (p<0.05).
For the HPEF formulation, the FPFED ≤5 was 19.72±2.98% with the Alvesco R©
mouthpiece compared to 5.15±0.42% with the Flixotide R© mouthpiece (p<0.05).
The throat deposition was 52.58±5.42% with the Alvesco R© mouthpiece compared
to 86.38±1.02% with the Flixotide R© mouthpiece.
The Alvesco R© mouthpiece seemed to be more suitable for the delivery of both so-
lution formulations as it increased the fraction of fine particles and greatly reduced
the throat deposition. This could help to reduce the inflammations and side effects
observed when the throat is repeatedly exposed to the API.
It was therefore decided to use the Alvesco R© mouthpiece to test the HEF and
HPEF formulations.
4.4.6 Effect of actuation forces on aerosolisation
In this set of experiments, the size of particles issued from the HF, HEF and HPEF
formulations was studied with different actuation forces. One actuation force was
provided by a “healthy” female user and two forces of 30 N and 50 N were automated
with the use of a pneumatic piston. For each formulation, the three forces were
tested. The Flixotide R© mouthpiece was used for the suspension formulation and
the Alvesco R© mouthpiece was used for the two solution formulations.
Effect of the actuation force on the size distribution of the suspension
formulation containing HFA134a and FP
The deposition profile of the suspension formulation according to the type of actu-
ation force is shown in Figure 4.9. The NGI tests conducted at 30 N were repeated
more than 7 times because of the high variability of the results. The latter could
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be due to the fact that in some NGI tests, the canisters were not fully actuated at
this low actuation force.
Figure 4.9: In vitro deposition profile of the suspension formulation using three
types of actuation forces. n=8 for the 30 N actuation, n=5 for the 50 N actuation
and n=4 for the manual actuation provided by a “healthy” female user.
Figure 4.9 showed that the 30 N and 50 N actuation forces did not lead to any
changes in the deposition pattern of the HF sprays. However, the throat deposition
was increased significantly when the pMDI was actuated manually (p<0.05).
The spray characteristics of the suspension formulation when the pMDI was ac-
tuated with the two piston forces and manually by a “healthy” female user, are
summarised in Table 4.10.
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30 N 50 N by hand
Mean±SD Mean±SD Mean±SD
Device(%) 9.74±2.85 8.53±2.06 7.19±1.55
Throat (%) 31.91±1.38 31.90±3.62 38.69±2.50
FPFED ≤5 (%) 53.04±3.65 54.92±5.07 50.54±2.03
FPFED ≤2.5 (%) 34.55±3.24 36.19±3.86 34.49±1.59
MMAD (µm) 2.35±0.24 2.26±0.19 2.09±0.07
Table 4.10: Summary of the deposition and size characteristics of the suspension
formulation when the pMDI was actuated at 30 N, 50 N and manually. n=8 for the
30 N actuation, n=5 for the 50 N actuation and n=4 for the manual actuation.
Table 4.10 reveals that the three types of forces used did not have a significant
effect (p>0.05) on any of the metrics except throat deposition which increased
significantly with the manual actuation (p<0.05).
Effect of the actuation force on the size distribution of the formulation
containing HFA134a, ethanol and FP
The deposition profiles of the HEF formulation according to the type of actuation,
presented in Figure 4.10, show that the automated actuations are associated with a
higher variability than the manual actuations. One can also observe that the man-
ual actuations of the “healthy” female user resulted in higher throat depositions
than the automated actuations at 30 N and 50 N. However, as the automated actua-
tions resulted in highly variable results, this difference was not significant (p>0.05).
The overall profiles obtained with both automated forces were comparable.
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Figure 4.10: In vitro deposition profile of the HEF solution formulation using three
types of actuation; n=7 for the 30 N actuation, n=4 for the 50 N actuation and n=4
for the manual actuation provided by a “healthy” female user.
The characteristics of the HEF spray when the pMDI was actuated with the two
piston forces and manually are presented in Table 4.11.
30 N 50 N by hand
Mean±SD Mean±SD Mean±SD
Device(%) 19.00±14.56 16.54±7.35 17.97±1.09
Throat (%) 28.01±12.23 25.05±13.54 40.98±0.92
FPFED ≤5 (%) 64.93±12.37 68.32±16.21 46.98±1.28
FPFED ≤2.5 (%) 60.57±12.09 63.76±15.86 41.91±1.00
MMAD (µm) 0.58±0.09 0.58±0.06 0.74±0.05
Table 4.11: Summary of the deposition and size characteristics of the HEF formu-
lation when the pMDI was actuated at 30 N, 50 N and manually; n=7 for the 30 N
actuation, n=4 for the 50 N actuation and n=4 for the manual actuation.
Table 4.11 shows that the FPF values decreased significantly when the pMDI




The device deposition was not significantly altered by any type of actuation. The
throat deposition and MMAD increased when the formulation was actuated man-
ually. However, these differences were not significant due to large variations in the
results obtained with the pneumatic piston.
Effect of the actuation force on the size distribution of the formulation
containing HFA134a, ethanol, PEG400 and FP
The deposition profile of the HPEF formulation according to the type of actuation
is shown in Figure 4.11.
Figure 4.11: In vitro deposition profile of the HPEF solution formulation when the
pMDI was actuated at 30 N, 50 N and manually; n=6 for the 30 N actuation, n=5
for the 50 N actuation and n=4 for the manual actuation.
Figure 4.11 shows that the percentage of FP deposited on each stage was not altered
by any type of actuation (p>0.05).
The characteristics of the HPEF spray when the pMDI was actuated with two
different piston forces and manually is presented in Table 4.12.
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30 N 50 N by hand
Mean±SD Mean±SD Mean±SD
Device (%) 17.60±1.63 17.68±2.17 19.96±3.44
Throat (%) 50.30±3.54 51.12±2.53 52.58±5.42
FPFED ≤5 (%) 23.04±2.63 22.59±0.52 19.72±2.98
FPFED ≤2.5 (%) 12.80±1.44 12.34±0.44 10.76±1.74
MMAD (µm) 3.94±0.28 3.93±0.15 4.16±0.19
Table 4.12: Summary of the deposition and size characteristics of the HPEF for-
mulation when the pMDI was actuated at 30 N, 50 N and manually; n=6 for the
30 N actuation, n=5 for the 50 N actuation and n=4 for the manual actuation.
It can be seen from Table 4.12 that the device deposition, throat deposition, FPFs
and MMAD were not affected by the type of actuation (p>0.05). There was no
statistical difference between the three types of actuation forces for any parameters
listed in Table 4.12 (p>0.05).
4.5 Discussion
4.5.1 Suitability of the HPLC assay
The HPLC assay characteristics such as linearity, accuracy, repeatability and sen-
sitivity were in line with the International Conference on Harmonisation (ICH)
guidelines (ICH, 2005).
The linearity was determined using 5 concentrations as stated in the ICH guidelines
and the R2 values were greater than 0.999 for both Equations (4.16) and (4.17)
presented in Section 4.4.1. This indicates a good linearity for concentrations of FP
in the range of 0.5µg·mL−1 to 50µg·mL−1.
The percentage recovery of FP for each accuracy standard, calculated using Equa-




The values of the drug recovery as a percentage of the theoretical dose content per
actuation shown in Table 4.6 were all within the 80% to 120% range specified in
the ICH guidelines which indicates a good accuracy level.
The limit of quantification (LOQ) of FP was calculated using Equation (4.5) given
by the ICH guidelines. The LOQ was sufficiently low to allow the accurate quan-
tification of the drug depositing on each stage of the NGI for all NGI tests.
4.5.2 Effect of formulation design on spray characteristics
The fact that the HF formulation had a significantly lower MMAD and higher FPF
values than the Flixotide R© formulation can be explained by different FP concen-
trations in the two formulations (p<0.05). The Flixotide R© pMDI delivers 125µg
FP per metered dose compared to approximately 30µg FP for the HF formula-
tion. At higher drug concentrations, drug particles tend to aggregate more and
might form bigger clusters leading to higher MMAD values and lower FPF values
(Michael et al., 2001). Cripps et al. (2000) found similar results when comparing a
125µg and a 250µg Flixotide R© formulations. The MMAD of the 125µg Flixotide R©
formulation was 2.4µm compared to 2.6µm for the 250µg Flixotide R© formulation.
The fact that Cripps et al (2000) found a 2.4µm MMAD compared to the 2.89µm
MMAD in this work might be explained by the use of an ACI in their measurements
instead of a NGI in this work.
The MMAD of 1.29±0.22µm for the HEF formulation was in the same range as
the 1.1±0.1µm MMAD obtained by Brambilla et al (1999) when testing a similar
formulation. The FPFRD ≤5 is approximately 34% for Brambilla et al which is
much higher than the FPFRD ≤5 of 13.51± 2.47% found in this work. The higher
FPF value obtained by Brambilla could be explained by the smaller nozzle orifice
diameter he used (0.33 mm compared to 0.50 mm in this work).
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The MMAD of 4.12±0.37µm for the HPEF formulation is in line with the MMAD
obtained by Brambilla et al (1999) when testing a comparable formulation. They
found a MMAD of 4.4µm when using a pMDI with a nozzle orifice diameter of
0.33 mm. The slightly lower MMAD in this work could be explained by the fact
that the formulation used by Brambilla et al contained 21% w/w of semi-volatile
and non-volatile components compared with 15% w/w in this work.
The FPFRD ≤5 is approximately 12% for Brambilla et al (1999), which is much
higher than the 4.90% in this work. This could be be due to the use of different
nozzle orifice diameters (0.33 mm in Brambilla et al ’s work compared to 0.50 mm
in this work). However, the higher nozzle orifice diameter in this work should
theoretically also lead to a high MMAD. This discrepancy between the MMAD
and FPF values might be explained by the way the MMAD is calculated.
The MMAD only takes into account particles depositing on stages 1 to 8 of the NGI
and therefore does not include the biggest particles depositing in the device and
on the throat. It is possible that the HPEF spray contained a large fraction of big
particles (which would explain the low FPF value). However those large particles
would tend to remain trapped in the device or to deposit on the throat. As a result
they would not be taken into account in the MMAD which would remain low.
The MMAD of the HPEF formulation is also comparable to the value of 3.82±0.09µm
obtained by Haynes et al (2004) when they tested a solution formulation contain-
ing 0.1% w/w nimesulide, 5%w/w PEG and 15%w/w ethanol using an ACI. The
smaller MMAD found by Haynes et al might be due to different pMDIs designs.
As there is no mention of device parameters in Haynes et al work, it is difficult to
elaborate on the difference observed.
Table 4.8 and Figure 4.6 showed that the particles deposition pattern varied ac-
cording to the formulation tested. The throat deposition was significantly lower
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for the HF formulation compared with the HEF and HPEF formulations (p<0.05).
This could be explained by the fact that the HEF and HPEF formulations had
evaporated less than the HF formulation upon reaching the throat. As a result
they had more momentum and therefore impacted more on the back of the throat.
The HPEF formulation which was the less volatile formulation had therefore the
highest throat deposition of all formulations (p<0.05).
Although the throat deposition of the HEF formulation was significantly higher
than the HF formulation, the MMAD of the HF formulation was higher than the
MMAD of the HEF formulation. This could be explained by the fact that in
impaction testing, the MMAD only refers to the fraction of formulation which gets
past the throat. As a result, a formulation might have a low MMAD (as the HEF
formulation had in this work) and still have a high throat deposition.
The MMAD of the HF formulation might be higher than the MMAD of the HEF
formulation because the API is not dissolved in suspension formulations. As a re-
sult, the residual droplets cannot be smaller than the diameter of the API particles
initially used to manufacture the formulation. In solution formulations, the API is
dissolved so the minimum residual size is not limited by the size of the micronised
drug used in the formulation (Michael et al., 2001).
The D50 of the micronised FP used to manufacture the suspension formulation
and measured using a Malvern Mastersizer X as described in Section 4.2.2, was
2.76±0.03µm. This value should theoretically correspond to the residual size of
the FP particles once all propellant has evaporated. However, the MMAD of the
HF formulation was 2.09±0.07µm.
This difference could be attributed to the fact that the size of the micronised FP
was evaluated using a laser diffraction instrument (Malvern Mastersizer X) whereas
the size of the residual particles was measured with a NGI. The fact that LDA and
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impaction methods never measure exactly the same particles size can explain the
difference obtained between the size of the initial micronised drug particles and the
residual drug particles (Haynes et al., 2004).
The formulation having the highest MMAD was the HPEF formulation contain-
ing PEG400, which is agreement with Haynes et al (2004). When increasing the
PEG concentration from 0.5% to 20%, they found that the MMAD increased from
1.95±0.05µm to 4.09±0.15µm, respectively. This might be due to the fact that at
increased concentrations of PEG, the formulations become less volatile, leading to
a lower evaporation and higher size of residual droplets.
The formulation design significantly altered the FPFED ≤5 for each formulation
(p<0.05). It had a value of 50.54±2.03% for the HF formulation compared to
14.43±2.64% for the HEF formulation and 5.15±0.42% for the HPEF formulation.
These findings would suggest that a higher concentration of semi-volatile and non-
volatile components increases the size of particles and leads to a higher throat
deposition and a lower FPF, which is in agreement with the findings of Brambilla
et al (1999) and Haynes et al (2004).
4.5.3 Effect of mouthpiece design on spray characteristics
The type of mouthpiece used influenced significantly the deposition pattern of the
aerosol for both solution formulations (p<0.05). Device deposition was higher,
throat deposition was lower and all FPF values were higher with the Alvesco R©
mouthpiece compared with the Flixotide R© mouthpiece (p<0.05).
The higher device deposition obtained for both solution formulations with the
Alvesco R© mouthpiece could be due to the fact that it is longer (37 mm compared




The lower throat deposition obtained with the Alvesco R© mouthpiece might be due
to the fact that big particles that would normally impact on the throat might
instead remain trapped in the longer mouthpiece, therefore decreasing the amount
of particles available for throat deposition.
The FPFED ≤ 5 of the HEF formulation in Table 4.9 was compared to the theo-
retical FPFED ≤ 5 obtained using Equation (4.13) discussed in Section 4.3.3.
Equation (4.13) developed by Lewis (2007) gives a theoretical FPFED ≤ 5 of 14.58%
with the Flixotide R© mouthpiece of 0.50 mm nozzle orifice diameter. This value is
close to the result of 13.51±2.47% reported in Table 4.9.
Equation (4.13) gives a theoretical FPFED ≤ 5 of 54.22% with the Alvesco R© mouth-
piece of 0.20 mm nozzle orifice diameter. This value is comparable to the result of
46.98±1.28% found in Table 4.9.
The results are therefore in line with the work of Lewis (2007) and Clark (1991)
who established that the FPF of a spray is inversely proportional to the diameter
of the nozzle orifice.
The results are also in agreement with the findings of Brambilla et al (1999)
who studied the effect of nozzle orifice diameters on fine particle fractions. They
found that the FPF≤4.7 (%) almost tripled when using a nozzle orifice diameter of
0.25 mm compared to a nozzle orifice diameter of 0.42 mm. They mainly attributed
this increase in the FPF value to a reduction of the throat deposition when using
the smaller nozzle orifice. A smaller nozzle orifice may indeed lead to the formation
of smaller initial droplets which might impact less on the throat as illustrated in
Equation (4.11) developed by Stein et al (2012).
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For a formulation containing HFA134a, ethanol, glycerol and API, Brambilla et al
found a FPFRD ≤4.7 of 16% with a 0.42 mm nozzle orifice diameter compared with
42% with a 0.25 mm nozzle orifice diameter. Those percentages cannot be directly
compared to the data in this work as the present formulation contains 5% w/w of
PEG400 versus 1.3% w/w in Brambilla’s formulations. The higher concentration
of PEG400 in this work can explain the fact that the FPFRD ≤5 is smaller for the
HPEF formulation compared to Brambilla’s findings. However the nozzle orifice
diameter effect was similar to the effect reported by Brambilla, as the FPFRD ≤5
also tripled from 4.90±0.45% with the Flixotide R© mouthpiece of 0.50 mm nozzle
orifice diameter to 15.71±1.66% with the Alvesco R© mouthpiece of 0.20 mm nozzle
orifice diameter.
For the HEF formulation, the FPFRD ≤5 also almost tripled from 13.51±2.47%
for the Flixotide R© mouthpiece versus 38.54±1.43% with the Alvesco R© mouthpiece.
Contrary to Brambilla et al (1999) who found that the MMAD was not significantly
altered when decreasing the nozzle orifice from 0.42 mm to 0.25 mm in a HFA
solution formulation, the MMAD decreased significantly for the HEF formulation
when the diameter of the mouthpiece was decreased from 0.50 mm to 0.20 mm
(p<0.05). The reduction in MMAD when using a mouthpiece with a smaller nozzle
orifice diameter is consistent with the work of Polli et al (1969) who found that the
MMAD decreased from 11µm to 3.2µm when using mouthpieces of nozzle orifice
diameters of 0.61 mm and 0.46 mm respectively.
For the HPEF formulation, the MMAD was not altered by the type of mouthpiece
used. This might be explained by the fact that the PEG400 is a viscous liquid which
does not evaporate during the atomisation of the spray and therefore represents
the main factor dictating the residual size of the droplets. This might also be
due to the fact that even if the Flixotide R© mouthpiece would aerosolise bigger
particles than the Alvesco R© mouthpiece, the higher throat deposition associated
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with the HPEF formulation when using the Flixotide R© mouthpiece would prevent
the particles from reaching past the throat. As a result, they would not be included
in the MMAD calculations.
When applying Equation (4.12) developed by Lewis (2007), to the HPEF formu-
lation, a MMAD of 3.91µm was calculated. This theoretical value is comparable
to the 4.12±0.37µm and 4.16±0.19µm MMAD values obtained with the Alvesco R©
and Flixotide R© mouthpieces respectively. This result is therefore in line with the
findings of Lewis (2007) who reported that for HFA-based solution formulations,
the MMAD is primarily influenced by the concentration of non-volatiles in the
formulation.
The Flixotide R© mouthpiece was associated with higher throat depositions for the
HEF and HPEF formulations. As high throat depositions can be associated with
decreased pMDIs efficiencies and increased risks of side effects, it was decided
that the Alvesco R© mouthpiece was more suitable for the delivery of both solution
formulations and would therefore be used in this work.
4.5.4 Effect of actuation forces on spray characteristics
This work showed that the deposition patterns of sprays actuated at two different
forces using a pneumatic piston were similar. The actuation of the canisters at
30 N and 50 N did not lead to any statistical difference in the percentage drug
deposition on any stage of the NGI, in the FPFs or in the MMAD for any of the
three formulations (p>0.05). This might be due to the fact that the effect of the
forces provided by the pneumatic piston on the valve opening rate is non-significant.
Although the results were not significant due to the high standard deviation of the
measurements conducted with the pneumatic piston, Figures 4.9 and 4.10 showed
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that the manual actuation by the “healthy” female user led to increased throat
depositions for the two most volatile formulations (HF and HEF). This difference
might be explained by the gradual nature of the manual actuation compared to
the automated actuation, which might influence the valve opening rate.
The automated actuation might lead to a more abrupt opening of the valve ori-
fice due to the constant force of the pneumatic piston throughout the actuation.
This could cause a higher pressure gradient across the nozzle orifice earlier in the
aerosolisation process due to a more important propellant build up in the expansion
chamber. As the pressure gradient provides the energy to aerosolise the droplets,
the abrupt valve opening under automated actuations could lead to the aerosolisa-
tion of smaller droplets, which would cause a lower fraction of the spray to deposit
on the throat.
On the contrary, the manual actuation could lead to a slower opening of the valve
orifice, leading to a lower pressure gradient at the nozzle orifice and therefore to
the aerosolisation of larger droplets, causing a higher percentage of the spray to
deposit on the throat.
Once again, a strong difference in the throat depositions between the manual and
automated actuations was not correlated with a high difference in the MMAD.
This could be due the fact that the MMAD only takes into account the particles
entering the NGI.
These results would suggest that the automated actuations might lead to different
aerosolisation patterns compared to the manual actuations. For the HEF formu-
lation, there was more variability in the data obtained with the piston actuation
than with the manual actuation. It could be due to the fact that a higher pressure
gradient causes more turbulence in the spray and therefore contributes to a less
repeatable and stable deposition pattern.
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The HPEF formulation was not affected by the type of actuation force used (p>0.05).
This could be explained by the fact that the size of the particles was mostly dic-
tated by the presence of PEG400, a viscous and non-volatile excipient. As the
formulation is more viscous, even a more abrupt valve opening might not provide
a sufficient amount of energy to aerosolise the spray into smaller droplets. The
high variability associated with the automated actuations for the HF and HEF
formulations was not observed for this formulation. This could be explained by the
lower vapour pressure of the formulation, which might lead to a smaller level of
turbulence and a more stable aerosolisation process. This is in line with the work
of Ju et al. (2012) who showed that formulations containing a higher concentration
of non-volatile components tend to produce more steady puffs than more volatile
formulations.
4.6 Summary
The aim of this chapter was to study the deposition patterns of three pMDI formu-
lations depending on several parameters. The type of formulation used was shown
to affect the spray characteristics, with the less volatile formulations leading to the
aerosolisation of bigger droplets and increased throat depositions.
The device design was also shown to affect the deposition pattern of the aerosols as
a larger nozzle orifice was shown to accentuate the throat deposition and to reduce
the amount of fine particles.
Finally, the varying types of actuation tested showed that the magnitude of the
automated actuation forces did not have a significant effect on the deposition pat-
terns of any of the formulations. However, the manual actuation provided by a
“healthy” female user was shown to accentuate the throat deposition, especially
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for the most volatile formulations. The deposition profiles of the two most volatile
formulations may have been influenced by the abrupt nature of the automated
actuation which could increase the pressure gradient across the nozzle orifice and
lead to the aerosolisation of smaller droplets.
Further work is needed to understand which mechanisms of the actuation process
lead to the observed difference in the deposition patterns for the two most volatile
formulations. The automated actuations could then be modified to better mimic
manual actuations when conducting preliminary tests in pMDI development.
This chapter also highlighted a lack of correlation between a high MMAD and
a high throat deposition. The MMAD, although it represents a measure of the
particle size distribution, does not give information on particles impacting on the
throat as it only takes into account particles entering the NGI. As the efficiency of
a pMDI is directly linked to its throat deposition, another size parameter assessing
the size of particles deposited in the throat and in the NGI might be useful.
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Experimental validation of the
one-dimensional computational
model of metered dose inhaler
discharge
5.1 Introduction
5.1.1 Droplet diameter and oropharyngeal deposition
The efficiency of inhaled drug delivery is limited by its oropharyngeal deposition.
Kleinstreuer et al (2007) presented a summary of early modelling of throat depo-
sition obtained by Cheng et al (1999, 2003) to validate their computer simulation.
A graph showing the relationship between the impaction parameter (IP ) and the
percentage deposition in the mouth and throat regions using Cheng’s data and
Kleinstreuer’s computational results is shown in Figure 5.1 where IP is defined by
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Equation (5.1) (Kleinstreuer et al., 2007).
IP = d2pQ (5.1)
where dp is the particle diameter in µm and Q is the patient’s inhalation flow rate
in L·min−1.
Figure 5.1: Deposition efficiency in the human upper airway, plotted as a function
of the inertial parameter d2pQ as cited by Kleinstreuer et al (2007).
Figure 5.1 shows that the upper airway depositions increase with the inertial pa-
rameter IP . As at a given flow rate, IP is proportional to the square of the
diameter of the particle, it can be concluded that the particle size is a major factor
governing the deposition in the upper airways.
The results obtained from simulations studying the particles deposition in two hu-
man mouth-throat models developed by Jayaraju et al. (2008) show that larger
particles lead to an increased amount of particles depositing in the mouth and
throat regions. In vivo experiments by Ehtezazi et al. (2010) and clinical data
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gathered by Buhl (2006) also showed that a higher particles size leads to an in-
creased oropharyngeal deposition.
The primary atomisation of the spray, which describes the breaking up of the flow
into droplets inside the pMDI, was studied in chapters 2 and 3. It is of interest to
measure the particles size at several distances from the nozzle orifice in order to
understand the evolution of the particles dimensions from the nozzle orifice to the
respiratory system.
In this chapter, the velocity and size of the droplets were measured during their
atomisation downstream of the nozzle orifice, also referred to as secondary atomi-
sation. Secondary atomisation occurs after the primary atomisation which corre-
sponds to the boiling and evaporating of the formulation inside the device (Versteeg
et al., 2006). The velocity and size of the droplets during their transportation from
the nozzle orifice to the patient’s throat are of interest and were measured experi-
mentally using several laser techniques, at distances relevant to human oropharyn-
geal anatomy.
5.1.2 Droplets velocity and oropharyngeal deposition
Droplets velocity also increases the percentage deposition in the throat region (Stein
and Myrdal, 2006). This is illustrated by Equation (1.3), discussed in Chapter 1,
S = Bmp Up
which shows that the stopping distance of a particle increases when its velocity
increases.
Droplet velocity is governed by properties of the formulation such as its vapour
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pressure, which controls the velocity at which the formulation is discharged from
the expansion chamber. It is also influenced by the patient’s inspiratory flow rate
which affects significantly the aerosol velocity in the patient’s airways. The velocity
of the spray issued from a pMDI decreases rapidly from approximately 60 m·s−1
when exiting the device to a few meters per second (corresponding to the patient’s
inspiratory flow velocity) upon reaching the throat (Stein and Myrdal, 2006). This
is mainly due to the particles mass loss through their evaporation, making them
slow down upon interaction with the quiescent air (Hochrainer et al., 2005). As
particles velocity affects the efficiency of pMDIs by altering the amount of drug
impacting on the back of the throat, it was also of interest to study this parameter.
The velocity of several formulations was measured using a laser technique at several
distances, up to 10 cm away from the nozzle orifice.
Applications of laser techniques to measure the velocity of pMDI sprays
Laser Doppler anemometry (LDA) was used by Lee et al (1991) to calculate the
droplets velocity of pMDI sprays as a function of the distance from the orifice and
as a function of the aerosolisation time. Their results are discussed later in the
chapter. To the best knowledge of the author, no other work used LDA to obtain
velocity measurements from pMDI sprays.
LDA assumes all particles are spherical which represents a shortcoming of this
method for the measurements of particles issued from pMDIs as they might not
all be spherical (Versteeg and Hargrave, 2002). LDA is a suitable method for
the calculation of particles velocity at one point in the spray but cannot calculate
droplets velocities on an entire plane. This type of measurement is not optimal for
the study of pMDI sprays as it was shown that droplet velocities are lower on the
edges of the sprays compared to the centre (Crosland et al., 2009).
Dunbar et al (1996, 1997) conducted experiments to measure the velocity of a
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HFA134a spray 25 mm downstream of the nozzle orifice using phase Doppler parti-
cle analysis (PDPA) and high-speed photography; they reported maximum veloci-
ties of 60 m·s−1.
Wigley et al (2002) assessed droplets velocities at a distance of 2.6 mm from the
nozzle orifice using phase Doppler anemometry (PDA); they measured a velocity
peak of approximately 90 m·s−1. As PDA can only assess the velocity of droplets at
one point, many researchers have chosen to use particle image velocimetry (PIV)
as it can assess particles velocity over entire areas.
Work on the characterisation of aerosol sprays using PIV have been conducted by
Han et al. (2002) who investigated the effect of different airflow rates on particles
velocity inside the mouthpiece of a DPI and observed a highly turbulent flow at all
flow rates.
Crosland et al (2009) investigated the effect of a spacer on the velocity of pMDI
sprays using PIV. Their results revealed that the spacer did not have a strong
impact on the spray velocity and that the pMDI sprays had a higher velocity at
the positions located closer to the extremity of the mouthpiece. The effect of several
time delays after the actuation on the flow velocity was investigated by Crosland
et al (2009). Their results are shown in Figure 5.2.
Figure 5.2 shows that the spray velocity decreases between 2 ms and 10 ms delays
but increases between 10 ms and 40 ms delays. The effect of delays was further
studied in this work to understand better their influence on the exiting spray ve-
locity. Figure 5.2 also showed that an airflow of 30 L·min−1 did not affect strongly
the velocity profile of the spray. This shows that the recommended advice to breath
in a pMDI at a flow rate of 30 L·min−1 may not alter the spray velocity and its
potential impact on throat deposition (Keller, 1999).
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Figure 5.2: The vector velocity flow field and selected radial (vertical) profiles of
axial velocity for three time delays actuated into quiescent air (a to c) and with a
30 L·min−1 coflow (d to f) (Crosland et al., 2009).
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When converting the mass flow rate to a velocity using Equation (5.2), a 30 L·min−1
flow rate leads to a velocity of approximately 2 m·s−1 at the oropharynx. The low






where Uair is the velocity of air in m·s−1, Q is the volumetric flow rate of air in
m3·s−1 and Atrachea is the area of the trachea in m2 (Ali, 2008).
The recommended 30 L·min−1 flow rate might be aimed at directing the aerosol
through the respiratory tract. It might also affect the particles size and therefore
the particles deposition location within the respiratory tract. In order to under-
stand whether the flow rate has an effect on the size of particles aerosolised, particle
size measurements are carried later in the chapter at several flow rates. The effect
of the number of actuations on the performance of HFA-based salbutamol sulfate
sprays was also analysed by Crosland et al (2009) and it was shown that the velocity
profile did not change over the canister lifetime.
5.1.3 Particle size measurements
Particles size can be assessed using laser diffraction. As the angle of diffraction
of a laser upon contact with a particle is inversely proportional to the size of the
particle, laser diffraction uses diffraction angles to assess particles size.
The advantage of this method is that it can provide real-time and in-situ analysis
of aerosol droplets. This allows investigations on the dynamic character of the
aerosol. However, because the laser light is only scattered from the surface of the
droplets, laser diffraction cannot differentiate drug-containing particles from the
rest of the sample (Pu et al., 2011). Laser diffraction instruments can also suffer
237
Chapter 5
from beam steering, a phenomenon due to the change in refractive index caused
by the evaporation of the propellant which can create large phantom droplets that
are non existent in the spray. Laser diffraction assumes that particles are spherical
which might not be the case in all sprays (Mitchell et al., 2006), (Versteeg and
Hargrave, 2002).
Several instruments use laser diffraction to assess particles size. In this chapter,
the Helos from Sympatec R© and the Malvern Spraytec R© were employed.
Sympatec R©
The particle analyser Helos was developed by Sympatec R© GmbH (Clausthal-Zellerfeld,
Germany) in 1983 to measure particles of diameters 0.1µm to 8750µm (Sympatec,
2010). It was used by Pu et al (2011) to investigate the effect of different tem-
peratures and formulations on the particles sizes of HFA aerosols. Their results
showed that the droplets size decreased at increasing temperatures. This could
be explained by the fact that at higher temperatures, a formulation has a higher
vapour pressure and therefore a stronger evaporative power.
Pu et al (2011) also investigated the effect of non-volatiles on the size of particles by
comparing a formulation containing 0.2% w/w of a non-volatile component and 5%
w/w of ethanol with a 100% HFA formulation. The results show that the presence of
non-volatiles leads to an increase in particles size. The use of the Sprayer unit from
Sympatec allowed Pu et al to measure the spray at distances of 8 cm, 12 cm and
18 cm from the mouthpiece. The sprays contained more fine particles at 18 cm than
at 12 cm from the mouthpiece, it can thus be assumed that the particles measured
at 8 cm and 12 cm from the mouthpiece had not yet reached their residual size.
The latter results show that the Helos particle sizer from Sympatec R© can be used
successfully to assess the intermediate size of particles issued from pMDIs.
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The effect of varying flow rates on sprays issued from pMDIs and DPIs on the
residual size of particles has been studied using impaction instruments. However,
as their cut-off diameters generally depend on the flow rate at which they are
used, impaction devices are not ideal to study the effect of flow rate on particles
size (Feddah et al., 2000). The effect of several flow rates on the intermediate
size of pMDIs sprays has to the best knowledge of the author never been studied
although it could give valuable information on the probability of particles reaching
the respiratory system. For this reason, the effect of several flow rates on the size
of particles issued from three different formulations was studied using the Helos
from Sympatec R©.
Malvern SpraytecR©
The Malvern Spraytec R© can measure particles with a diameter ranging from 0.1µm
to 2000µm (malvern.com, 2012). This covers the range required for the character-
isation of pMDIs’ sprays. Malvern developed a multiple scattering analysis algo-
rithm, allowing the measurement of particles in higher concentration sprays than
traditional laser diffraction techniques. As a result, the Malvern Spraytec R© is able
measure sprays obscuring up to 98% of the laser intensity and could therefore be
used to measure particles closer to the nozzle orifice.
The Malvern Spraytec R© can also measure the particles size as a function of the
distance from the nozzle orifice. This is of interest as the particle size distribution
of pMDI sprays varies with this distance. This represents the main advantage of
the Malvern Spraytec R© over the Helos from Sympatec R© and impaction devices.
The Malvern Spraytec R© was used by Haynes et al (2004) to study the effect of
temperature on pMDIs sprays. Their results showed that the particles size of the
spray decreased at increasing temperatures.
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According to Haynes et al (2004), the Malvern Spraytec R© overestimates the parti-
cles size of HFA-based aerosols compared to the Andersen cascade impactors (ACI).
This could be due to the fact than when entering the laser measurement zone, the
spray is not yet fully evaporated and might lead to the measurement of droplets
which contain propellant. In comparison, the ACI only assesses the particle size
distribution of the drug particles. Inhalation cells can be used to reduce this effect
as they allow the spray to evaporate more completely before entering the measuring
zone. However, measurements with an inhalation cell do not give information on
the size of particles as they enter the throat, but rather on the particles residual
size. In order to assess the chance of impaction on the throat based on particles
size, it might be more relevant to measure particles as they would behave in real
life (i.e. without inhalation cells).
The oversizing of the Malvern Spraytec R© might also be due to the fact that im-
pactors do not measure the particle size distribution of all droplets but only of those
able to get past the induction port which might also contribute to the difference in
particle size distribution obtained with both methods.
The variation of the refractive index in the aerosol cloud might affect the Malvern
Spraytec R© results. When measuring particle size near the nozzle orifice (closer
than 10 cm), the evaporation of the liquid phase might erratically alter the path of
the laser beam, leading to the creation of large “phantom” droplets (malvern.com,
2007). In order to reduce the laser light refraction due to the high vapour mass
near the orifice, one can remove the “phantom” droplets by “killing” the detector
channels measuring the largest droplets. However, when doing this, large droplets
present in the spray might not be detected (Dunbar, 1996).
Application to pMDI sprays
Laser diffraction is not highly recommended for the characterisation of suspension
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formulations because it cannot differentiate between drug-containing and drug-free
particles, which are both present in suspensions sprays (Pu et al., 2011). Therefore,
the measurements might not characterise drug particles but pure propellant parti-
cles. In order to get an even number of API droplets when measuring suspension
formulations, the pMDI can be shaken before each measurement.
The results obtained with laser diffraction on suspension sprays cannot be directly
compared to impaction measurements as impactors measure only the size of drug-
containing droplets. However, Pilcer et al showed a good correlation in the particles
size obtained by impaction and laser diffraction when testing formulations issued
from DPIs (Pilcer et al., 2008).
As the active pharmaceutical ingredient (API) is assumed to be homogeneously
dissolved into solution formulations, the fact that laser diffraction devices do not
perceive the difference between drug-containing and drug free droplets would not
represent an issue for those formulation types (Pu et al., 2011). In solution for-
mulations, laser diffraction has be shown to be an efficient tool to characterise the
particles size change depending on the formulations and solvents employed.
Although laser diffraction instruments might be less accurate and consistent than
impaction instruments, they represent a much faster alternative to particle sizing
and can therefore be used when screening many formulations at early stages in
product development.
Pu et al (2011) used the Helos from Sympatec R© to assess the particle size distri-
bution of pMDIs sprays obtained under different conditions. As the Helos does
not allow the measurement of particles size as a function of the distance from the
nozzle orifice, in this work it was decided to use the Helos as well as the Malvern
Spraytec R© to obtain more comprehensive data on the spray development.
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In their experiments, Clark (1996) as well as Smyth and Hickey (2003) used the
Malvern 2600 launched in 1980 (Vines, 2010). The Malvern 2600 employed the
Fraunhofer analysis to assess particles size. This method gives less accurate results
than the Mie theory used in the Malvern Spraytec R© when studying particles smaller
than 25µm which corresponds to the particles size measured by Clark (1996) as
well as Smyth and Hickey (2003) (Mitchell et al., 2006). In their data, Smyth
and Hickey (2003) observed a multimodal particle size distribution. As Fraunhofer
theory has been reported to bias results in the presence of multimodal distributions
towards the mode with the most significant peak, the results of Smyth and Hickey
might have been affected (Mitchell et al., 2006).
The Malvern Spraytec R© operates with a laser twice more powerful than the Malvern
2600 and can capture more data at a faster rate (malvern.com, 2012). The Malvern
Spraytec R© can also operate at lower transmissions than the Malvern 2600 which
might give a better accuracy for the measurements of high density flows such as
pMDI sprays near the nozzle orifice (Strakey, 2003).
5.1.4 Aims and objectives
In Chapter 4, the effect of the actuation force on the aerodynamic size distribution
of the droplets was studied. In the current chapter its influence on both the size and
velocity of the droplets was investigated using laser diffraction and PIV respectively.
It was of interest to capture those properties at several distances and times in the
aerosolisation process in order to understand the spatial and temporal development
of pMDIs sprays.
The aim of this chapter was to characterise the effect of several actuation forces,
formulations and device parameters on the velocity and size of particles issued from
pMDIs using laser-based analytical techniques.
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The objectives to address this aim were:
- the investigation of the effect of the formulation on the velocity and size of the
aerosolised particles using PIV, the Malvern Spraytec R© and the Sympatec R©.
-the study of the influence of the environmental temperature on spray characteris-
tics using the Malvern Spraytec R©.
5.2 Materials and equipment
The equipment used in this chapter included:
• a filling crimping machine (Pamasol, Switzerland)
• aluminium canisters from Valois (Marly Le Roi, France)
• 50µL non-continuous valves from Valois (Marly Le Roi, France)
• an experimental aluminium rig connected to a switch providing automated
actuation of the canisters (see Section 4.2.7 in Chapter 4)
• a Flixotide R© mouthpiece (Allen and Hanburys Ltd, Middlesex, UK)
• an Alvesco R© mouthpiece (Takeda Pharmaceuticals International GmbH, Zurich,
Switzerland)
• a 36 cm/14.5” high gauge (Rabone Chesterman, Sheffield, UK)




The equipment used for the PIV measurements were:
• a Dantec PCO Camera equipped with a green filter (Dantec, Massachusetts,
USA)
• a FlowManager software version 4.5 (Dantec, Massachusetts, USA)
• a Flowmap system HUB (Dantec, Massachusetts, USA)
• a Peltier device (Dantec, Massachusetts, USA)
• a NewWave Solo laser of wavelength 532 nm (New Wave Research ESI, Port-
land, Oregon)
The equipment used for the Sympatec R© measurements were:
• a Sympatec R© LD particle-sizer and its Windox 5 software (HELOS Compact,
Model KA), (Sympatec GmBH, Clausthal-Zellerfeld, Germany)
• a wash bottle (HELOS Compact, Model KA), (Sympatec GmBH, Clausthal-
Zellerfeld, Germany)
• Whatman lens cleaning tissue (Whatman, Kent, UK)
• acetone analytical reagent (Fisher Scientific, Loughborough, UK)
The equipment used for the Malvern Spraytec R© measurements were:
• a Malvern Spraytec R© 97 and its software RTSizer version 5.41 (Malvern,
Worcestershire, UK)
• a drying oven Type VT6 (Thermo Fisher Scientific, MA, United States)
The equipment used to measure the velocity of the canister during actuations were:
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• a linear variable differential transformer (LVDT) Solartron Metrology DC25
(West Sussex, UK)
• a USB 6211 analog to digital converter (National Instrument, Berkshire, UK)
5.3 Device design
In order to measure the spray velocity at the nozzle orifice, a transparent mouth-
piece in plastic was designed with a 3D printer to let the laser illuminate the flow.
However, it was found that it was not sufficiently transparent to allow the laser
to penetrate sufficiently. It was thus decided to measure the particles velocities
outside the mouthpiece.
For the PIV measurements, all formulations were tested with the Flixotide R© mouth-
piece as the stem of Valois 50µL valves could not fit in the Alvesco R© mouthpiece.
Although this did not represent an issue in the previous chapter in which a few
actuations were required for each test, it was problematic in the PIV experiments
as the canister was displaced during the multiple measurements required in PIV
measurements and could not be repositioned for fear of disturbing the alignment
of the whole system.
The closest location from the nozzle orifice for the velocity measurements therefore
corresponded to the distance between the nozzle orifice and the extremity of the
Flixotide R© mouthpiece, which was 25 mm. For the particle size measurements
with the Sympatec R© and the Malvern Spraytec R©, the Flixotide R© mouthpiece with
a nozzle orifice diameter of 0.50 mm was used for the suspension formulation. For
the two solution formulations, the Alvesco R© mouthpiece with a length of 37 mm
and a nozzle orifice diameter of 0.20 mm was used.
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5.4 Manufacture of formulations
The pure propellant formulations were manufactured by crimping the canisters with
the Valois 50µL valves and forcing approximately 20 g of HFA134a under pressure
in each canister using the filling crimping machine (Pamasol, Switzerland).
The HF, HEF and HPEF formulations were prepared as described in Section 4.2.2
of Chapter 4. Table 5.1 shows the composition of the formulations studied in this
chapter.
Names of the formulations
HFA134a HF HEF HPEF
FP - 0.05% 0.05% 0.05%
HFA134a 100% ' 99.95% ' 84.95% ' 84.95%
Ethanol - - 15% 10%
PEG400 - - - 5%
Table 5.1: Percentage by weight of each component of the studied formulations.
5.5 Experimental method
5.5.1 PIV measurements of sprays issued from pMDIs
An experimental analysis based on 2D-PIV data was performed. The canister sup-
port was painted in matt black to minimise any potential light reflection. The
measurements were performed using a Dantec Dynamics PIV system. The laser
used was a pulsed Nd:YAG laser, emitting light at 532 nm with a maximum fre-
quency of 15 Hz. The images were recorded using a Dantec PCO Camera with a
1280×1024 pixel CCD cooled by a Peltier module to improve the signal-to-noise
ratio. The laser control, the laser/camera synchronisation, the data acquisition
and processing were handled by a hardware module (FlowMap System Hub) and
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a software (FlowManager) installed on a PC.
The actuation of the canister by pneumatic cylinder and the PIV system recording
were coordinated using a purpose-built electrical trigger. The PIV was set up to
receive a signal from this external trigger. A delay could be implemented in order
to record the images at a specific delay after the actuation. Figure 5.3 represents
a schematic of the PIV setup.
Figure 5.3: Schematic of the PIV setup.
The 2D instantaneous velocity vectors were determined on a vertical plane crossing
the pMDI’s plane of symmetry. At least 250 instantaneous measurements were per-
formed for each experimental condition. A period of 10 s separated each canister
actuation.
The velocity was measured at the extremity of the mouthpiece located at a dis-
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tance of 25 mm from the nozzle orifice. However due to intense scattering of the
mouthpiece, the measurements in the area were deemed unreliable. It was decided
to only use data at a distance of 10 mm from the mouthpiece extremity (35 mm
from the nozzle orifice).
The time between two consecutive laser pulses, the interrogation area size and the
characteristics of the data analysis were carefully selected after preliminary tests
in order to maximise the measurements accuracy. For each actuation, two frames
separated by a 10µs delay were recorded using one laser pulse per frame. Each
pulse had a duration of 0.01µs.
Each time the canister was replaced within one set of measurements, the camera
image was closely studied to ensure the measurement zone had not been modified.
Between each test, a new calibration was done in order to obtain well-focused mea-
surements and to calculate the scale at which the measurements were conducted.
A typical frame obtained when calibrating the system is shown in Figure 5.4.
Figure 5.4: Picture of a HFA134a spray allowing the calibration of the system.
A FlowManager tool referred to as a mask was applied to all images to remove
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any noise related to the canister and its mouthpiece. A cross-correlation algorithm
was then applied to the masked images to extract meaningful velocities. It was
performed on a rectangular grid with 50% overlap between adjacent cells; the final
interrogation area was set at 32×32 pixels which corresponded to a dimension of
1.5 mm×1.5 mm and gave a spatial resolution of 0.75 mm.
5.5.2 Sympatec R© measurements of sprays issued from pMDIs
The Helos device operates with a HeNe-laser of 632.8 nm wavelength. An inhaler
cell that increased the distance from the nozzle orifice to the measuring zone to
approximately 6 cm was used. The measurements were triggered at an optical
concentration of 1%. The flow rate through the metering device was monitored
using a Venturi meter. A wash bottle collected the fine particles and prevented
them from entering the vacuum pump of the Sympatec R©.
Before each measurement the pMDI was shaken for 10 s before being fired in the
central adapter. For each set of experiments, a minimum of three replicates samples
was tested. The background was checked before each pMDI actuation, and every
five actuations, the inhaler cell was cleaned with a Whatman lens cleaning tissue
(Whatman, Kent, UK) and acetone (Fisher Scientific, Loughborough, UK). A delay
of 10 s was used between each shot to avoid cooling of the metering chamber. In
each plot obtained with the Windox software, the 10th (D10), 50th (D50) and
90th (D90) percentile of the cumulative particle under-size frequency distribution




5.5.3 Malvern Spraytec R© measurements of sprays issued
from pMDIs
The Malvern Spraytec R© 97 and its software RTSizer version 5.41 configured for
a measurement frequency of 2.5 kHz was used, giving the measurements a time
resolution of 400µs. The laser used was a 5 mW HeNe laser of 632.8 nm wavelength.
The data acquisition system contained 36 light detectors, each capturing the light
diffracted from particles of different sizes.
As the particles in the centre of the spray have a higher velocity and undergo less
turbulence than the peripheral droplets, the canister was placed so that the laser
measuring zone was located at the centre of the plume (Liu et al., 2012). The size
of particles was measured at two locations:
• close from the end of the mouthpiece (4 cm from the nozzle orifice)
• 7.5 cm from the nozzle orifice (which would represent approximately the lo-
cation of the throat when the pMDI is used by a patient)
The standard operating procedure (SOP) defining measurement parameters such
as the hardware configuration, the triggering mechanisms and the type of recording
method is described below.
The 100 mm focal lens which has a particle size range between 0.5µm and 200µm
was chosen for this experiment.
The Mie theory of light used by the Malvern technology requires data such as
the refractive indexes of the media and measured sample. The media refractive
index was the air refractive index (1.00+0.00i) and the particulate refractive index
was set to the value of the refractive index of HFA134a (1.17+0.00i) (Stone and
Zimmerman, 2011), (Solvay, 2008).
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The duration of the measurement was set to 2 s and the measurement was triggered
manually with the canister actuation.
The instrument was set to flash mode and a frequency of 2.5 kHz was used.
For each measurement, all the frames of the spray were averaged and the mean
particle size distribution was used to determine the D50.
The noise level was recorded before each set of experiment. The alignment and
background of the system were checked prior each measurement by running a back-
ground measurement to ensure that the optics had not been contaminated during
previous measurement.
For each set of experiments, a minimum of three measurements was conducted.
When studying the effect of temperature, the canister was heated by storing it
in a drying oven (Thermo Fisher Scientific, MA, United States) one hour before
the experiment. As the room was kept at 20 ◦C, the experiments were conducted
quickly in order for the canister to remain at constant temperature.
The data were reduced in all measurements by removing the detector channels
that might have been affected by beam steering. As the first 8 detectors measure
particles with a diameter greater than 76.56µm, it was decided not to take them
into account in order to “kill” the large “phantom” droplets. This procedure should
not affect the results as particles issued from pMDIs have a diameter lower than





5.6.1 PIV measurements of sprays issued from pMDIs
Influence of formulation design on spray characteristics
The axial velocity of two formulations is shown in Figure 5.5. The velocity values
were selected at different vertical coordinates depending on the distance from the
mouthpiece in order to follow the downward shape of the spray.
Figure 5.5: Velocity of two formulations as a function of the distance from the end
of the mouthpiece. Each data point represents a mean of n≥250 determinations.
Figure 5.5 shows that for both formulations, the velocity of the droplets decreases
significantly as they travel away from the mouthpiece. The HFA134a formulation
was faster, with a velocity ranging from 12 m·s−1 to 4 m·s−1 compared to a velocity
of 6 m·s−1 to 2 m·s−1 for the HPEF formulation.
The turbulence level of the spray U ′ is defined as the variation of each velocity
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where U ′ is the turbulence of the spray in m.s−1 , Un represents each individual
velocity value in m.s−1 and U¯ is the mean velocity of all measurements in m.s−1 ·
The turbulence level of the spray is plotted in Figure 5.6.
Figure 5.6: Turbulence of the spray as a function of the distance from the end of the
mouthpiece for a pure HFA134a and a HPEF sprays. Each data point represents
a mean of n≥250 determinations.
The HFA134a formulation had a turbulence ranging from approximately 3 m·s−1
to 5 m·s−1 compared to the HPEF formulation which had a turbulence of approxi-
mately 2 m·s−1 to 4 m·s−1.
Influence of actuating forces on spray velocity
Figure 5.7 shows the resulting vector velocity flow field obtained after data analysis.
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Figure 5.7: The vector velocity flow field of axial velocity for a HFA134a spray at
the extremity of a Flixotide R© mouthpiece after the mask and the cross-correlation
were applied. Mean of n≥250 determinations.
Figure 5.7 shows velocities ranging from 12 m·s−1 to 7 m·s−1 from the extremity of
the mouthpiece to a distance of 35 mm from the mouthpiece respectively. Crosland
et al (2009) obtained velocities in the range of 60 m·s−1 to 20 m·s−1 at 2.5 mm and
17.5 mm from the extremity of the mouthpiece respectively for a HFA134-based
formulation. The field of view in Crosland’s work is significantly lower than the
one used in the current work, which could explain the difference between the results
obtained in both experiments. Crosland et al measured the exit velocities of the
spray close to the extremity of the mouthpiece whereas in the current work, the




Figure 5.7 also reveals a slight downward slope of the spray in line with Crosland et
al (2009) who reported a spray direction ranging from 0.2◦ to 5.8◦ below horizontal.
The effect of varying the actuation forces was tested on pure HFA134a canisters and
can be seen in Figure 5.8. Forces of 30 N, 40 N and 50 N were studied. The velocity
profiles as a function of the actuation force were obtained by spatially bin averaging
the data over zones of 2 mm on the entire measurement region. The velocity values
were selected at different vertical coordinates depending on the distance from the
mouthpiece in order to follow the downward shape of the spray.
Figure 5.8: Particles velocity as a function of the distance from the end of the
mouthpiece for 3 actuation forces for a HFA134a aerosol. Each data point repre-
sents a mean of n≥250 determinations.
Figure 5.8 shows that the actuation force did not affect the particles velocity. All
forces led to a spray velocity of around 12 m·s−1 at a distance of 1 cm from the
mouthpiece and approximately 4 m·s−1, 5 cm from the mouthpiece.
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Influence of delays on spray velocity
The influence of the time interval between the actuation and the measurement of
the spray velocity was studied. The measurements were realised with no delay,
50 ms, 100 ms and 200 ms delays. The effect of the delays on the spray velocity
along the spray trajectory can be seen in Figure 5.9.
Figure 5.9: Effect of time delays on mean axial velocity for a HFA134a aerosol.
Each data point represents a mean of n≥250 determinations.
The velocity values were again selected at different vertical coordinates depending
on the distance from the mouthpiece in order to follow the downward shape of
the spray. The average of all velocities along the spray trajectory was then calcu-
lated for each delay and the time-resolved velocity profile of the spray shown in
Figure 5.10 was plotted.
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Figure 5.10: Temporal profile of a HFA134a spray at several time delays over the
whole spray trajectory. Each data point represents a mean of n≥250 determina-
tions.
It can be seen that the spray reached its maximum velocity 50 ms after its actuation.
Its velocity then decreases as the delay increases. However, as the turbulence level
of HFA134a aerosols is ranging from 1.5 m·s−1 to 4 m·s−1, the observed effect of
delays on the velocity of the spray might not be significant and the experiments
would need to be repeated to confirm this trend.
5.6.2 Sympatec R© measurements of sprays issued from pMDIs
Effect of formulation design on spray characteristics
The HF, HEF and HPEF sprays were compared when actuated by hand at a flow
rate of 30 L·min−1. This flow rate was chosen as it was used in the next generation
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impactor (NGI) measurements in Chapter 4 and could therefore allow a better
comparison of the results obtained with the NGI and the Sympatec R©. However,
the latter measured the spray at a distance of 6 cm from the nozzle orifice, assessing
the intermediate size of the particles whereas the NGI measured their residual size.
The D50 of the three formulations can be seen in Table 5.2.
HF HEF HPEF
Mean±SD Mean±SD Mean±SD
D50 (µm) 3.78±0.14 2.49±0.13 4.14±0.10
Table 5.2: D50 values of the three formulations obtained with the Sympatec
R© when
actuated by a “healthy” female user at a flow rate of 30 L·min−1. Mean of n=3
determinations for each formulation.
The average D50 of particles issued from the suspension formulation containing
drug particles of 2.76±0.03µm diameter was 3.78±0.14µm. The percentage of
particles of diameter ≤5µm was approximately 87.7±2.7%.
The average D50 of the HEF formulation for the three measurements was 2.49±0.13µm,
which is significantly lower than the D50 value of the suspension formulation (p<0.05).
For the HEF formulation, the percentage of particles of diameter ≤5µm varied be-
tween 95% and 100%, which is significantly higher than the value obtained for the
suspension formulation (p<0.05).
The HPEF formulation, with a D50 of 4.14±0.10µm aerosolised significantly larger
particles than the HF and the HEF formulations (p<0.05). The percentage of
particles of diameter ≤5µm for the HPEF formulation was 62.3±1.2 %, which is
significantly lower than the percentages of particle of diameter ≤5µm obtained for
the HF and HEF formulations (p<0.05).
The D50 of both solution formulations cannot be directly compared to the D50 of
the suspension formulation as both solution formulations were aerosolised using
the Alvesco R© mouthpiece of nozzle orifice diameter 0.20 mm whereas the suspen-
258
Chapter 5
sion formulation was aerosolised using the Flixotide R© mouthpiece of nozzle orifice
diameter 0.50 mm.
Effect of airflow rate on spray characteristics
The effect of the flow rate on the particle size distribution of the HF, HEF and
HPEF formulations was also studied using the Sympatec R©. The effect of a 30 L·min−1
and a 60 L·min−1 flow rates on the HF formulation can be seen in Figure 5.11.
Figure 5.11: Particle size distribution of the HF formulation actuated by hand at
flow rates of 30 L·min−1 and 60 L·min−1.
Figure 5.11 shows that both flow rates result in varying particle size distribution
curves. The 60 L·min−1 flow rate results in a shift of the particle size distribution
curve towards the left, signalling a higher percentage of fine particles when the
higher flow rate is used. The average of the D50 for the three measurements was
3.05±0.01µm for the 60 L·min−1 flow rate and 3.79±0.14µm for the 30 L·min−1
flow rate.
This effect was also observed with the HEF and HPEF formulations as shown in
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Figures 5.12 and 5.13 respectively. The average of the D50 for the three mea-
surements of the HEF aerosol was 2.49±0.13µm at the 30 L·min−1 flow rate and
1.28±0.08µm at the 60 L·min−1 flow rate. A higher percentage of particles smaller
than 1µm can be observed at the 60 L·min−1 flow rate in Figure 5.12.
Figure 5.12: Particle size distribution of the HEF formulation actuated by hand at
flow rates of 30 L·min−1 and 60 L·min−1.
Figure 5.13: Particle size distribution of the HPEF formulation actuated by hand
at flow rates of 30 L·min−1 and 60 L·min−1.
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The average of the D50 for the three measurements of the HPEF formulation was
3.88±0.05µm at a flow rate of 60 L·min−1 and 4.14±0.10µm at a flow rate of
30 L·min−1.
For the three formulations, the 60 L·min−1 flow rate led to significantly smaller D50
values (p<0.05). The uniformity index is a measure ranging from 1 to 100 used
to characterise the homogeneity of particle sizes (Hanna and York, 1998). It was





where UI corresponds to the uniformity index (Hanna and York, 1998).
The D50 and uniformity index values of the three formulations at both flow rates
are shown in Table 5.3.
HF HEF HPEF
Flow rate
30 60 30 60 30 60
(L·min−1)
D50 (µm) 3.79 3.05 2.49 1.28 4.14 3.88
UI 53.02 34.11 40.93 28.55 21.15 19.25
Table 5.3: D50 and uniformity index values of the three formulations obtained
with the Sympatec R© when actuated by a “healthy” female user at flow rates of
30 L·min−1 and 60 L·min−1. Mean of n=3 determinations at each flow rate.
Table 5.3 shows that the uniformity index significantly decreases at the higher
flow rate for the HF and HEF formulations (p<0.05) and slightly decreases for the
HPEF formulation. It also shows that at the recommended flow rate of 30 L·min−1,
the uniformity index is significantly lower for the HPEF formulation compared to
the HF and HEF formulations and is significantly higher for the HF formulation
compared to the HEF and HPEF formulations (p<0.05).
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Effect of actuation force on spray characteristics
The effect of two actuation forces provided by a pneumatic piston on the particle
size distribution of the HEF formulation can be seen in Figure 5.14.
Figure 5.14: Particle size distribution of the HEF formulation actuated by a pneu-
matic piston at 30 N and 50 N at a flow rate of 30 L·min−1.
Figure 5.14 shows that the actuation force delivered by the pneumatic piston had
no significant effect on the particle size distribution of the aerosols. The average of
the D50 for the three measurements of the HEF formulation actuated at 30 N was
1.46±0.15µm and 1.38±0.06µm at 50 N.
However, it can be seen in Figure 5.15 that the manual actuation provided by the
“healthy” female user led to the aerosolisation of coarser particles compared to
automated actuations. The uniformity index had a value of 27.39% and 26.97% for
the 30 N and 50 N actuations respectively compared to a significantly higher value
of 60.82% for the actuation of the “healthy” female user (p<0.05).
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Figure 5.15: Particle size distribution of the HEF formulation at a flow rate of
30 L·min−1 actuated by a “healthy” female user and by a pneumatic piston at 30 N
and 50 N.
5.6.3 Malvern Spraytec R© measurements of sprays issued
from pMDIs
Particle size measurements at 4 cm from the nozzle orifice
The data measured at 4 cm from the nozzle orifice for the three formulations and
three types of actuations at two temperatures are shown in Table 5.4 which reveals
that the D90 of the HF formulation for all experiments was significantly larger than





30 N actuation at 20 ◦C
D10 (µm) 2.04±0.44 1.99±0.36 2.85±0.81
D50 (µm) 10.84±1.75 6.86±0.68 11.41±4.53
D90 (µm) 72.14±0.86 20.44±9.76 41.30±25.89
50 N actuation at 20 ◦C
D10 (µm) 1.46±0.18 1.82±0.51 2.59±0.71
D50 (µm) 8.87±1.13 6.14±0.53 9.23±2.45
D90 (µm) 72.41±0.32 13.91±1.91 29.84±16.96
Manual actuation at 20 ◦C
D10 (µm) 3.85±0.05 3.09±0.40 4.14±0.39
D50 (µm) 11.71±0.25 8.29±0.42 10.87±1.09
D90 (µm) 73.39±0.23 28.12±11.76 30.66±11.25
Manual actuation at 40 ◦C
D10 (µm) 3.28±0.28 2.26±0.61 2.72±0.53
D50 (µm) 55.73±19.67 4.93±0.17 6.96±0.90
D90 (µm) 74.56±0.70 20.17±5.82 18.59±7.06
Table 5.4: D50 obtained using the Malvern Spraytec
R© at 4 cm from the nozzle
orifice. Manual actuations provided by a “healthy” female user. Mean of n≥3
determinations for each data.
As the two solution formulations were tested using the same mouthpiece, a direct
comparison of those formulations was possible. Table 5.4 shows that the diameters
of particles issued from the HEF formulation were consistently lower than those
issued from the HPEF formulation. In all experimental conditions, the D50 values
were lower for the HEF formulation compared to the HPEF formulation.
It is suggested that the high variability of the results observed in Table 5.4 might
be due to the close distance of the measurement zone to the nozzle orifice. As a
result, a new set of experiments was realised at 7.5 cm from the nozzle orifice.
Particle size measurements at 7.5 cm from the nozzle orifice
Although it is difficult to find a value for the nozzle orifice to back of the throat
distance, it was possible to estimate it based on several articles (Finlay, 2001),
(Battagel et al., 2002), (Kim and Park, 2011). It was assumed that the distance
from the nozzle orifice to the back of the throat was approximately 7.5 cm and
that this distance could be used to describe the properties of the droplets as they
penetrate the respiratory system.
264
Chapter 5
The data obtained at 7.5 cm from the nozzle orifice for the three formulations and
three types of actuations at two temperatures are shown in Table 5.5. It reveals
that most D50 values were significantly smaller when the spray was measured at




30 N actuation at 20 ◦C
D10 (µm) 0.94±0.01 2.31±0.57 1.48±0.39
D50 (µm) 2.53±0.04 6.53±1.06 6.38±0.56
D90 (µm) 5.85±1.11 19.84±3.59 16.70±1.36
50 N actuation at 20 ◦C
D10 (µm) 1.06±0.12 1.48±0.26 1.43±0.15
D50 (µm) 2.65±0.10 5.42±0.35 6.01±0.32
D90 (µm) 7.31±0.65 13.13±0.81 15.30±0.71
Manual actuation at 20 ◦C
D10 (µm) 0.84±0.18 3.35±0.13 3.55±0.03
D50 (µm) 2.71±0.22 7.83±0.19 9.74±0.29
D90 (µm) 12.89±5.54 16.57±0.51 21.05±1.07
Manual actuation at 40 ◦C
D10 (µm) 2.30±0.46 2.09±0.62 3.17±0.49
D50 (µm) 3.19±0.29 4.57±0.98 5.42±0.68
D90 (µm) 4.18±0.45 14.04±3.21 17.09±4.21
Table 5.5: D50 obtained using the Malvern Spraytec
R© at 7.5 cm from the nozzle
orifice. Manual actuations provided by a “healthy” female user. Mean of n≥3
determinations for each data.
It can be seen that the D50 of the spray was influenced by the formulation compo-
nents. For all measurements, the D50 values of the HF formulation were significantly
smaller than the D50 values of the HEF formulation (p<0.05) and the D50 values of
the HEF formulation were in almost all cases slightly smaller than the D50 values
of the HPEF formulation.
Table 5.5 also shows that both solution formulations had significantly lower D50
values when the canisters were heated at 40 ◦C compared to when they were kept
at 20 ◦C (p<0.05).
Finally, the manual actuation provided by the “healthy” female user was shown to
lead to higher D50 values than both automated actuations.
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Evaluation of the spray duration using the Malvern SpraytecR©
The spray duration issued from the three formulations was measured. It was defined
as the lapse of time during which the intensity of the laser signal was lower than
98% of its initial value. This intensity threshold might explain the shorter duration
observed with the Malvern Spraytec R© for the HF formulation compared to the
PIV set up which continued measuring particles after a delay of 200 ms after the
actuation. The duration of the three formulations can be seen in Table 5.6.
HF HEF HPEF
Mean±SD Mean±SD Mean±SD
Duration (s) 0.06±0.02 0.21±0.005 0.26±0.010
Table 5.6: Sprays duration measured at a distance of 7.5 cm from the nozzle orifice
at 20 ◦C. Mean of n≥3 determinations for each formulation.
Table 5.6 shows that the duration of the plume is significantly affected by the
type of formulation aerosolised (p<0.05). The suspension formulation has a signif-
icantly lower duration than both solution formulations and the HPEF formulation
produces sprays with the longest durations compared to the HF and HEF formu-
lations (p<0.05).
5.7 Discussion
5.7.1 PIV measurements of sprays issued from pMDIs
Comparison to other works
The velocity profiles obtained in Figure 5.8 were higher than the LDA results
obtained by Lee et al (1991) when measuring a mixture of CFC-11 and CFC-12
(30/70% w/w) with a ratio of surfactant to drug of 1/10. They found a velocity of
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7.5 m·s−1 to 5 m·s−1 at a distance of 30 mm from the nozzle orifice (Lee et al., 1991).
The lower velocity measured by Lee et al (1991) can be explained by the fact that
propellants CFC-11 and CFC-12 have a vapour pressure of 89 kPa and 580 kPa
respectively whereas HFA134a used in the present work has a vapour pressure of
590 kPa (Smyth and Hickey, 2011). Although CFC sprays are expected to have a
lower initial velocity due to their lower vapour pressure, the velocity of HFA aerosols
might reduce more as the spray travels away from the nozzle as they are made of
smaller droplets which would decelerate more in contact with air than bigger CFC
droplets. This might explain that CFC sprays are found to be approximately twice
faster as HFA sprays at a distance of 10 cm from the nozzle (Hochrainer et al.,
2005).
The present findings were in line with the high-speed photography results of Dhand
et al (1988) who calculated a spray exit velocity in the range of 13 m·s−1 to 15 m·s−1
for four commercial CFC-based pMDIs (Dunbar, 1996).
However, the present PIV results were not in line with Clark’s PDA velocity data of
35 m·s−1 at a distance of 5 cm from the nozzle orifice with a formulation containing
CFC-12 and 1% sorbitan trioleate. The velocity difference could be explained by
the fact that Clark used 100µL valves compared to the 50µL valves used in this
work. Higher metering volumes were shown to lead to bigger droplets and might
therefore allow, due to higher mass conservation of big droplets, to better maintain
the droplets velocity throughout their trajectory. This could contribute to explain
the high velocity profiles obtained by Clark a few centimetres downstream of the
nozzle orifice (Newman et al., 1982).
However, the 35 m·s−1 velocity reported by Clark at a distance of 5 cm from the
nozzle orifice remains higher than velocities reported in sprays studies at similar
distances from the nozzle orifice. For example, Crosland et al found velocities of
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20 m·s−1 to 30 m·s−1 when measuring a HFA134a formulation at a distance of 1.5 cm
from the extremity of the mouthpiece corresponding to a distance of approximately
4 cm from the nozzle orifice (Crosland et al., 2009).
Hochrainer et al (2005) also found considerably lower velocities than Clark when
testing formulations with similar vapour pressures. While Clark reports a velocity
of approximately 18 m·s−1 at a distance of 10 cm from the nozzle orifice, Hochrainer
found velocities of 5.6 m·s−1 to 6.3 m·s−1 for varying CFC-based formulations at the
same location (Hochrainer et al., 2005).
Although CFC-based formulations have been shown to have a velocity approxi-
mately twice higher compared to their equivalent HFA-based formulations at dis-
tances of 10 cm from the nozzle, this still does not explain the much higher velocity
values found by Clark compared to authors who also measured CFC-based for-
mulations (Hochrainer et al., 2005). The experimental method of Clark was not
sufficiently detailed to enable any conclusion to be drawn (Clark, 1996).
As PIV measurements are thought to measure the velocity of liquid droplets, the
velocities measured using PIV should correspond to the velocity of the liquid phase
calculated in the simulation in Chapter 3 using a similar nozzle orifice diameter.
The 17 m·s−1 maximum liquid phase velocity calculated at the nozzle orifice in
Chapter 3 is in line with the 12 m·s−1 maximum velocity measured approximately
25 mm downstream of the nozzle orifice using PIV.
Influence of formulation design on spray characteristics
The difference of velocities observed in Figure 5.5 between the two formulations
can be explained by the higher vapour pressure of the pure propellant formulation
compared to the HPEF formulation.
The velocities follow the same trend as the PDA velocity measurements of Liu et al
268
Chapter 5
(2012) at a distance of 2 cm from the end of the mouthpiece (approximately 5 cm
from the nozzle orifice) although they are slightly lower in magnitude (Dunbar,
1996). When measuring several suspension formulations containing only drug and
HFA134a whose vapour pressures should be similar to the pure HFA134a formu-
lations measured in Figure 5.5, Liu et al found velocities in the range of 10 m·s−1
to 20 m·s−1 compared to the 8 m·s−1 velocity obtained with the pure HFA134a
formulation at the same location in the present work.
The formulation most similar to HPEF that Liu et al studied is Proventil HFA
which contains HFA134a, ethanol and oleic acid. When measuring the velocity of
a Proventil spray, Liu et al found a velocity of 6.5 m·s−1 compared to the 4 m·s−1
velocity obtained with the HPEF formulation at the same location in the present
work.
The HFA134a formulation which has a higher vapour than the HPEF formulation,
has the highest turbulence level. This can be explained by the fact that a higher
vapour pressure leads to a higher velocity. For both formulations, the turbulence
level decreased as the distance from the nozzle orifice increased. This can be
explained by the fact that at longer distances from the nozzle orifice, the spray
velocity decreases, leading to a lower level of turbulence.
Influence of actuating forces on spray velocity
In Chapter 4, the manual actuations provided by a “healthy” female user led to
an increased throat deposition compared to two automated actuations forces of
varying magnitudes. No effect was reported between the automated actuation
forces of varying magnitudes. In the PIV experiments, the manual actuation could




In this chapter, the magnitude of the three automated actuation forces had no
discernible effect on the spray velocity. This might be due to the fact that although
the magnitude of actuating forces could theoretically have an effect on the valve
opening rate, this effect was not significant in reality or too small to be detected
in the PIV measurements.
The velocities for the three actuation forces ranged from 12 m·s−1 to 4 m·s−1 at
35 mm and 90 mm from the nozzle orifice respectively. As a typical flow rate rec-
ommended for pMDI is 30 L·min−1 which corresponds to a velocity of approximately
2 m·s−1 at the oropharynx, the flow rate might have an effect on the velocity of
the particles when the latter reach the throat (Keller, 1999). The flow rate did
not have an effect in Crosland’s work captured at the extremity of the mouthpiece
where the spray velocity was significantly higher than the velocity of air through
the trachea (Crosland et al., 2009). However, it might have an effect nearer the
patient’s throat where the spray and user airflow velocities are comparable.
Influence of delays on spray velocity
The peak velocity observed 50 ms after the onset of actuation in Figures 5.9 and 5.10
could be due to a change of flow regime during the aerosolisation process. At the
nozzle orifice, the spray is first critical due to the high pressure gradient between
the metering chamber and atmospheric pressure. After this initial velocity peak,
the flow becomes subcritical as a higher fraction of liquid builds up in the expansion
chamber. As the flow starts evaporating in the expansion chamber, the pressure
builds up, leading to a critical flow and higher spray velocity (Wigley et al., 2002).
After it reaches its maximal pressure, the pressure in the expansion chamber de-




The 50 ms delay could therefore represent the time needed for the flow to reach a
sonic state for a HFA134a spray. The peak velocity delay would depend on several
factors such as the expansion chamber volume, the nozzle to valve orifice ratio
and the vapour pressure of the formulation. This finding is in agreement with
Crosland’s PIV measurements in which a peak velocity was found approximately
60 ms after the actuation of the canister (Crosland et al., 2009).
In their computational model and PDA work on HFA134a-based formulations
shown in Figure 3.22 in Chapter 3, Wigley et al (2002) found velocity peaks 50 ms
and 70 ms after the actuation respectively. However, the magnitude of the velocity
was much higher in their work. This could be due to the fact that they measured
the velocity at the nozzle orifice whereas the velocity in the current study was
measured 35 mm downstream of the nozzle orifice.
Lee et al (1991) also found a peak velocity approximately 70 ms after the actuation
in their time-resolved LDA measurements of a CFC-11 and CFC-12 mixture.
According to Dunbar’s PDA work, a first velocity peak occurs upon actuation of
the canister and a second peak occurs approximately 0.07 s later. Although the
first peak was not identified in this work, the timing of the peak observed seem to
be in line with the second peak described by Dunbar (Dunbar, 1996).
5.7.2 Sympatec R© measurements of sprays issued from pMDIs
Effect of formulation design on particle size distribution
The results shown in Table 5.2 are in line with the results of Pu et al (2011) obtained
with a Helos from Sympatec R©. When measuring the size of particles issued from a
suspension formulation containing API of median diameter 1.77µm, they obtained




In their Sympatec Inhaler 2000 R© measurements, Jones et al. (2005) found that
approximately 78% of particles had a diameter ≤6.4µm when measuring a suspen-
sion formulation containing FP with an initial D50 of 4.07±0.29µm. In this work
the micronised FP had a D50 of 2.76±0.03µm and 88% of particles had a diameter
≤5µm. The higher percentage of fine particles in this work can be explained by
the lower size of FP particles used compared to the size of FP particles used in
Jones’s work. It also shows that aggregation of the drug particles in the formula-
tion occurred only to an insignificant level, which might be due to the extremely
low concentration of FP in the formulation.
The lower D50 of the HEF formulation compared to the suspension formulation
could be due to the fact that the HEF formulation is a solution formulation in
which drug particles are completely dissolved contrary to suspension formulations
in which drug particles stay intact and might therefore contribute to higher D50
values. It could also be due to the use of mouthpieces of different nozzle orifice
diameters for each formulation. The HEF formulation was aerosolised using the
Alvesco R© mouthpiece which has a nozzle orifice diameter of 0.20 mm in comparison
with the Flixotide R© mouthpiece used to aerosolise the suspension mouthpiece which
has a nozzle orifice of 0.50 mm and might therefore have led to the aerosolisation
of coarser droplets.
The HPEF had a significantly higher D50 than the HEF formulation. This is to
be expected as the HPEF formulation contained 5% w/w of PEG400 which can be
used to control the size of particles issued from pMDIs by increasing the viscosity
and reducing the volatility of formulations (Ash and Ash, 2004).
The low uniformity index of the HPEF formulation compared to the HF formulation
observed in Table 5.3 could be due to the fact that the HF formulation only contains
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drug particles and propellant so that once the propellant has evaporated, the size of
the droplets would be relatively uniform whereas the HPEF formulations contains
components such as ethanol and PEG400. As those components have varying rates
of evaporation, the Sympatec R© might measure different particles size, leading to a
less uniform particle size distribution (Stein and Myrdal, 2006).
Effect of airflow rate on the particle size distribution of the HEF and
HPEF formulations
The aerosolisation of smaller droplets at the higher flow rate can be explained by the
fact that it might increase the level of turbulence in the spray. This would in turn
increase the amount of energy available for evaporative mass transfer, resulting into
finer particles. The evaporation of the droplets to form fine particles could explain
the lower uniformity index observed at the higher flow rate. This phenomenon was
negligible for the HPEF formulation; as HPEF droplets contain the viscous and
non-volatile component PEG400, they might not be able to aerosolise in smaller
droplets, even at an increased flow rate.
The effect of the flow rate on the particle size distribution is in agreement with
Jones’s findings. However, the increase in the D50 values obtained at the low flow
rate in Jones’s work was less significant than in the present work. This might be
due to the fact that the difference between the high and low flow rates tested in
Jones’ work was only approximately 10 L·min−1 compared to 30 L·min−1 in this
work.
Effect of actuation force on the particle size distribution of the HEF
formulation
The fact that the manual actuations provided by a “healthy” female user led to
the aerosolisation of coarser particles compared to the automated actuations is
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similar to the NGI findings in Chapter 4. Manual and automated actuations have
different characteristics such as the high velocity of the automated piston believed
to lead to a faster opening of the metering valve. It was decided to investigate
the characteristics of the manual and automated actuations in order to understand
what might cause the differences in the aerosolisation process observed throughout
this work.
Comparison of the NGI and the Sympatec R© results
The D50 of 3.79µm obtained with the Sympatec
R© for the HF formulation was
higher than the MMAD of 2.09µm obtained with the NGI in Chapter 4.
The D50 of 2.49µm obtained with the Sympatec
R© for the HEF formulation was
also higher than the MMAD of 0.74µm obtained with the NGI.
The D50 of 4.14µm obtained with the Sympatec
R© was however in line with the
MMAD value of 4.16µm obtained for the HPEF formulation with the NGI.
The Sympatec R© overestimated the size of the particles issued from the two most
evaporative formulations. This could be due to the fact that the Sympatec R© mea-
sures the size of the entire droplets including volatile and semi-volatile compo-
nents, whereas NGIs only assess the residual size of the particle. As a result,
the Sympatec R© measured the particles before the volatile components had time to
fully evaporate. On the contrary, due to the presence of the viscous PEG400 in
the HPEF formulation, HPEF particles might not further evaporate downstream
of the Sympatec R© measurement zone and might therefore retain their large size
when being measured with the NGI.
To limit the overestimation of particles size in the Sympatec R© measurements, the
distance between the nozzle orifice and the measurement zone could be increased.
Sympatec R© has developed a simulation throat that can be placed between the
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mouthpiece and the laser measurement zone. This would allow to measure the
particle size distribution of a formulation as it enters the throat which would provide
measurements comparable to the NGI.
The Malvern Spraytec R© is able to measure sprays at different distances from the
nozzle orifice. As the aim of this work was to understand the evolution of particles
characteristics from the nozzle orifice to the throat of a potential user, the Malvern
Spraytec R© was used in the next series of experiments.
5.7.3 Malvern Spraytec R© measurements of sprays issued
from pMDIs
Particle size measurements at 4 cm and 7.5 cm from the nozzle orifice
In Stein and Myrdal’s work, the size of the initial droplets was calculated based on
the residual or intermediate droplets size with the help of Equations (5.5) and (5.6)














where MMDin, MMDinter and MMDre are respectively the initial, intermediate
and residual mass median diameters (MMDs) in µm, ρin, ρinter and ρre are respec-
tively the densities of initial, intermediate and residual droplets in kg·m−3 and CNV
and Ccosol are respectively the percentages by weight of non-volatiles and cosolvents
in the formulation.
As Equations (5.5) and (5.6) only take into account the rate of evaporation due
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to the evaporative nature of a component and not the evaporation due to the
turbulence of the flow, they represent only an approximation of initial droplet
sizes. The aim of this work was to provide empirical data on the spray at several
locations in its trajectory, which is the reason why the Malvern Spraytec R© was
used.
In the present work, the two solution formulations were tested using the same
mouthpiece, which makes a direct comparison of those formulations possible. It
can be seen in Table 5.4 that the HPEF formulation led to significantly higher D50
values than the HEF formulation for all experiments (p<0.05). This agrees with
Equation (5.6), developed by Stein et al, which shows that the intermediate size
of droplets increases at increasing non-volatiles concentrations (Stein and Myrdal,
2006), (Stein et al., 2012).
The data in Table 5.4 were measured at a distance of 4 cm from the nozzle orifice
and might not all be relevant due to their high standard deviations. This is in
agreement with the findings of Moren and Hathaway who measured the particle
size distribution of a commercial pMDI using laser holographic microscopy 3 cm
downstream from the nozzle orifice (Dunbar, 1996). They measured a D50 of 36µm
and observed a large standard deviation. They attributed the large range of particle
sizes to the fact that at a small distance from the nozzle orifice, some droplets
containing multiple drug particles as well as large quantities of propellant and
surfactant might have a significant effect on the D50.
The high standard deviations in Table 5.4 could be attributed to the same reason.
This would be particularly the case for the HF formulation being issued from
the Flixotide R© mouthpiece which has a higher nozzle orifice diameter than the
Alvesco R© mouthpiece used for the HEF and HPEF formulations and could therefore
lead to the aerosolisation of bigger droplets near the nozzle orifice. This could
276
Chapter 5
explain the significantly higher D90 of the HF formulation compared to the D90 of
both solution formulations. This finding would tend to show that the diameter of
the nozzle orifice has an impact on the initial particle size distribution of aerosols.
Errors in the D90 might also be due the variation of the refractive index in the
aerosol cloud caused by the evaporation of the liquid phase, which erratically alters
the path of the laser beams, particularly for measurements close to the nozzle
orifice. This effect would be particularly pronounced for the HF formulation. As
it is the most volatile formulation, it could have undergone a more intense flashing
at the nozzle orifice during primary atomisation and a more intense evaporation
during the secondary atomisation when the particles were measured.
This in line with the findings of Clark (1996) who observed beam steering effects
and therefore did not use particle sizing results obtained closer than 5 cm from the
nozzle orifice when using a Malvern 2600 laser diffraction sizer with a 100 mm focal
length lens. Clark stated that measurements with a Malvern 2600 should only be
conducted 8 cm to 24 cm from the nozzle orifice. It has been reported that the
Malvern 2600 can give accurate measurements at transmissions of 2.5% compared
to the Malvern Spraytec R© which is said to be accurate at transmissions as low as
2%. This means that the Spraytec R© can analyse sprays of higher concentration
and can therefore measure particles closer to the nozzle orifice than the Malvern
2600 (Strakey, 2003).
Other errors could be due to the presence of irregular-shaped particles such as
shear ribbons. The latter are droplets created during primary atomisation when
the liquid phase covering the walls of the expansion chamber and nozzle orifice
breaks up in ligaments before being aerosolised in droplets (Versteeg and Hargrave,
2002). The ligaments and ribbons can cause deviations in the scattering profiles
recorded in the region near the nozzle orifice and may lead to errors in particle size
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distributions (Haynes et al., 2004).
The high variability of the measurements might also be caused by the high con-
centration of droplets so close from the nozzle orifice, which might have prevented
accurate laser measurements (Wigley et al., 2002). For this reason, the next set of
measurements was realised at a distance of 7.5 cm from the nozzle orifice.
Table 5.4 and 5.5 show that particles measured 7.5 cm away from the nozzle orifice
tend to be smaller than particles measured 4 cm from the nozzle orifice. This is
expected, as the sprays should have evaporated more completely when measured
further from the nozzle orifice. Liu et al (2012) observed a similar trend when
measuring pMDIs sprays using PDA at 3 cm and 6 cm from the nozzle orifice.
For all 9 pMDIs sprays measured, the droplets were smaller when the spray was
measured at a distance of 6 cm from the nozzle orifice (Liu et al., 2012).
Those results are also in line with the data obtained by Haynes et al (2004) with
the Malvern Spraytec R©. It was found that aerosols measured using a USP throat
combined with a 20 cm extension contained smaller droplets compared to aerosols
measured using solely a USP throat. Haynes et al attributed this change to a more
complete evaporation of the spray when the extension was used.
The present work differed from Haynes et al ’s work as the evolution of the droplets
size from the extremity of the mouthpiece to a typical back of the throat distance
was investigated. The size of particles potentially entering the throat of a user was
therefore determined.
At 7.5 cm from the nozzle orifice, the D50 of the HEF solution at 20
◦C was
7.83±0.19µm when the pMDI was actuated manually. Haynes et al found a D50
of 3.64±0.12µm when measuring a placebo formulation with HFA134a and 15%
ethanol. The lower values of Haynes et al might be due to the fact that when con-
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ducting the measurements, they used a USP throat in which the biggest particles
impacted prior the Malvern Spraytec R© measurements. In this work, however, the
particles were measured directly after exiting the pMDI. The difference in the D50
agrees with the Malvern Mastersizer results of Ding et al (2000) who found that
the size of particles issued from various CFC-based pMDI sprays decreased when
using a USP throat compared to the measurements without a USP throat (Haynes
et al., 2004).
Clark (1996) was the first to measure experimentally the size of particles issued from
pMDIs. After modifying a metering valve to obtain continuous sprays, he measured
the size of particles issued from those sprays using a Malvern 2600 and found D50
values of 6.5µm (for a pure CFC-12 formulation) and 9µm (for a formulation
containing 2% surfactant) at a distance of approximately 8 cm from the nozzle
orifice. The present results follow the same trend as Clark’s results as at a distance
of 7.5 cm from the nozzle orifice, the HF formulation containing only drug and
propellant had a D50 of 2.71±0.22µm compared to a D50 of 9.74± 0.29µm for
the HPEF formulation containing 5% of PEG400. The higher D50 of the HPEF
formulation compared to the formulation with the highest surfactant concentration
in Clark’s work might be explained by the fact that the formulation in the present
work contains 5% of non-volatiles compared to 2% in Clark’s work. The lower D50
obtained for the HF formulation could be due to the fact that Clark used CFC-12
known to issue bigger particles than HFA134a (Smyth, 2003). It could also be due
to the smaller nozzle orifice diameter used in the present work compared to Clark’s
work (i.e. 0.50 mm compared to 0.60 mm) (Clark, 1996).
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Effect of actuation force on the particle size distribution of the three
formulations
Table 5.5 showed that the change in the automated actuation forces did not affect
the size of the particles. However, it can be noticed that at the higher actuation
force, the standard deviation was smaller. This might be because the canister
was not always properly actuated at 30 N as it represents the minimum force that
could actuate the canister. This would mean that the deposition process was more
repeatable at 50 N compared to 30 N. This was however not the case in Chapter 4, in
which both automated actuations were associated with high standard deviations.
However, the measurements are slightly different in this chapter; the NGI, an
impaction device, tests the size as well as the velocity of the particles whereas the
Malvern Spraytec R© measures only particles size. This could mean that although
the velocity was constant at both forces (resulting in similar deposition in the NGI),
the size of the particles was less variable at the highest actuation force. This would
agree with the PIV measurements in which a constant velocity was observed at the
three actuation forces tested.
The manual actuation provided by a “healthy” female user led to the aerosolisation
of coarser droplets compared to both automated actuations although the type of
actuation had no significant effect on the suspension formulation (p>0.05). This is
in agreement with the results obtained with the NGI shown in Figures 4.9 and 4.10
in Chapter 4, and with the Sympatec R© in Figure 5.15.
The characteristics of the actuation stroke are believed to be responsible for the
aerosolisation of sprays with different particle size distributions. This finding is of
interest as it suggests that by actuating the spray in a different manner, the emitted
particles could be smaller and the throat deposition could be decreased. Different
types of automated and manual actuations should be analysed in order to identify
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what led to the difference between the manual and the automated actuations.
Effect of temperature on the particle size distribution of the three for-
mulations
The fact that the higher temperature led to a decrease of the particle sizes of both
solution formulations is in line with the results of Polli et al (1969) that were shown
in Chapter 3 and with the results of Haynes et al (2004).
Haynes and coworkers (2004) investigated the effects of temperature and non-
volatiles concentration on the residual size of the droplets using a Malvern Spraytec R©.
They found that equilibrating the Qvar 50 and Proventil HFA pMDIs at 40 ◦C
and 55 ◦C led to a reduction of the D50 compared to when the formulations were
maintained at room temperature.
As Haynes et al (2004) measured the effect of temperature on the size of particles
which reached past a throat extension, they could not assess the potential effect of
temperature on throat deposition itself. In this chapter, the effect of temperature
on the size of particles was studied at the supposed throat location. As a result,
the present work might be more informative on the potential amount of drug that
could deposit in the throat.
The observed effect of temperature on particles size is also in line with the work of
Pu et al (2011) using a Sympatec R© discussed earlier in this chapter. They showed
that the size of the particles issued from a pMDI decreased as the temperature
increased from 15 ◦C to 30 ◦C when measured at 8 cm and 12 cm from the extremity
of the mouthpiece (Pu et al., 2011).
The change in temperature had no significant effect on the suspension formulation.
This might be due to the fact that the HF, as the most volatile formulation, had
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already completely evaporated at 7.5 cm from the nozzle orifice. The remaining
particles measured would correspond to the micronised drug particles; the size of
which is determined by the primary particles in the formulation and would therefore
not be affected by temperature changes.
The 2.71±0.22µm D50 of the suspension formulation was in the same range as
the value of 2.76±0.03µm obtained when the FP particles were measured by laser
diffraction as described in Section 4.2.2 in Chapter 4 (Jaffari et al., 2013). This
would mean that at 7.5 cm from the nozzle orifice, the HFA134a in the suspension
formulation had completely evaporated and the aerosol was composed solely of FP
particles.
However, the initial MMD might be affected by temperature change at the nozzle
orifice where the formulation has not yet evaporated. This was shown in the simu-
lation which calculated a MMD of 85µm at 293 K compared with 45µm at 313 K
at the nozzle orifice.
Duration of the sprays issued from the three formulations
The short duration of the suspension formulation compared to the two solution
formulations in Table 5.6 can be explained by the nozzle orifice diameter of the
Flixotide R© mouthpiece. As it is more than twice the size of the nozzle orifice di-
ameter of the Alvesco R© mouthpiece used for the two solution formulations, the
suspension formulation is discharged significantly faster than the other two formu-
lations.
The simulation discharge time shown in Figure 3.4 is longer compared to the dis-
charge of the suspension formulation obtained with the Malvern Spraytec R©. This
might be due to the fact that the metering valve had a volume of 63µL in the
simulation compared to 50µL in the present chapter.
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However, it is also a possibility that the Malvern Spraytec R© might not be able
to record all droplets from the most evaporative HF formulation, as they would
evaporate faster than the two formulations containing semi-volatile or non-volatile
components. This could also explain the difference in durations observed between
the simulation developed in Chapter 3 and the durations shown in Table 5.6. The
simulation duration of approximately 0.17 s is more in line with the duration of the
two less evaporative HEF and HPEF formulations.
Dhand et al (1988) measured the duration of the sprays issued from four com-
mercially available CFC-based pMDIs using high-speed photography. They found
that the sprays lasted between 0.065 s and 0.095 s depending on the pMDI tested
(Dunbar, 1996).
These short durations could be due to the fact that the camera used by Dhand et al
(1988) might not be able to perceive the particles towards the end of the aerosoli-
sation process at which point the aerosol would be almost completely evaporated.
In comparison, the plumes measured in the current work corresponded to the time
during which the sprays obscure more than 2% of the laser intensity.
Hochrainer et al (2005) found spray durations in the range of 0.15 s to 0.36 s de-
pending on the type of pMDI studied using a video recording method. Gabrio found
spray durations of between 0.16 s and 0.51 s when investigating several marketed
pMDIs using a quick-response thermocouple (Gabrio et al., 1999).
As the HPEF formulation is less evaporative than the HEF formulation, it could
have obscured the laser path for a longer period, contributing to the significantly
longer duration of the HPEF spray compared to the HEF spray (p<0.05). As the
HEF formulation results in the aerosolisation of smaller droplets than the HPEF
formulation and that smaller droplets do not always scatter a sufficient amount
of light to be recognised as a valid signal, the HEF spray might not be properly
283
Chapter 5
measured towards the end of the aerosolisation when particles reach small sizes
(Liu et al., 2012). This could also contribute to the smaller duration of the HEF
formulation compared to the HPEF formulation.
5.7.4 Comparison of the measurements using the Sympatec R©,
Malvern Spraytec R© and the Next Generation Im-
pactor
Malvern Spraytec R© is believed to overestimate the particle size distribution of
HFA-based pMDIs (Haynes et al., 2004). Haynes et al (2004) found that for a
given formulation, the D50 (obtained from the Malvern Spraytec
R©) was significantly
larger than the MMAD (obtained from the NGI).
This might be due to the fact that during the laser measurements, components less
volatile than propellants such as ethanol are still evaporating (their evaporation
could last approximately 2 s as suggested by Haynes et al (2004)). This results in
the measurements of droplets bigger than the residual droplets measured with the
NGI. This is in agreement with the results of this work. Table 5.7 compares the
data obtained with the NGI in Chapter 4 with the data obtained with the Malvern




Mean ± SD Mean ±SD Mean± SD
Sympatec R© - D50 (µm) 3.78±0.14 2.49±0.13 4.14±0.10
30 L·min−1 airflow, no throat
Malvern Spraytec R© - D50 (µm) 2.71±0.22 7.83±0.19 9.74±0.29
No airflow, no throat
NGI - MMAD (µm)
2.09±0.07 1.29±0.22 4.16±0.19
30 L·min−1 airflow, throat
Table 5.7: Summary of the D50 and MMAD obtained for the HF, HEF and HPEF
formulations with manually actuated pMDIs - HF formulation aerosolised using
the Flixotide R© mouthpiece, HEF and HPEF formulations aerosolised using the
Alvesco R© mouthpiece. Mean of n≥3 determinations for each data.
The differences shown in Table 5.7 between the MMAD and the D50 values have
also been reported by Smyth and Hickey (2003) when they compared D50 values
obtained from a Malvern 2600 instrument with the MMAD values obtained with
an ACI. They found that the MMAD values were several factors lower than the
D50 values. This might be explained by the fact that they did not insert a throat
between the nozzle orifice and the measurement zone when using the Malvern 2600.
As a result the biggest particles in the spray were included in the Malvern particle
size distribution.
When using a NGI, the biggest particles tend to deposit in the throat and this
phenomenon is accentuated by the 30 L·min−1 entraining flow drawn through the
apparatus. The particles depositing in the throat are not included in the calcula-
tion of the MMAD. The biggest particles than can enter the NGI apparatus and
subsequently be included in the MMAD calculation have a diameter of 11.72µm
which corresponds to the cut-off diameter of the first stage of the NGI at 30 L·min−1
flow rate.
Although, the MMAD and the D50 obtained from the Malvern Spraytec
R© were
comparable for the suspension formulation, the D50 was higher than the MMAD
for both solution formulations. This could be due to the fact that at 7.5 cm away
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from the nozzle orifice, which corresponds approximately to the distance to a user’s
throat, the particles issued from the less volatile formulations (both solution for-
mulations) were not completely evaporated and thus had not yet reached their
residual size.
The high particle size of both solution formulations obtained with the Malvern
Spraytec R© at 7.5 cm from the nozzle orifice could also be observed in the NGI
experiments by considering the throat deposition associated with each formulation.
The high particle size distribution and high momentum of particles issued from both
solution formulations before entering the NGI was illustrated in Chapter 4 by their
high throat deposition (77.04±3.17% for the HEF formulation and 86.38±1.02%
for the HPEF formulation as shown in Table 4.8 in Chapter 4).
On the contrary, the particles issued from the suspension formulation were sus-
pected to have completely evaporated and to have reached their residual size upon
entering the laser measurement zone due to their higher vapour pressure. This is
illustrated by the comparatively lower throat deposition of the HF formulation ob-
served in the NGI experiments in Chapter 4 (38.69±2.50%), and by the resultant
observation that the HF formulation had comparable MMAD and D50 values from
the Malvern Spraytec R©.
A closer agreement between those two techniques might be achieved if the evapora-
tion of all volatile components of the spray is complete by the time the spray enters
the laser measurement zone (Haynes et al., 2004). However, the most crucial ex-
perimental set up to modify in order to obtain comparable sizes across the different
techniques would be the use of a throat similar to the one used in the NGI measure-
ments in both laser diffraction methods. The laser measurements would therefore
only include the particles exiting the throat in the particle size distribution of the
aerosol, as the NGI does.
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Table 5.7 shows that the results obtained with the Sympatec R© and the NGI were
comparable. This could be due to the fact that a 30 L·min−1 flow rate was used
in both methods whereas it was not used in the Malvern Spraytec R©. As seen
in Figure 5.11 in this chapter, a high flow rate could contribute to a more intense
evaporation of particles. This is explained by the fact that a high flow rate provides
a greater energy to the aerosol to evaporate during the secondary atomisation of the
formulation. The presence of a flow rate in both the Sympatec R© and the NGI could
therefore contribute to the smaller particles sizes measured with those apparatus.
The highest D50 value measured by the Sympatec
R© for the suspension formulation
might be due to the fact that it was measured closer to the nozzle orifice (6 cm)
than in both the NGI and Malvern Spraytec R© measurements. The suspension
formulation was aerosolised with the Flixotide R© mouthpiece which, with its large
orifice diameter, could increase the initial particle size distribution of a formulation
close to the nozzle orifice.
The oversizing of the particles using the laser diffraction methods might also be
due to the fact that large particles always scatter a sufficient amount of light. On
the contrary, smaller droplets might not always scatter a sufficient amount of light
to be recognised as valid signals. This might result in a fraction of the smaller
droplets in the spray not being taken into account in the assessment of the particle
size distribution (Liu et al., 2012).
Due to fundamental differences in the measuring principles behind each technique,
it is not possible to directly compare the sizes of particles measured with the
different methods. However, the particle sizes determined using all techniques
are relevant and give different information which can be combined to assess the
characteristics of the formulations over their entire aerosolisation process. The
NGI provides information on the characteristics of the spray most likely to enter
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the respiratory system based on both size and velocity of particles whereas the
laser methods can give information on the size and velocity of particles at different
times and locations in the aerosolisation process.
5.8 Piston behaviour in manual and automated
actuation
In order to understand what caused the different aerosolisation patterns between
the manual and automated actuations in the NGI, Malvern R© and Sympatec R© mea-
surements, the velocity of the canister when actuated with the pneumatic piston
and manually was studied throughout the actuation event. As in Chapter 3, the
displacement of the pneumatic piston was measured using a linear variable differ-
ential transformer (LVDT) whose output was captured on a computer by means of
a USB 6211 analog to digital converter (National Instrument, Berkshiron the spray
as for all e, UK) at a sampling frequency of 1 kHz. The distance travelled by the
stem when it was fully actuated was found to be approximately 3.5 mm which is in
the same order of magnitude as the value of 5 mm found by Pu et al (2011) when
using the Sprayer device from Sympatec R© in their experiments. The actuations





























’Healthy’ female adult actuation
Figure 5.16: Displacement of the canister as a function of time during an automated
actuation and a “healthy” female adult actuation.
Figure 5.16 shows that the automated actuation led to a faster displacement of the
canister, translating into a faster opening of the metering valve compared to the
actuation provided by the “healthy” adult female user. In Chapter 3, the period
during which the valve remains fully open was assumed not to have an effect on the
spray as for all actuations, the valve orifice remained open for a longer time than
the entire aerosolisation duration. This is also the case in Figure 5.16 which shows
that the automated actuation and the actuation provided by the female user have
comparable durations that are both longer than the discharge of the formulation.
The velocity of the canister during its actuation was calculated for the 30 N, 50 N




30 N actuation 50 N actuation female inexperienced
adult* female adult*
Canister velocity
0.17 0.28 0.023 0.0018
(m·s−1)
Table 5.8: Canister velocity during the 30 N, 50 N and manual actuations. Mean of
n≥3 determinations for each actuation type. *both adults were part of the research
team.
The automated actuation using a Sprayer device from Sympatec R© in Pu et al ’s
work had a maximum velocity of 0.125 m·s−1 which is lower than the velocity of the
automated actuations in this work but much higher than the velocity of both types
of manual actuations (Pu et al., 2011). In Liu et al ’s work, the automated actuation
was provided using the SprayVIEW MDx automated actuator (Proveris Scientific
Corporation, Marlborough, MA). The piston had a velocity of 0.050 m·s−1, which
is comparable, although still approximately twice the velocity of the actuation
provided by the “healthy” female adult in the present work (Liu et al., 2012).
Table 5.8 shows that both manual actuations led to significantly slower displace-
ments of the canister than the 30 N and 50 N actuations, causing a slower opening
of the valve orifice area (p<0.05). The difference was less pronounced between
the two automated actuations although the 50 N force led to a significantly faster
opening of the valve orifice area than the 30 N force (p<0.05).
This difference in canister velocity could be due to the fact that the component of
the force along the axis of the canister might change during the manual actuation
process. On the contrary, the automated actuations were provided by the pneu-
matic piston which was perfectly aligned with the axis of the canister during the
entire duration of the actuation.
The faster opening of the pMDI valve with the automated actuations could lead to
a greater discharge from the metering chamber into the expansion chamber earlier
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in the aerosolisation process. As a result, the pressure build up in the expansion
chamber might be greater, leading to a more intense flashing at the nozzle orifice
and to the aerosolisation of smaller particles. This could be the reason for the lower
throat deposition and smaller particle size observed with the automated actuations
in the experiments throughout this work. Equation (2.53) presented in Chapter 2,
indeed showed an inversely proportional relationship between the pressure build up
in the expansion chamber and the size of the aerosolised droplets (Dunbar, 1996).
Those experimental results are in line with the simulation results in which a higher
valve opening rate led to the formation of smaller droplets at the nozzle orifice due
to a higher pressure build up in the expansion chamber.
5.9 Summary
This chapter investigated the velocity and size of droplets issued from pMDIs when
modifying several parameters such as formulation design, mouthpiece design, ac-
tuation force and temperature.
When comparing two formulations, the PIV measurements showed that the initial
velocity was higher for the formulation with the highest vapour pressure.
The Malvern Spraytec R© showed that the formulations with the lowest vapour pres-
sures remained suspended in the air for a longer time.
Changes in formulations influenced the particle size distributions in measurements
obtained with both laser diffraction instruments. The particle size distribution of
the three formulations obtained using the Malvern Spraytec R© and the Sympatec R©
were in the same order of magnitude as the NGI results obtained in Chapter 4




The Malvern Spraytec R© measurements provided evidence that smaller nozzle ori-
fices diameters lead to longer spray durations. This finding is of interest as a longer
spray duration could help certain pMDI users synchronising the actuation of their
device with their inhalation.
The effect of temperature on the size of the droplets was assessed using the Malvern
Spraytec R© and agrees with the simulation results in Chapter 3. The fact that
higher temperatures might lead to smaller droplets being aerosolised is of foremost
importance as users in different environments might not all benefit from the same
device efficiency.
Measurements with both the Malvern Spraytec R© and the Sympatec R© showed that
the type of actuation (manual versus automated) had an effect on the particle
size distribution of the aerosols confirming the simulation and NGI results. This
is explained by the fact that the valve opening rate was lower with the manual
actuations compared with the automated actuations.
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Summary of thesis and conclusion
6.1 Findings of the present investigation
This thesis investigated the aerosolisation process of sprays issued from pMDIs.
The initial, intermediate and residual properties of the droplets were determined
using a simulation and several experimental methods. The aim of the thesis was
to uncover factors that might influence the efficiency of pMDIs by studying their
effect on the characteristics of the aerosolised sprays.
Although it is known that a significant fraction of the geriatric population has
trouble to generate the minimum force to actuate their pMDIs correctly (Armitage
and Williams, 1988), the effect of the actuation forces on device efficiency has to
the best knowledge of the author received little study. It was therefore decided
to investigate their effects on the valve orifice opening rate and ultimately on the
properties of the aerosolised spray.
It was found that a “healthy” female adult actuation was associated with a fast
displacement of the canister. This translated in a significantly faster opening rate
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of the valve orifice (approximately ten times higher) than when a “weak” and
inexperienced female research team member actuated the canister.
It was found that automated actuation forces led to a valve orifice opening rate
significantly higher than the valve opening rate of the “healthy” female user. This
is relevant as in some studies using automated actuations, the velocity of the can-
ister was significantly higher than for both “healthy” and “weak” female adults.
When conducting studies using automated actuations, scientists should be cautious
to use canister displacement velocities that match those of real pMDI users. Al-
though apparatus such as the SprayVIEW MDx automated actuator and Sprayer
device from Sympatec R© allowing modifications of the actuation characteristics,
have been used in works such as Liu et al ’s and Pu et al ’s respectively, both works
used highly different actuation profiles. This suggests a standardised method to
optimally simulate user actuation has yet to be developed. A one-dimensional
model was developed to study the properties of the spray at the nozzle orifice
where experimental measurements are difficult to conduct. The exit velocity and
mass median diameter (MMD) of the spray, the two factors most affecting the
efficiency of pMDIs, were studied. When implementing the valve opening rate of
a “healthy” female in the simulation, lower MMD values were obtained than at
the lower rate of valve opening of the “weak” and inexperienced female user. This
finding is critical as pMDI users with a lower actuation force such as geriatric or
paediatric populations as well as users affected by arthritis might aerosolise sprays
formed of bigger particles than healthy adults users, increasing drug deposition on
the throat and therefore reducing their device efficiency.
An increase in temperature led to the formation of sprays of higher velocities with
lower MMD values at the nozzle orifice and to a lower residual mass of the formula-
tion in the metering chamber. The calculation of residual mass after each actuation
was of interest as they might prevent pMDI users from getting accurate doses of
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API at the target locations. This effect of temperature on the spray may be an
issue as patients using their pMDIs in varying environments or in environments
with high differences between outdoor and indoor temperatures might not benefit
from the same device efficiency.
The computational model was modified in order to simulate the discharge of sus-
pension formulations. The results were in line with the literature, which suggests
that the simulation could be used to investigate suspension formulations.
In all the results obtained from the simulation, the main factor affecting the size
and velocity of the droplets was the expansion chamber pressure which could be
modified by manipulating the nozzle to valve orifice diameter ratio. Lower nozzle
to valve orifice diameter ratios increased the expansion chamber pressure, therefore
decreased the MMD values and increased the exit velocity of the spray. This is
relevant as devices with varying valve to nozzle orifice diameter ratios could be
designed to fit the needs of different types of users and environments in order to
optimise the performance of pMDIs.
In this thesis, the effect of certain parameters on the spray characteristics could
be assessed on the spray’s entire trajectory using several experimental techniques.
Laser techniques were used to measure the intermediate properties of the droplets
while the NGI determined the residual size of the droplets. Both methods are
important as they give information on the size the drug particles might have upon
reaching the throat and the target site.
The effect of actuation forces reported in the simulation was also observed in the
NGI experiments in which the automated actuations reduced the throat deposition
compared to the manual actuation of the “healthy” female. This might be due to
the fact that the automated actuation, with a significantly higher valve opening
rate than the manual actuation, led to a higher pressure gradient at the nozzle
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orifice, causing the aerosolisation of smaller particles.
A mouthpiece with a high nozzle orifice diameter and a short length led to an
increased throat deposition for both solution formulations compared to a mouth-
piece with a lower nozzle orifice diameter and longer length. This shows that
varying the mouthpiece design could be used to obtain different spray deposition
patterns. Longer mouthpieces could contribute to reduce the throat deposition.
This is in line with the simulation results in which a smaller orifice diameter led to
the aerosolisation of smaller droplets at the nozzle orifice.
When comparing three formulations, the formulation containing PEG400 was less
affected by the different actuation forces. It might mean that formulations contain-
ing viscous and non-volatile components have a more stable aerosolisation process
due to their lower evaporation rate and are less influenced by a change in experi-
mental conditions such as the valve orifice opening rate.
After calculating the initial properties of the droplets by means of a computational
simulation and measuring their residual properties with a NGI, the characteristics
of the intermediate droplets were assessed using diverse laser methods. The ve-
locities measured with the particle image velocimetry (PIV) were in line with the
liquid phase velocities calculated in the simulation. The PIV work on several for-
mulations showed that the pure propellant formulation had a faster initial velocity
than the HPEF formulation, which can be explained by the lower vapour pressure
of the latter.
In the Malvern Spraytec R© measurements, it was found that increasing the temper-
ature from 20 ◦C to 40 ◦C decreased the particle size distribution for the HEF and
HPEF formulations which is in line with the simulation results in which the MMD
values at the nozzle orifice decreased at higher temperatures. The Sympatec R© and
Malvern Spraytec R© measurements concurred with the NGI results, revealing bigger
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particles aerosolised with the HPEF formulation compared with the HF and HEF
formulations.
The effect of the valve opening rate was similar with the Sympatec R©, Malvern
Spraytec R©, NGI and simulation results. The Sympatec R© measured bigger parti-
cles in the HEF formulation with the manual actuation of the “healthy” female
compared to automated actuations. This coincides with the higher NGI throat
deposition measurements obtained with the manual actuation; this is also in line
with the high MMD values obtained at low valve orifice opening rates (such as
those provided by manual actuations) in the simulation. When using the Malvern
Spraytec R©, the manual force with a low valve opening rate also tended to lead to the
aerosolisation of bigger droplets compared to the automated actuations although
the trend was weaker than with the NGI and the Sympatec R© measurements.
It was found that, although giving results in the the same order of magnitude,
the three particle sizing methods could not be directly compared as they each use
different operating principles.
6.2 Recommendations for future work
The computational model has several limitations, including the assumption that
the propellant vapour behaves as an idea gas in the expansion chamber. This might
not be accurate as the pressure in the expansion chamber is relatively high and the
vapour phase is not dry. The pressure in the expansion chamber could instead be
measured using a pressure sensor. An empirical equation correlating the expansion
chamber pressure to diverse parameters such as the nozzle orifice diameter to valve
diameter ratio could be developed.
The residual mass of propellant in the metering chamber at the end of the simulated
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formulation discharge was very high in the present work. This might be explained
by the fact that the evaporation of the propellant due to heat transfer with the
surroundings at the end of the discharge was not taken into account. In future
works, the evaporation of the remaining propellant could be simulated. This would
increase the pressure in the metering chamber, allowing a longer discharge of the
formulation, which would in turn reduce the residual mass in the metering chamber.
In the simulation of suspension formulations, the equation used to calculate the
MMD could be improved in order to take into account the size and agglomeration
of particles in the formulation.
Although, the present model can take into account the presence of FP, it can-
not simulate the discharge of formulations containing components that dissolve in
HFA134a. This limitation is due to the fact that the model only uses the equations
of state of pure HFA134a which could not be applied to mixtures of components
dissolved in HFA134a. The model could therefore be improved to simulate the
discharge of several types of formulations such as solution formulations.
In the current literature the velocities at the nozzle orifice obtained from models
range from 19 m·s−1 to 225 m·s−1 (Ju et al., 2010), (Dunbar, 1996). The velocity
measurements inside or at the extremity of the mouthpiece are not reliable and
values ranging from 60 m·s−1 (Crosland et al., 2009) to 90 m·s−1 have been reported
(Wigley et al., 2002).
A computational fluid dynamics (CFD) model could be developed to give a more
detailed analysis of the discharge through the device. It could be combined with
the present model, using its outputs as boundary conditions, to simulate the flow
between the nozzle orifice and the extremity of the mouthpiece where experimental
measurements are difficult to conduct.
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As actuation profiles and velocities of the valve opening have never been extensively
investigated, it would be of interest to study the actuation profiles of several patient
populations using a linear variable differential transformer (LVDT) in order to
assess the variations in the actuation process according to the type of population
studied. Automated actuations if used in in vitro studies could thus be set up to
better mimic the hand actuation of diverse users.
The actuation of “weak” pMDI users should be studied to determine whether they
can achieve a sufficient expansion chamber pressure to aerosolise the spray in fine
particles and thus benefit from an optimal efficiency of their device.
The MMAD values commonly used in impaction works can sometimes be mislead-
ing as they only take into consideration the size of particles depositing within the
NGI. It might thus be helpful to create another size parameter taking into account
all droplets emitted from the device, as it would give a better insight on potential
throat depositions. In order to compare the velocities of several formulations us-
ing PIV, a time-resolved analysis should be implemented as the time needed for
the flow to reach its sonic regime varies with the vapour pressure of each formula-
tion. The phase Doppler anemometry (PDA) technique could therefore be used. A
larger measuring zone should be studied to capture the velocity profile of the spray
upon reaching the patients’ throat as this velocity represents one of the main factor
determining the amount of drug depositing on the back of the throat. It would
also be of interest to compare the manual and automated actuations using PIV
to understand the role of the valve opening rate on the velocity of the aerosolised
droplets.
A second camera would allow measurements of the size of droplets issued from the
spray, using droplet imaging velocimeter and sizer (DIVAS). Those measurements
would be of interest as they could provide information on the size of the droplets
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from the extremity of the mouthpiece to the back of the throat. This method could
validate the particle sizing results obtained with the NGI, the Sympatec R© and the
Malvern Spraytec R©.
Finally, the Malvern Spraytec R© and PIV measurements should be made with an ac-
companying co-current airflow to represent more realistically the conditions under
which pMDIs are used instead of being conducted in quiescent air as was done in
this work. Certain laser measurements apparatus such as the Malvern Spraytec R©
could also be used in combination with an impactor to combine information on the
size of the particles during their trajectory with their deposition location.
6.3 Personal contribution to the field
This thesis provides an extensive range of experimental measurements, using and
comparing results obtained from three particle sizing methods, including one im-
paction technique and two laser-based techniques. Those three methods have never
been combined in a single piece of work. This thesis could therefore represents a
good literature review for future studies on aerosol particle sizing.
To the best knowledge of the author, the simulation developed in Chapter 2 rep-
resents the first modelling work simulating the rate of opening of the valve orifice.
The simulation was also modified to model the discharge of suspension formula-
tions and could be further improved to model any formulation design, including
solution formulations. This model also provides the boundary conditions required
in computational fluid dynamics works modelling the behaviour of the aerosol near
the nozzle orifice where experimental measurements are difficult to obtain.
The temperature at which the inhaler is kept and used was shown to influence the
spray characteristics, with low temperatures leading to the aerosolisation of larger
300
Chapter 6
droplets. Although, the effect of temperature was reported in the literature, it
has not been previously incorporated into a model. The effect of temperature is
not taken into account when prescribing inhalers in diverse environments although
this work shows that pMDIs might need to be designed for a specific range of
temperatures in order to maximise their performance.
This work has demonstrated that actuation forces might affect the size of the
droplets aerosolised from a pMDI, with low actuation forces producing significantly
larger droplets. This represents a novel and critical finding that needs to be con-
sidered, as weak patients might represent a large part of pMDI users and may not
be able to benefit from an optimal device efficiency.
Those factors might not be critical for the delivery of drugs to the lungs. However,
with pMDIs evolving towards the delivery of more expensive drugs with stronger
side effects to the systemic circulation, the devices will need to deliver drugs more
accurately in order to limit the risk of side effects and reduce the cost of therapy.
Appropriate forces of actuation and temperature ranges might help pMDI drug
delivery to be more reliable and accurate and therefore need to be investigated
further.
The effect of different formulations and device parameters were investigated com-
putationally and experimentally. To the best knowledge of the author, the effect
of several types of cosolvents had never been previously studied while keeping the
other formulation components at constant concentrations. It was seen that each
excipient produced aerosols with different characteristics. As a result, different
formulation designs might be used to improve aerosol properties according to the
temperature at which it is used and the actuation force of the user.
The effect of device design on the spray characteristics was also studied. The role
of the valve opening rate, investigated for the first time in this work, and the ratio
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of the nozzle to valve orifice diameter affect the size distribution of the aerosol
through the modification of the pressure gradients across both orifices. As a result,
it is thought that device designs could also be manipulated in order to yield certain
spray properties for specific types of users under different environmental conditions.
In conclusion, this thesis has investigated the applicability of a new computational
approach which can successfully predict the aerosolisation performance of pMDIs.
This represents a potentially successful tool for widespread application to aid in
silico formulation and device engineering. One particularly novel aspect has been
the incorporation of patient use factors, in term of device handling competencies.
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Density of air (Rogers and Mayhew, 1995)
ρa = 1.6665× 10−5 × T 2 − 0.013864× T + 3.8351 (A.1)
where T is the temperature in K.
Density of liquid HFA134a (Klea134a, 2011)
ρl = 89.838713u







with Tcrit = 374.18 K.
Density of vapour HFA134a (Klea134a, 2011)
ρv = −5583.8u4 + 13688.75u3 − 11368.8u2 + 3335.18u− 113.501 (A.3)







ρv = −2202.55u4 + 5252.284u3 − 3500.71u2 + 84.07428u+ 388.752 (A.4)









Specific enthalpy of liquid HFA134a (Klea134a, 2011)








Specific enthalpy of vaporisation of HFA134a (Klea134a, 2011)
hlvp = 219.1886u








Specific enthalpy of vapour HFA134a (Klea134a, 2011)
hvp = 61.5016u








Vapour pressure of HFA134a (Tillner-Roth and Baehr, 1994)




(−7.686556 v + 2.311791 v 32 − 2.039554 v2 − 3.583758 v4)
)
(A.8)
for 180 K < T < 374.15 K, where v = 1− T
Tcrit
and Pcrit = 4.056 29× 106 Pa
Specific heat capacity of the gas phase of HFA134a at constant pressure
(Dunbar, 1996)
Cpg = 1.7812× 10−6 × T 3 − 2.8662× 10−3 × T 2 + 3.005× T + 143.897 (A.9)
for 223 K < T < 353 K.
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